Bicyclic compound

By developing bicyclic compounds of formula (Ia), (Ib), or (Ic) to regulate β-glucocerebrosidase activity, the lysosomal dysfunction caused by GBA1 mutation was resolved, realizing a potential therapeutic effect for Parkinson's disease.

WO2026237951A1PCT designated stage Publication Date: 2026-11-19SIMCERE PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096460
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-06-13
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing technologies have failed to effectively address the problem of lysosomal dysfunction leading to protein degradation and reduced enzyme activity in Parkinson's disease and related synucleopathies caused by GBA1 mutations.

Method used

Bicyclic compounds of formula (Ia), (Ib) or (Ic) or their stereoisomers or pharmaceutically acceptable salts are provided to restore lysosomal function, reduce lipid substrate accumulation, and inhibit pathological α-Syn aggregation by modulating the activity of β-glucocerebrosidase.

Benefits of technology

It restores lysosomal function, reduces lipid substrate accumulation, and inhibits pathological α-Syn aggregation, providing a potential new drug strategy for the treatment of Parkinson's disease and related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026096460_19112026_PF_FP_ABST
    Figure CN2026096460_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a compound represented by formula (Ia), or (Ib) or (Ic), or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof as an allosteric modulator of β-glucocerebrosidase (GCase), preferably for treating neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Bicyclic compounds

[0001] Cross-references to related applications

[0002] This application claims priority and benefits to Chinese patent application No. 202510606873.5 filed with the China National Intellectual Property Administration on May 12, 2025, and Chinese patent application No. 202510789957.7 filed with the China National Intellectual Property Administration on June 13, 2025, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] This disclosure pertains to the field of pharmaceutical technology, specifically relating to bicyclic compounds as allosteric regulators of β-glucocerebrosidase (also known as acid β-glucosidase, D-glucosyl-N-acylsphingosine glucosylhydrolase, or GCase), pharmaceutical compositions containing such bicyclic compounds, and their use in the prevention or treatment of neurodegenerative diseases. Background Technology

[0004] β-Glucocephalinase is an enzyme with glucosylceramidinase activity that metabolizes glycosphingolipid glucosylceramide (GlcCer) into ceramide and glucose. β-Glucocephalinase exhibits maximum activity at pH 5.5 (the pH of the lysosomal compartment). Within the lysosome, it remains membrane-bound and degrades its substrate, glucocerebroside (GluCer). It requires the activation of the protein Saposin C and negatively charged lipids to achieve maximum catalytic activity, ensuring the normal functioning of cellular protein degradation and cell signaling.

[0005] Mutations in GBA1 (the gene encoding the lysosomal enzyme glucocerebrosidase) are one of the most common known genetic risk factors for the development of Parkinson's disease and related synucleinopathies, and also a cause of the rare autosomal storage disorder Gaucher disease. GBA1 mutations can lead to protein degradation, disruption of lysosomal targeting, and reduced enzyme performance in lysosomes. Gaucher disease is phenotypic, presenting in both neuropathic and non-neuropathic forms. Patients with Gaucher disease and heterozygous carriers have an increased risk of developing Parkinson's disease and Lewy body dementia. Reduced GCase activity levels have been detected in different brain regions of Parkinson's disease patients. Furthermore, studies have shown that GCase modulators can restore lysosomal function, reduce lipid substrate accumulation, and thus inhibit pathological α-Syn accumulation. Therefore, GCase modulators are considered a strategy for developing new drugs to alleviate and treat Parkinson's disease. Summary of the Invention

[0006] This disclosure provides compounds of formula (Ia) or (Ib) or (Ic) or their stereoisomers or pharmaceutically acceptable salts thereof.

[0007] in,

[0008] The ring C is selected from the following structural groups:

[0009] Indicates a single bond or a double bond;

[0010] G 1 Selected from CR 2 , N or NR 3 ;

[0011] G 2 Selected from CR 2 , N or C(O);

[0012] Q 1 Q 2 Independently selected from CR 2 Or N;

[0013] V is selected from O, S, or NH;

[0014] Each R c The components are independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl is optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0015] Each R 2 It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0016] R 3 Selected from H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C4 alkoxy;

[0017] W is selected from key, -CR a R b -, C(O), O or S;

[0018] R a R b It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0019] Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12bridged cycloalkyl, 7-12 membered spirocyclic, 7-12 membered fused heterocyclic or 5-12 membered bridged heterocyclic;

[0020] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0021] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0022] Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0023] n is selected from 0, 1, or 2;

[0024] p and q are independently selected from 0, 1, or 2;

[0025] M1 is selected from O, S, or CR. 6a R 7a M2 is selected from CR 8a Or N; M3 is selected from CR 9a Or N;

[0026] R 6a R 7a R 8a R 9a It is independently selected from H, deuterium, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0027] d1, d2, c1, c2, v1, and v2 are independently selected from 0, 1, or 2;

[0028] T is selected from CR 2 Or N.

[0029] In some implementations, in formula (Ia) or formula (Ib),

[0030] The ring C is selected from the following structural groups:

[0031] Each R cThe components are independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl is optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0032] Each R 2 It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0033] R 3 Selected from H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C4 alkoxy;

[0034] W is selected from key, -CR a R b -, C(O), O or S;

[0035] R a R b It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0036] Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12 bridged cycloalkyl, 7-12 membered spirocyclic, 7-12 membered fused heterocyclic or 5-12 membered bridged heterocyclic;

[0037] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0038] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0039] Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0040] n is selected from 0, 1, or 2;

[0041] p and q are independently selected from 0, 1, or 2;

[0042] M1 is selected from O, S, or CR. 6a R 7a M2 is selected from CR 8a Or N; M3 is selected from CR 9a Or N;

[0043] R 6a R 7a R 8a R 9a It is independently selected from H, deuterium, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0044] d1, d2, c1, c2, v1, and v2 are independently selected from 0, 1, or 2.

[0045] On the other hand, this disclosure provides a compound of formula (Ia) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0046] in,

[0047] The ring C is selected from the following structural groups:

[0048] Indicates a single bond or a double bond;

[0049] G 1 Selected from CR 2 , N or NR 3 ;

[0050] G 2 Selected from CR 2 , N or C(O);

[0051] Q 1 Q 2 Independently selected from CR 2 Or N;

[0052] V is selected from O, S, or NH;

[0053] Each R c The components are independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl is optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0054] Each R 2It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0055] R 3 Selected from H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C4 alkoxy;

[0056] W is selected from key, -CR a R b -, C(O), O or S;

[0057] R a R b It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0058] Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C5-C 12 bridged cycloalkyl, 7-12 membered spirocyclic, 7-12 membered fused heterocyclic or 5-12 membered bridged heterocyclic;

[0059] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0060] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0061] Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0062] n is selected from 0, 1, or 2;

[0063] p and q are independently selected from 0, 1, or 2.

[0064] In some implementation schemes, Indicates a single key, G 1 For NR 3 G 2 It is C(O).

[0065] In some implementation schemes, G represents a double bond.1 Selected from CR 2 Or N, G 2 Selected from CR 2 Or N.

[0066] In some implementation schemes, Q 1 Q 2 At least one of them is N.

[0067] In some implementation schemes, Q 1 Q 2 Only one of them is N. In some implementations, Q 1 For CR 2 And Q 2 For N. In some implementations, Q 1 Let N be the number of elements and Q be the number of elements. 2 For CR 2 .

[0068] In some implementations, V is selected from O or NH.

[0069] On the other hand, this disclosure provides a compound of formula (Ib) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0070] in,

[0071] Each R c The group is independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 heterocyclic groups, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 heterocyclic groups is independently and optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0072] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0073] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0074] Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0075] n is selected from 0, 1, or 2;

[0076] p is selected from 0, 1, or 2;

[0077] M1 is selected from O, S, or CR. 6a R 7a M2 is selected from CR 8a Or N; M3 is selected from CR 9a Or N;

[0078] R 6a R 7a R 8a R 9a It is independently selected from H, deuterium, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0079] d1, d2, c1, c2, v1, and v2 are independently selected from 0, 1, or 2.

[0080] In some implementations, both v1 and v2 are 0.

[0081] In some implementations, d1, d2, c1, and c2 are independently selected from 0 or 1.

[0082] In some implementations, d1 and d2 are independently selected from 0 or 1; c1 and c2 are both 0.

[0083] In some implementations, d1 and d2 are both 0; c1 and c2 are selected from 0 or 1.

[0084] In some implementations, d1 and d2 are both 1; c1 and c2 are both 0.

[0085] In some implementations, at least one of M2 and M3 is N.

[0086] In some implementations, M2 is N and M1 is CR. 6a R 7a M3 is CR 8a .

[0087] In some implementations, M2 is N, M1 is CH2, and M3 is CH.

[0088] On the other hand, this disclosure provides a compound of formula (Ic) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0089] in,

[0090] Each R cThe group is independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 heterocyclic groups, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 heterocyclic groups is independently and optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0091] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0092] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0093] Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0094] n is selected from 0, 1, or 2;

[0095] p is selected from 0, 1, or 2;

[0096] M1 is selected from O, S, or CR. 6a R 7a M2 is selected from CR 8a Or N; M3 is selected from CR 9a Or N;

[0097] R 6a R 7a R 8a R 9a It is independently selected from H, deuterium, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0098] d1, d2, c1, c2, v1, and v2 are independently selected from 0, 1, or 2;

[0099] T is selected from CR 2 Or N.

[0100] In some implementation schemes, R cIt is selected from C1-C6 alkyl, C1-C6 alkoxy, 4-6 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, 4-6 heterocyclic or 5-6 heteroaryl is independently and optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0101] In some implementation schemes, R c It is selected from C1-C6 alkyl, C1-C6 alkoxy, 4-6 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, 4-6 heterocyclic or 5-6 heteroaryl is optionally substituted by a halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0102] In some implementation schemes, R c It is selected from C1-C6 alkyl, C1-C6 alkoxy, 4-6 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, 4-6 heterocyclic or 5-6 heteroaryl is optionally substituted by a halogen or a C1-C6 haloalkyl.

[0103] In some implementation schemes, R c Selected from C1-C3 alkyl, C1-C3 alkoxy, aziridine butyl, piperidinyl, pyrazolyl, The C1-C3 alkyl, C1-C3 alkoxy, azacyclic butyl, piperidinyl, pyrazolyl, Each can be independently and optionally substituted with halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

[0104] In some implementation schemes, R c It is selected from C1-C3 alkyl, C1-C3 alkoxy, aziridine, piperidinyl or pyrazolyl, wherein each of the C1-C3 alkyl, C1-C3 alkoxy, aziridine, piperidinyl or pyrazolyl is optionally substituted by a halogen or a C1-C6 haloalkyl.

[0105] In some implementation schemes, R c Selected from CH3, -OCH2CHF2, CH2CHF2,

[0106] In some implementation schemes, R c Selected from -OCH2CHF2, CH2CHF2,

[0107] In some implementation schemes, R c It is a C1-C6 alkyl group that has been substituted with halogen.

[0108] In some implementation schemes, R c It is CH2CHF2.

[0109] In some implementation schemes, R 2 It is selected from H, C1-C6 alkyl or C1-C4 alkoxy.

[0110] In some implementation schemes, R 2 Selected from H, CH3 or -OCH3.

[0111] In some implementation schemes, R 2 For H.

[0112] In some implementation schemes, R 3 Selected from H or C1-C6 alkyl groups.

[0113] In some implementation schemes, R 3 Selected from H, CH3 or CH2CH3.

[0114] In some implementation schemes, R 3 Selected from H or CH3.

[0115] In some implementation schemes, R 3 It is CH3.

[0116] In some embodiments, the cyclic C is selected from the following structural groups: Among them, R 2 R 3 R c And n is defined as described above.

[0117] In some embodiments, the cyclic C is selected from the following structural groups: Among them, R 2 R 3 and R c As defined above.

[0118] In some embodiments, the cyclic C is selected from the following structural groups: Among them, R 2 R 3 R c And n is defined as described above.

[0119] In some embodiments, the cyclic C is selected from the following structural groups: Among them, R 2 R 3 and Rc As defined above.

[0120] In some implementations, W is selected from a bond, -CH2-, C(O), O, or S.

[0121] In some implementations, W is selected from either a key or an O.

[0122] In some implementations, W is the key.

[0123] In some embodiments, ring B is selected from 7-12 subspirocyclic, 7-12 subfused heterocyclic, or 5-12 subbridged heterocyclic groups.

[0124] In some embodiments, ring B is selected from 7-10 subspirocyclic heterocyclic groups, 7-10 subfused heterocyclic groups, or 5-10 subbridged heterocyclic groups.

[0125] In some implementations, ring B is selected from 7-12 member subspirocyclic groups.

[0126] In some implementations, ring B is selected from 3-membered / 6-membered subspiroheterocyclic groups, 4-membered / 4-membered subspiroheterocyclic groups, 4-membered / 5-membered subspiroheterocyclic groups, 4-membered / 6-membered subspiroheterocyclic groups, 5-membered / 5-membered subspiroheterocyclic groups, or 5-membered / 6-membered subspiroheterocyclic groups.

[0127] In some implementations, ring B is selected from 5-membered / 5-membered subspiroheterocyclic groups, 4-membered / 4-membered subspiroheterocyclic groups, 4-membered / 5-membered subspiroheterocyclic groups, 5-membered / 6-membered subspiroheterocyclic groups, or 4-membered / 6-membered subspiroheterocyclic groups.

[0128] In some implementations, ring B is selected from 4-membered / 4-membered subspiroheterocyclic groups, 4-membered / 5-membered subspiroheterocyclic groups, or 4-membered / 6-membered subspiroheterocyclic groups.

[0129] In some implementation schemes, ring B is selected from:

[0130] In some implementations, ring B is selected from 7-12 member subfused heterocyclic groups.

[0131] In some implementations, ring B is selected from 3-membered / 5-membered subfused heterocyclic groups, 6-membered / 6-membered subfused heterocyclic groups, 5-membered / 6-membered subfused heterocyclic groups, or 5-membered / 5-membered subfused heterocyclic groups.

[0132] In some implementations, ring B is selected from 5-membered / 6-membered subfused heterocyclic groups or 5-membered / 5-membered subfused heterocyclic groups.

[0133] In some implementations, ring B is selected from 5-membered / 5-membered subfused heterocyclic groups.

[0134] In some implementations, ring B is selected from 5-membered heteroaryl and 6-membered heterocyclic groups.

[0135] In some embodiments, ring B is selected from 5-membered heteroaryl and 6-membered heterocyclic groups, wherein the 5-membered heteroaryl contains 1, 2 or 3 nitrogen atoms.

[0136] In some implementation schemes, ring B is selected from...

[0137] In some implementations, ring B is a 5-12 quintic subbridged heterocyclic group.

[0138] In some implementations, ring B is a 6-9 quintic subbridged heterocyclic group.

[0139] In some implementations, ring B is a 7- or 8-membered subbridged heterocyclic group.

[0140] In some embodiments, the 7-12 fused heterocyclic group, the 7-12 sub-spirocyclic group, or the 5-12 sub-bridged heterocyclic group each independently contains one, two, or three heteroatoms independently selected from N, O, or S.

[0141] In some embodiments, the 7-12-membered subspirocyclic heterocyclic group, the 7-12-membered subfused heterocyclic group, or the 5-12-membered subbridged heterocyclic group each independently contains one, two, or three heteroatoms independently selected from N or O.

[0142] In some embodiments, the 7-12 fused heterocyclic group, the 7-12 sub-spirocyclic group, or the 5-12 sub-bridged heterocyclic group each independently contains one or two heteroatoms independently selected from N.

[0143] In some embodiments, the 3- or 6-membered subspirocyclic heterocyclic group, the 4- or 4-membered subspirocyclic heterocyclic group, the 4- or 5-membered subspirocyclic heterocyclic group, the 4- or 6-membered subspirocyclic heterocyclic group, the 5- or 5-membered subspirocyclic heterocyclic group, the 5- or 6-membered subspirocyclic heterocyclic group, the 3- or 5-membered subfused heterocyclic group, the 6- or 6-membered subfused heterocyclic group, the 5- or 6-membered subfused heterocyclic group, the 5- or 5-membered subfused heterocyclic group, the 6- or 9-membered subbridged heterocyclic group, or the 7- or 8-membered subbridged heterocyclic group each independently contains one, two, or three heteroatoms independently selected from N or O.

[0144] In some embodiments, ring B is selected from the following structural groups:

[0145] X1 is selected from O, S or CR. 6 R 7 X2 is selected from CR 8 Or N; X3 is selected from CR 9 Or N;

[0146] R 6 R 7 R 8 R9 It is independently selected from H, deuterium, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0147] s, m, and r are independently selected from 0, 1, or 2;

[0148] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0149] q' is selected from 0 or 1;

[0150] "q" is selected from 0 or 1.

[0151] In some implementations, X1 is selected from O or CR. 6 R 7 .

[0152] In some implementations, X1 is CR 6 R 7 .

[0153] In some implementations, X1 is CH2.

[0154] In some implementations, at least one of X2 and X3 is N.

[0155] In some implementations, X2 is selected from CH or N.

[0156] In some implementations, X3 is selected from CH or N.

[0157] In some implementation schemes, R 6 R 7 R 8 R 9 It is independently selected from H, deuterium or C1-C6 alkyl.

[0158] In some implementation schemes, R 6 R 7 R 8 R 9 Each of them is H independently.

[0159] In some implementations, s, m, and r are independently selected from 0 or 1.

[0160] In some implementations, q' is 0; q” is 0.

[0161] In some embodiments, ring B is selected from the following structural groups:

[0162] Among them, Z1 and Z2 are independently selected from CR10 Or N;

[0163] R 10 Selected from H, deuterium, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0164] t, f, g, and k are independently selected from 0, 1, or 2;

[0165] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0166] q' is selected from 0 or 1;

[0167] "q" is selected from 0 or 1.

[0168] In some implementations, ring B is a 4-6 member monocyclic heterocyclic group.

[0169] In some implementation schemes, ring B is

[0170] In some implementation schemes, R 10 Selected from H, deuterium, or C1-C6 alkyl groups.

[0171] In some implementation schemes, R 10 For H.

[0172] In some implementations, at least one of Z1 and Z2 is N.

[0173] In some implementations, Z1 is N, and Z2 is selected from CH or N.

[0174] In some implementations, Z1 is CH or N, and Z2 is selected from N.

[0175] In some implementations, Z1 is N and Z2 is CH.

[0176] In some implementations, Z1 is CH, and Z2 is selected from N.

[0177] In some implementations, Z1 is N and Z2 is N.

[0178] In some implementations, t is 1.

[0179] In some implementations, k is 1.

[0180] In some implementations, f and g are selected from 0 or 1.

[0181] In some implementations, both f and g are 0.

[0182] In some implementations, both f and g are 1.

[0183] In some implementations, q' is 0 and q” is 0.

[0184] In some embodiments, ring B is selected from the following structural groups:

[0185] Among them, Y1 and Y2 are independently selected from N or CH;

[0186] Z is selected from CH2 or CH2CH2;

[0187] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0188] q is selected from 0, 1 or 2.

[0189] In some implementations, at least one of Y1 and Y2 is N.

[0190] In some implementations, Y1 and Y2 are independently both CH. In some implementations, Y1 and Y2 are independently both N.

[0191] In some implementation schemes, ring B is selected from...

[0192] In some implementation schemes, ring B is selected from...

[0193] In some implementation schemes, Selected from the following structures:

[0194] In some implementations, ring A is selected from C5-C. 10 Cycloalkyl, 4-9 membered heterocyclic, 5-6 membered heteroaryl or phenyl.

[0195] In some implementations, ring A is a 5-10 membered heteroaryl or phenyl group.

[0196] In some implementations, ring A is a 5-10 membered heteroaryl group.

[0197] In some implementations, ring A is a 5-6 membered heteroaryl group.

[0198] In some embodiments, ring A is pyridinyl or pyrimidinyl.

[0199] In some implementations, ring A is selected from...

[0200] In some implementations, ring A is pyridyl.

[0201] In some implementations, ring A is

[0202] In some implementation schemes, R 1 Selected from CN, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 alkoxy, wherein each of the C1-C6 alkyl or C1-C6 alkoxy is optionally substituted independently by NH2, OH, halogen or C1-C6 alkyl.

[0203] In some implementation schemes, R 1 Selected from halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or C1-C6 alkoxy groups, wherein each of the C1-C6 alkyl groups or C1-C6 alkoxy groups is optionally substituted independently by NH2, OH, halogens, or C1-C6 alkyl groups.

[0204] In some implementation schemes, R 1 It is selected from halogens, C1-C6 alkyl groups, or C1-C6 haloalkyl groups.

[0205] In some implementation schemes, R 1 Selected from C1-C6 haloalkyl groups.

[0206] In some implementation schemes, R 1 It is CF3.

[0207] In some implementation schemes, Selected from the following structures:

[0208] In some implementation schemes, Selected from the following structures:

[0209] In some implementation schemes, Selected from the following structures:

[0210] In some implementation schemes, Selected from the following structures:

[0211] In some implementation schemes, It has the following structure:

[0212] In some implementation schemes, R 4It is selected from deuterium, OH, halogen, =O, C1-C6 alkyl or C1-C6 haloalkyl.

[0213] In some implementation schemes, R 4 Selected from deuterium, =O or C1-C6 alkyl groups.

[0214] In some implementation schemes, R 4 Selected from deuterium, =O, or CH3.

[0215] In some implementation schemes, R 4 Selected from deuterium or =O.

[0216] In some implementation schemes, R 4 =O.

[0217] In some implementations, p is selected from 0 or 1. In some implementations, p is 1.

[0218] In some implementations, q is selected from 0 or 1. In some implementations, q is 0.

[0219] In some implementations, n is selected from 0 or 1. In some implementations, n is 1.

[0220] In some implementations, n is 1 or 2.

[0221] On the other hand, this disclosure also provides a compound of formula (Id) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0222] in,

[0223] G 1 G 2 Selected from CR 2 Or N;

[0224] Each R 2 It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0225] Each R c The group is independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups is independently and optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0226] n is selected from 0, 1, or 2;

[0227] L is selected from bonds, NH, C(O), O, -CR 11 R 12-or-O-CR 11 R 12 -;

[0228] R 11 R 12 Independently selected from H or C1-C6 alkyl groups;

[0229] W is selected from key, -CR a R b -, O or S;

[0230] R a R b It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0231] Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12 bridged cycloalkyl, 7-12 membered spirocyclic heterocyclic group, 7-12 membered fused heterocyclic group, 5-12 membered bridged heterocyclic group or 4-6 membered monocyclic heterocyclic group;

[0232] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0233] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0234] Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0235] p and q are independently selected from 0, 1, or 2.

[0236] In some implementations, L is selected from O, -CR 11 R 12 -or-O-CR 11 R 12 -

[0237] In some implementations, L stands for key.

[0238] On the other hand, this disclosure also provides a compound of formula (Ie) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0239] in,

[0240] Each R c The group is independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups is independently and optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0241] n is selected from 0, 1, or 2;

[0242] L is selected from the bond, O, or -O-CR. 11 R 12 -;

[0243] R 11 R 12 Independently selected from H or C1-C6 alkyl groups;

[0244] W is selected from key, -CR a R b -, O, S, NHC(O) or C(O)O;;

[0245] R a R b It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0246] Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12 bridged cycloalkyl, 7-12 membered spirocyclic heterocyclic group, 7-12 membered fused heterocyclic group, 5-12 membered bridged heterocyclic group or 4-6 membered monocyclic heterocyclic group;

[0247] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0248] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0249] Each R 1The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0250] p and q are independently selected from 0, 1, or 2.

[0251] In some implementations, L stands for key.

[0252] In some implementation schemes, R 11 R 12 It is independently selected from H or CH3.

[0253] On the other hand, this disclosure also provides a compound of formula (If) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0254] in,

[0255] X is selected from N or CR;

[0256] R is selected from H or C1-C6 alkyl groups;

[0257] Each R c The group is independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups is independently and optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0258] n is selected from 0, 1, or 2;

[0259] L is selected from bonds, NH, C(O), O, -CR 11 R 12 -or-O-CR 11 R 12 ;

[0260] R 11 R 12 Independently selected from H or C1-C6 alkyl groups;

[0261] W is selected from key, -CR a R b -, O or S;

[0262] R a R b It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy;

[0263] Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12 bridged cycloalkyl, 7-12 membered spirocyclic heterocyclic group, 7-12 membered fused heterocyclic group, 5-12 membered bridged heterocyclic group or 4-6 membered monocyclic heterocyclic group;

[0264] Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0265] Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl;

[0266] Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl.

[0267] p and q are independently selected from 0, 1, or 2.

[0268] On the other hand, this disclosure also provides a compound of formula (Ig) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0269] in,

[0270] Each R c The group is independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups is independently and optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0271] L is selected from bonds, NH, C(O), O, -CR 11 R 12 -or-O-CR 11 R 12 -;

[0272] R 11 R 12 Independently selected from H or C1-C6 alkyl groups;

[0273] Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12 bridged cycloalkyl, 7-12 membered spirocyclic, 7-12 membered fused heterocyclic or 5-12 membered bridged heterocyclic;

[0274] Each R 13 Independently selected from deuterium, OH, NH2, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl, wherein the OH, NH2, C1-C6 alkyl or C3-C6 cycloalkyl are optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 haloalkoxy;

[0275] q is selected independently from 1 or 2.

[0276] In some implementations, L is selected from either a bond or -CH2.

[0277] In some implementation schemes, each R 13 The components are independently selected from OH, NH2, =O, C1-C6 alkyl, and C1-C6 haloalkyl, wherein the OH, NH2, or C1-C6 alkyl is optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 haloalkoxy.

[0278] In some implementation schemes, R 13 Selected from

[0279] On the other hand, this disclosure provides the following compounds or their isomers or pharmaceutically acceptable salts,

[0280] On the other hand, this disclosure provides pharmaceutical compositions comprising compounds of formula (Ia) or (Ib) or (Ic) or (Id) or (Ie) or (If) or (Ig) of this disclosure, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients.

[0281] On the other hand, this disclosure provides a method for preventing or treating GCase-mediated diseases in mammals, comprising administering to a mammal, preferably a human, a therapeutically effective amount of a compound of formula (Ia) or (Ib) or (Ic) or (Id) or (Ie) or (If) or (Ig) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0282] On the other hand, this disclosure provides the use of compounds of formula (Ia) or (Ib) or (Ic) or (Id) or (Ie) or (If) or (Ig) or their stereoisomers or pharmaceutically acceptable salts or pharmaceutical compositions thereof in the preparation of medicaments for the prevention or treatment of GCase-mediated diseases.

[0283] On the other hand, this disclosure provides the use of compounds of formula (Ia) or (Ib) or (Ic) or (Id) or (Ie) or (If) or (Ig) or their stereoisomers or pharmaceutically acceptable salts or pharmaceutical compositions thereof in the prevention or treatment of GCase-mediated diseases.

[0284] On the other hand, this disclosure provides compounds of formula (Ia) or (Ib) or (Ic) or (Id) or (Ie) or (If) or (Ig) for the prevention or treatment of GCase-mediated diseases, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

[0285] In some implementations, the GCase-mediated disease is a disease that benefits from GCase allosteric regulation.

[0286] In some implementations, the GCase-mediated diseases are selected from neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

[0287] Any embodiment of any aspect of this disclosure may be combined with other embodiments without contradiction. Furthermore, in any embodiment of any aspect of this disclosure, any technical feature may be applied to the same technical feature in other embodiments without contradiction.

[0288] Terminology Definitions and Explanations

[0289] Unless otherwise stated, the terms used in this disclosure have the following meanings: the definitions of groups and terms recorded in this disclosure, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in the examples, etc., can be arbitrarily combined and combined with each other. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When trade names appear herein, they are intended to refer to the corresponding product or its active ingredient.

[0290] In this article Indicates the connection site.

[0291] In this article It indicates a single or double bond.

[0292] The term "stereoisomer" refers to isomers that are produced by different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers and diastereomers.

[0293] The compounds disclosed herein may have asymmetric atoms such as carbon, sulfur, nitrogen, and phosphorus atoms, or asymmetric double bonds, and therefore may exist in specific geometric or stereoisomeric forms. Specific geometric or stereoisomeric forms may be cis and trans isomers, E- and Z-type geometric isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof or other mixtures, such as mixtures enriched with enantiomers or diastereomers. All such isomers and mixtures thereof are within the scope of the definition of the compounds disclosed herein. Alkyl groups or other substituents may contain additional asymmetric carbon atoms, asymmetric sulfur atoms, asymmetric nitrogen atoms, or asymmetric phosphorus atoms. All such isomers involved in all substituents, and mixtures thereof, are also included within the scope of the definition of the compounds disclosed herein. The compounds containing asymmetric atoms disclosed herein can be isolated in optically active pure form or in racemic form. The optically active pure form can be separated from racemic mixtures or synthesized using chiral starting materials or chiral reagents.

[0294] The term "substituted" refers to the substitution of one or more hydrogen atoms on a specific atom by a substituent, provided that the valence state of the specific atom is normal and the resulting compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are substituted; oxo substitution does not occur on aromatic groups.

[0295] The terms “optional” or “optionally” mean that the event or condition subsequently described may or may not occur, including both the occurrence and non-occurrence of said event or condition. For example, “optionally” substituted with a halogen means that the ethyl group can be unsubstituted (CH2CH3), monosubstituted (CH2CH2F, CH2CH2Cl, etc.), polysubstituted (CHFCH2F, CH2CHF2, CHFCH2Cl, CH2CHCl2, etc.), or fully substituted (CF2CF3, CF2CCl3, CCl2CCl3, etc.). Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.

[0296] When any variable (e.g., R) a R b When a group appears more than once in the composition or structure of a compound, its definition is independent in each case. For example, if a group is surrounded by two R... b Replaced, then each R b Each has its own independent options.

[0297] When a substituent is cross-bonded to two atoms on a ring, it can bond with any atom on that ring.

[0298] Unless otherwise specified, the linking direction of the linking groups mentioned in this article is arbitrary. For example, when ring B in the structural unit "W-ring BO" is selected from... At this time, ring B can be connected in a left-to-right direction to form the following unit "ring". Alternatively, the following units can be formed by connecting them from right to left.

[0299] When a substituent is cross-bonded to two atoms on a ring, it can bond to any atom on that ring. For example, structural units. R represents c Substitution can occur at any position on the pyrazole ring. For example...

[0300] C in this article m -C n It refers to having an integer number of carbon atoms in the range mn. For example, "C1-C 10 "" means that the group can have 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.

[0301] The term "alkyl" refers to a compound with the general formula C1. n H 2n+1 The alkyl group can be straight-chain or branched. The term "C1-C" refers to the hydrocarbon group. 10"Alkyl" can be understood as representing a straight-chain or branched saturated hydrocarbon group having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Specific examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, and 2,2-dimethylbutyl. 1,1-Dimethylbutyl, 2,3-Dimethylbutyl, 1,3-Dimethylbutyl, or 1,2-Dimethylbutyl, etc.; the term "C1-C6 alkyl" can be understood as referring to alkyl groups having 1, 2, 3, 4, 5, or 6 carbon atoms, specific examples including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc. The term "C1-C3 alkyl" can be understood as referring to straight-chain or branched saturated alkyl groups having 1, 2, or 3 carbon atoms. The "C1-C6"... 10 "alkyl" can include the range of "C1-C6 alkyl" or "C1-C3 alkyl", and the "C1-C6 alkyl" can further include "C1-C3 alkyl".

[0302] The term “halogenated alkyl” is intended to include both monohalogenated and polyhalogenated alkyl groups. For example, the term “C1-C6 haloalkyl” means a C1-C6 alkyl group as defined above that is substituted with one or more halogens, including but not limited to trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl, etc.

[0303] The term "alkoxy" refers to the substitution of a hydrogen atom on the hydroxyl group of a straight-chain or branched alcohol by an alkyl group; it can be understood as "alkyloxy" or "alkyl-O-". The term "C1-C"... 10 "Alkoxy" can be understood as "C1-C 10 "alkyloxy" or "C1-C" 10 Alkyl-O-"; the term "C1-C6 alkoxy" can be understood as "C1-C6 alkyloxy" or "C1-C6 alkyl-O-". The "C1-C" 10 "Alkoxy" can include the range of "C1-C6 alkoxy" and "C1-C3 alkoxy", and the "C1-C6 alkoxy" can further include "C1-C3 alkoxy".

[0304] The term "haloalkoxy" is intended to include both monohaloalkoxy and polyhaloalkoxy. For example, the term "C1-C6 haloalkoxy" refers to a C1-C6 alkoxy group as defined above that is substituted with one or more halogens.

[0305] The term "cycloalkyl" refers to a fully saturated carbon ring existing in the form of a monocyclic, fused, bridged, or spirocyclic ring. Unless otherwise indicated, the carbon ring is typically a 3- to 14-membered ring. The term "C3-C" is also used. 12 "Cycloalkyl" can be understood as representing a saturated monocyclic, fused, spirocyclic, or bridged ring having 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 carbon atoms. Specific examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, spiro[4.5]decyl, etc. The term "C3-C" 12 "Cycloalkyl" can include "C3-C6 cycloalkyl". The term "C3-C6 cycloalkyl" can be understood as indicating a saturated monocyclic or bicyclic hydrocarbon ring having 3, 4, 5 or 6 carbon atoms. Specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0306] The term "spirocycloalkyl" refers to a cycloalkyl group existing in a spirocyclic form. Preferably, it is a 7- to 12-membered spirocycloalkyl group (e.g., 7, 8, 9, 10, 11, or 12). More preferably, it is a 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered spirocycloalkyl group. Wherein, A-membered / B-membered spirocycloalkyl refers to a spirocyclic group formed by an A-membered monocyclic ring and a B-membered monocyclic ring sharing a single atom. Specific examples of spirocycloalkyl groups include, but are not limited to:

[0307] The term "spirocycloalkyl" refers to a divalent group derived from a "spirocycloalkyl" group as defined herein.

[0308] The term "fused cycloalkyl" refers to a cycloalkyl group existing in a fused ring configuration. Preferably, it is 7 to 12-membered (e.g., 7, 8, 9, 10, 11, or 12-membered). More preferably, it is a 3 / 5-membered, 6 / 6-membered, 5 / 6-membered, or 5 / 5-membered fused cycloalkyl group. Wherein, A-membered / B-membered fused cycloalkyl refers to a fused ring formed by an A-membered monocyclic ring and a B-membered monocyclic ring sharing two adjacent atoms. Specific examples of fused cycloalkyl groups include, but are not limited to:

[0309] The term “pyrocycloalkyl” refers to a divalent group derived from a “pyrocycloalkyl” group as defined herein.

[0310] The term "bridged cycloalkyl" refers to a cycloalkyl group present as a bridged ring. Preferred are 5- to 12-membered bridged cycloalkyl groups (e.g., 5, 6, 7, 8, 9, 10, 11, or 12-membered). Specific examples of bridged cycloalkyl groups include, but are not limited to:

[0311] The term “bridged cycloalkyl” refers to a divalent group derived from a “bridged cycloalkyl” group as defined herein.

[0312] The term "heterocyclic group" refers to a fully saturated or partially saturated (not aromatic as a whole) monocyclic, fused-ring, spirocyclic, or bridged ring containing 1, 2, 3, 4, or 5 heteroatoms or heterogroups (i.e., groups containing heteroatoms). These "heteroatoms or heterogroups" include, but are not limited to, nitrogen (N), oxygen (O), sulfur (S), phosphorus (P), boron (B), -S(=O)2-, -S(=O)-, -P(=O)2-, -P(=O)-, -NH-, -S(=O)(=NH)-, -C(=O)NH-, or -NHC(=O)NH-. The term "4-12 membered heterocyclic group" refers to a heterocyclic group with 4, 5, 6, 7, 8, 9, 10, 11, or 12 ring atoms, containing 1, 2, 3, 4, or 5 heteroatoms or heterogroups independently selected from those described above. "3-10 membered heterocyclic groups" include "4-7 membered heterocyclic groups", wherein specific examples of 4 membered heterocyclic groups include, but are not limited to, azirrocyclobutane, thioheterocyclobutane, or oxoheterocyclobutane; specific examples of 5 membered heterocyclic groups include, but are not limited to, tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoalkyl, pyrazolyl, pyrrolinyl, 4,5-dihydrooxazolyl, or 2,5-dihydro-1H-pyrrolyl; specific examples of 6 membered heterocyclic groups include, but are not limited to, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazinyl, trithiaalkyl, tetrahydropyridinyl, or 4H-[1,3,4]thiadiazinyl; and specific examples of 7 membered heterocyclic groups include, but are not limited to, diazacycloheptane. The heterocyclic group can also be a bicyclic group, wherein specific examples of 5,5-membered bicyclic groups include, but are not limited to, hexahydrocyclopentano[c]pyrrolo-2(1H)-yl or; specific examples of 5,6-membered bicyclic groups include, but are not limited to, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl or 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl. Optionally, the heterocyclic group can be a benzofused cyclic group of the above-mentioned 4-7-membered heterocyclic groups, specific examples of which include, but are not limited to, dihydroisoquinolinyl, etc. The term "4-10 membered heterocyclic group" can include the ranges of "5-10 membered heterocyclic group," "4-7 membered heterocyclic group," "5-6 membered heterocyclic group," "6-8 membered heterocyclic group," "4-10 membered heterocyclic alkyl group," "5-10 membered heterocyclic alkyl group," "4-7 membered heterocyclic alkyl group," "5-6 membered heterocyclic alkyl group," and "6-8 membered heterocyclic alkyl group." "4-7 membered heterocyclic group" can further include the ranges of "4-6 membered heterocyclic group," "5-6 membered heterocyclic group," "4-7 membered heterocyclic alkyl group," "4-6 membered heterocyclic alkyl group," and "5-6 membered heterocyclic alkyl group." Although some bicyclic heterocyclic groups in this disclosure partially contain a benzene ring or a heteroaromatic ring, the heterocyclic group as a whole is still non-aromatic. The term "spirocyclic group" refers to a heterocyclic group existing as a spirocyclic ring.Preferably, it is a 7- to 12-membered spirocyclic group (e.g., 7, 8, 9, 10, 11, or 12-membered). More preferably, it is a 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered spirocyclic group. Wherein, an A-membered / B-membered spirocyclic group refers to a spirocyclic group formed by an A-membered monocyclic ring and a B-membered monocyclic ring sharing a single atom. Specific examples of spirocyclic groups include, but are not limited to:

[0313] The term "spiroheterocyclic group" refers to a divalent group derived from a "spiroheterocyclic group" as defined herein.

[0314] The term "fused heterocyclic group" refers to a heterocyclic group that exists as a fused ring. Preferably, it is a 7- to 12-membered heterocyclic group (e.g., 7, 8, 9, 10, 11, or 12-membered). More preferably, it is a 3- or 5-membered fused heterocyclic group, a 6- or 6-membered fused heterocyclic group, a 5- or 6-membered fused heterocyclic group, or a 5- or 5-membered fused heterocyclic group. Wherein, an A- or B-membered fused heterocyclic group refers to a fused ring formed by an A-membered monocyclic ring and a B-membered monocyclic ring sharing two adjacent atoms. Specific examples of fused heterocyclic groups include, but are not limited to:

[0315] The term "sub-fused heterocyclic group" refers to a divalent group derived from a "fused heterocyclic group" as defined herein.

[0316] The term "bridged heterocyclic group" refers to a heterocyclic group in which a bridged ring exists. Preferably, it is 5 to 12-membered (e.g., 5, 6, 7, 8, 9, 10, 11, or 12-membered). Specific examples of bridged heterocyclic groups include, but are not limited to:

[0317] The term "subbridged heterocyclic group" refers to a divalent group derived from a "bridged heterocyclic group" as defined herein.

[0318] The term "aryl" refers to an aromatic ring group consisting of an all-carbon monocyclic or fused polycyclic aromatic cyclic group with a conjugated π-electron system. Aryl groups can have 6-20, 6-14, or 6-12 carbon atoms. The term "C6-C"... 20 "Aryl" can be understood as an aryl group having 6 to 20 carbon atoms. Specifically, it refers to a ring with 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring with 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring with 10 carbon atoms ("C9 aryl"). 10 Aryl groups, such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl; or rings having 13 carbon atoms (“C”). 13 Aryl groups, such as fluorene groups; or rings with 14 carbon atoms (“C”). 14 Aryl), for example, anthracene. The term "C6-C" is used. 10"Aryl" can be understood as an aryl group having 6 to 10 carbon atoms. Specifically, it refers to a ring with 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring with 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring with 10 carbon atoms ("C9 aryl"). 10 Aryl), such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl. The term "C6-C" is used. 20 "Aryl" can contain "C6-C 10 Aryl.

[0319] The term "heteroaryl" refers to an aromatic monocyclic or fused polycyclic system containing at least one ring atom selected from N, O, or S, with the remaining ring atoms being C. The term "5-10-membered heteroaryl" can be understood to include monocyclic or bicyclic aromatic ring systems having 5, 6, 7, 8, 9, or 10 ring atoms, particularly 5, 6, 9, or 10 ring atoms, and containing 1, 2, 3, 4, or 5, preferably 1, 2, or 3 heteroatoms independently selected from N, O, and S. Specifically, the heteroaryl group is selected from thienyl, furanyl, pyrroleyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl or thiadiazolyl and their benzo[derivatives], such as benzofuranyl, benzothienyl, benzothiazolyl, benzooxazolyl, benzoisooxazolyl, benzoimidazolyl, benzotriazolyl, indazole, indolyl or isindolyl; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl and their benzo[derivatives], such as quinolinyl, quinazolinyl or isoquinolinyl; or acrylinyl, inazinyl, purinyl and their benzo[derivatives]; or cyclolinyl, phthalazinyl, quinazolinyl, quinoxolinyl, naphthidyl, pteridinyl, carbazolyl, acrylinyl, phenazinyl, phenothiazinyl or phenothiazinyl. The term "5-6 heteroaryl" refers to an aromatic ring system having 5 or 6 ring atoms, and containing 1, 2 or 3, preferably 1-2 heteroatoms independently selected from N, O and S.

[0320] The term "halogen" or "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0321] The term "treatment" means administering the compound or preparation described in this application to improve or eliminate a disease or one or more symptoms related to said disease, and includes:

[0322] (i) Suppress the disease or disease state, that is, curb its development;

[0323] (ii) Relieve the disease or disease state, even if the disease or disease state subsides.

[0324] The term “prevention” means administering the compound or formulation described in this application to prevent a disease or one or more symptoms associated with the disease, including preventing the occurrence of a disease or disease state in mammals, particularly when such mammals are susceptible to the disease state but have not yet been diagnosed with the disease state.

[0325] The term "therapeutic effective dose" means:

[0326] The amount of the disclosed compound used to treat a specific disease, condition or symptom, (ii) reduce, improve or eliminate one or more symptoms of a specific disease, condition or symptom, or (iii) delay the onset of one or more symptoms of a specific disease, condition or symptom described herein.

[0327] The amount of the disclosed compound constituting a “therapeutic effective amount” varies depending on the compound, the disease state and its severity, the route of administration, and the age of the mammal to be treated, but may routinely be determined by a person skilled in the art based on their own knowledge and the content of this disclosure.

[0328] Examples of the term "mammal" include, but are not limited to, any member of the class Mammalia: humans, non-human primates (e.g., chimpanzees and other apes and monkeys); livestock, such as cattle, horses, sheep, goats, and pigs; domesticated animals, such as rabbits, dogs, and cats; and laboratory animals, including rodents, such as rats, mice, and guinea pigs. In one embodiment of the methods and compositions provided herein, the mammal may be a human.

[0329] The term "pharmaceutical acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.

[0330] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt that has undergone acid or base addition, including salts formed by compounds with inorganic or organic acids, and salts formed by compounds with inorganic or organic bases.

[0331] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present disclosure or salts thereof with pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the disclosed compounds to an organism.

[0332] The term "pharmaceuticalally acceptable excipient" refers to excipients that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0333] The word “comprise” or “include” and its English variants such as comprises or comprising can be understood as having an open, non-exclusive meaning, that is, “including but not limited to”.

[0334] This disclosure also includes compounds of this disclosure that are identical to those described herein, but in which one or more atoms are labeled with isotopes whose atomic weights or mass numbers differ from those commonly found in nature. Examples of isotopes that can be incorporated into compounds of this disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as... 2 H, 3 H, 11 C 13 C 14 C 13 N、 15 N、 15 O、 17 O、 18 O、 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, etc.

[0335] Certain isotope-labeled compounds of this disclosure (e.g., using...) 3 H and 14 C-labeling can be used in the analysis of compound and / or substrate tissue distribution. Tritiumization (i.e., 3 H) and carbon-14 (i.e. 14 C) Isotopes are particularly preferred due to their ease of preparation and detectability. Positron-emitting isotopes, such as... 15 O、 13 N、 11 C and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy. The isotopically labeled compounds of this disclosure can typically be prepared by replacing the unlabeled reagent with an isotopically labeled reagent using a procedure similar to those disclosed in the schemes and / or examples below.

[0336] The pharmaceutical compositions disclosed herein can be prepared by combining the compounds disclosed herein with suitable pharmaceutically acceptable excipients, for example, in solid, semi-solid, liquid or gaseous formulations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalers, gels, microspheres and aerosols.

[0337] Typical routes of administration of the disclosed compounds or their pharmaceutically acceptable salts or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0338] The pharmaceutical compositions disclosed herein can be manufactured using methods well known in the art, such as conventional mixing, dissolving, granulation, emulsification, freeze drying, etc.

[0339] In some embodiments, the pharmaceutical composition is in an oral form. For oral administration, the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of this disclosure to be formulated into tablets, pills, lozenges, sugar-coated tablets, capsules, liquids, gels, pastes, suspensions, etc., for oral administration to patients.

[0340] Solid oral compositions can be prepared using conventional mixing, filling, or tableting methods. For example, they can be obtained by mixing the active compound with solid excipients, optionally milling the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into granules to obtain the core of a tablet or sugar-coated formulation. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, flow aids, or flavoring agents.

[0341] The pharmaceutical composition may also be suitable for parenteral administration, such as in suitable unit dosage forms of sterile solutions, suspensions or lyophilized products.

[0342] In all methods of administration of the compounds of general formula (Ia) or (Ib) described herein, or their stereoisomers or pharmaceutically acceptable salts thereof, the daily dose is from 0.01 mg / kg to 1000 mg / kg body weight, in the form of single or separate doses. Detailed Implementation

[0343] The invention will now be described in detail with reference to embodiments, but this does not imply any adverse limitation of the present disclosure. The present disclosure has been described in detail herein, including specific embodiments thereof. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present disclosure without departing from the spirit and scope thereof.

[0344] Unless otherwise specified, all reagents used in this disclosure are commercially available and can be used without further purification.

[0345] Unless otherwise stated, the proportions of mixed solvents are volume-based.

[0346] Unless otherwise stated, % refers to wt%.

[0347] Compounds are processed manually or Software naming conventions are used; commercially available compounds use supplier catalog names.

[0348] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts are measured in units of 10⁻¹⁰. -6 (ppm). The solvents used for NMR determination were deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., and the internal standard was tetramethylsilane (TMS).

[0349] The eluent described below can be a mixture of two or more solvents, with the ratio being the volume ratio of each solvent. For example, in a mixed eluent, petroleum ether / ethyl acetate = 4 / 1, which means that the volume ratio of petroleum ether / ethyl acetate is 4:1.

[0350] Abbreviations:

[0351] THF: Tetrahydrofuran; t-BuOK: Potassium tert-butoxide; TFA: Trifluoroacetic acid; DCM: Dichloromethane; DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene; EtOH: Ethanol; CDI: N,N'-carbonyldiimidazole; DMF: N,N-dimethylformamide; Dioxane: 1,4-dioxane; DIEA or DIPEA: N,N-diisopropylethylamine; Rf: Ratio of solute migration distance to mobile phase migration distance; Pd(dppf)Cl2: [1,1'-bis(diphenyl) [Fe3+] ferrocene; (Bpin)2: pinacol diboronate; EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Pyridine: pyridine; TMSCl: trimethylchlorosilane; LiHMDS: lithium bis(trimethylsilylamino)amine; CMBP: cyanomethylenetri-n-butylphosphine; Toluene: toluene; Ms: methanesulfonyl; Ts: p-toluenesulfonyl; Tf: trifluoromethanesulfonyl; Cbz: benzyloxycarbonyl; TMSCF3: trifluoromethyltrimethylsilane; TsCl: p-Toluenesulfonyl chloride; PhN(OTf)2: N-phenylbis(trifluoromethanesulfonyl)imide; KHDMS: potassium bis(trimethylsilyl)amino; STAB: sodium triacetoxyborohydride; TsOH: p-toluenesulfonic acid; XantPhos: 4,5-bisdiphenylphosphine-9,9-dimethyloxanthracene; NMP: N-methylpyrrolidone; EA: ethyl acetate; Pd2(dba)3: tris(dibenzylideneacetone)dipalladium; Triphosgene: triphosgene; DMAP: 4-dimethylaminopyridine; ACN: ethyl acetate Nitriles; CMPI: 2-chloro-1-methylpyridine iodide; CDI: N,N'-carbonyldiimidazole; TMAD: N,N,N',N'-tetramethylazodicarbonamide; H2O2 / usre: urea peroxide; TFAA: trifluoroacetic anhydride; TEA: triethylamine; TCFH: N,N,N',N'-tetramethylchloromethanemidane hexafluorophosphate; NMI: N-methylimidazole; TBAF: tetrabutylammonium fluoride; CMBP: cyanomethylenetri-n-butylphosphine; PMB: p-methoxybenzyl; mCPBA: m-chloroperoxybenzoic acid.

[0352] Example 1: 1-(2,2-difluoroethyl)-6-((7-(2-(trifluoromethyl)pyridin-4-yl)-7-azaspiro[3.5]non-2-yl)oxy)-1H-pyrazolo[3,4-b]pyrazine

[0353] Step 1: Synthesis of intermediates 1-2:

[0354] Compound 1-1 (250 mg) was dissolved in 5 mL of tetrahydrofuran. Potassium tert-butoxide (232 mg) was added at 0 °C, and the mixture was stirred for 5 minutes. Then, 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (271 mg) was added. The mixture was heated to 60 °C and stirred for 2 hours until the reaction was complete. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) to obtain the title compound 1-2 (300 mg).

[0355] Step 2: Synthesis of intermediates 1-3:

[0356] Compounds 1-2 (300 mg) were dissolved in 6 mL of dichloromethane, and trifluoroacetic acid (1.50 mL) was slowly added dropwise at 0 °C. The reaction solution was stirred at room temperature for 2 hours until the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain the title compound 1-3 (180 mg).

[0357] Step 3: Synthesis of Compound 1

[0358] 2-Trifluoromethyl-4-bromopyridine (102 mg), compounds 1-3 (180 mg), and potassium carbonate (170 mg) were dissolved in N,N-dimethylformamide (2 mL). The reaction was carried out after stirring at 80 °C for 10 hours. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) and high performance liquid chromatography (column: YMC TAR-C18, 30 * 150 mm, 5 μm; mobile phase: [water (containing 7 mmol / L ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 70-85%) to obtain title compound 1 (65.0 mg).

[0359] 1 H NMR (400MHz, DMSO-d6) δ8.37(s,1H),8.29(s,1H),8.25(d,J=6.0Hz,1H),7.21(d,J=2.6Hz,1H),7.10-6.99(m,1H),6.69-6.3 0(m,1H),5.40-5.24(m,1H),4.93-4.72(m,2H),3.51-3.38(m,4H),2.61-2.54(m,2H),2.07-1.94(m,2H),1.79-1.62(m,4H).

[0360] MS m / z(ESI): 469.0 [M+H] +

[0361] Example 2-10:

[0362] The synthesis method of Example 1 was followed, except that 6-chloro-1-(2,2-difluoroethyl)pyrazolo[3,4-b]pyrazine in step 1 was replaced with the starting materials in the table below, and the following compounds 2-10 were synthesized in the same manner.

[0363] Synthesis of intermediate 5-1:

[0364] At 0°C, 160 mg of 2,2-difluoroethanol was added to 5 mL of N,N-dimethylformamide, followed by 70 mg of sodium hydride. After stirring for 1 hour, 300 mg of 2,6-dichloropyrazine was added, and the mixture was brought to room temperature and stirred for 2 hours until the reaction was complete. The reaction solution was added to 10 mL of water and extracted with ethyl acetate (20 mL x 2). The organic layers were combined, washed with saturated brine, filtered, dried over anhydrous sodium sulfate, filtered again, concentrated under reduced pressure, and the residue was subjected to column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain the title compound 5-1.

[0365] MS m / z (ESI): 195.1 [M+H] +

[0366] Synthesis of intermediate 6-1:

[0367] Under nitrogen protection, 2,6-dichloropyrazine (150 mg), 1-(2,2-difluoroethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1H-pyrazole (260 mg), palladium acetate (20.0 mg), and potassium carbonate (250 mg) were added to 5 mL of 1,4-dioxane. 1 mL of water was added, and the mixture was heated to 80 °C and stirred for 6 hours until the reaction was complete. The reaction solution was added to 10 mL of water, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was subjected to column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain the title compound 6-1.

[0368] MS m / z (ESI): 245.1 [M+H] +

[0369] Synthesis of intermediate 9-1:

[0370] Under nitrogen protection, 2,6-dichloropyrazine (150 mg), 3,3-difluorozahexacyclic butane hydrochloride (120 mg), and potassium carbonate (250 mg) were added to N,N-dimethylformamide (5 mL). The reaction was stirred at room temperature for 4 hours until completion. The reaction solution was added to 20 mL of water, and extracted with ethyl acetate (20 mL * 2). The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was subjected to column chromatography (petroleum ether / ethyl acetate = 10 / 1) to give the title compound 9-1.

[0371] MS m / z(ESI): 206.0 [M+H] +

[0372] Synthesis of intermediate 10-1:

[0373] 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine (1.00 g) and cesium carbonate (3.53 g) were dissolved in N,N-dimethylformamide (10 mL). 2,2-Difluoroethyltrifluoromethanesulfonate (1.28 g) was added at 0 °C, and the reaction was carried out after stirring at room temperature for 2 hours. The mixture was diluted with 100 mL of water, extracted with ethyl acetate (50 mL x 3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether / ethyl acetate: 20:1–10:1) to obtain the title compound 10-1.

[0374] 1 H NMR(400MHz,Chloroform-d)δ8.06(s,1H),6.67-5.88(m,1H),4.86-4.64(m,2H),4.19(s,3H).

[0375] MS m / z(ESI): 249.0 [M+H] +

[0376] Examples 11-14:

[0377] The synthesis method of Example 1 was used, except that 1-1 in step 1 was replaced with the starting materials in the table below, and the following compounds 11-14 were synthesized in the same way.

[0378] Example 16: Following the synthesis method of Example 1, except that 2-trifluoromethyl-4-bromopyridine in step 3 was replaced with the starting material in the table below, the following compound 16 was synthesized in the same manner.

[0379] Example 17: 1-(2,2-difluoroethyl)-5-methyl-6-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.5]non-7-yl)oxy)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one

[0380] Step 1: Synthesis of intermediate 17-3:

[0381] Compound 14-1 (400 mg) was dissolved in 5 mL of tetrahydrofuran. Potassium tert-butoxide (400 mg) was added at 0 °C, and the mixture was stirred for 5 minutes. Then, compound 2-1 (400 mg) was added, and the mixture was heated to 80 °C and stirred for 2 hours until the reaction was complete. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol: 50 / 1) to obtain the title compound 17-3 (300 mg).

[0382] Step 2: Synthesis of intermediate 17-4:

[0383] Compound 17-3 (300 mg) was dissolved in 6 mL of dichloromethane, and trifluoroacetic acid (2.00 mL) was slowly added dropwise at 0 °C. The reaction solution was stirred at room temperature for 2 hours until the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain the title compound 17-4 (300 mg), which was used directly in the next step.

[0384] Step 3: Synthesis of Compound 17:

[0385] 4-Bromo-2-(trifluoromethyl)pyridine (100 mg), compound 17-4 (200 mg), and potassium carbonate (200 mg) were dissolved in N,N-dimethylformamide (3 mL). The reaction was carried out overnight with stirring at 80 °C. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by high performance liquid chromatography (column: YMC TAR-C18, 30 * 150 mm, 5 μm; mobile phase: [water (containing 7 mmol / L ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 60-90%) to obtain the title compound 17 (70.0 mg).

[0386] 1H NMR (400MHz, DMSO-d6) δ8.22(d,J=5.7Hz,1H),8.05(s,1H),6.72(d,J=2.1Hz,1H),6.60-6.23(m,2H),5.26-5. 21(m,1H),4.65(td,J=15.0,3.6Hz,2H),3.79-3.73(m,4H),3.34(s,3H),2.09-1.88(m,4H),1.80-1.76(m,4H).

[0387] MS m / z (ESI): 499.3 [M+H] +

[0388] Examples 18-20:

[0389] Referring to the synthesis method of Example 17, except that compound 14-1 in step 1 is replaced with the starting material in the table below, the following compounds 18-20 are synthesized in the same way.

[0390] Compound 21: 1-(2,2-difluoroethyl)-6-methyl-5-((7-(2-(trifluoromethyl)pyridin-4-yl)-7-azaspiro[3.5]non-2-yl)oxy)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

[0391] Step 1: Synthesis of compound 21-2:

[0392] Compound 21-1 (1.00 g) was dissolved in 10 mL of tetrahydrofuran, and methylamine hydrochloride (1.15 g) and 1,8-diazabicyclo[5.4.0]undec-7-ene (3.24 g) were added. The mixture was heated to 60 °C and stirred for 1 hour until the reaction was complete. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 9:1 to 3:2) to obtain the title compound 21-2 (767 mg).

[0393] 1 H NMR (400MHz, Chloroform-d) δ8.33-8.00(m,2H),6.45-6.05(m,1H),5.14-4.85(m,2H),3.07(s,3H).

[0394] Step 2: Synthesis of compound 21-3:

[0395] Compound 21-2 (667 mg) was dissolved in ethanol (6 mL) and water (1.2 mL), and iron powder (795 mg) and ammonium chloride (1.52 g) were added. The mixture was heated to 80 °C and stirred for 2 hours until the reaction was complete. The reaction solution was concentrated under reduced pressure, and 20 mL of ethyl acetate was added. After washing with saturated brine and drying with anhydrous sodium sulfate, the solution was filtered and concentrated to obtain crude compound 21-3 (580 mg, 99%) as an oily substance, which could be used directly in the next reaction without further purification.

[0396] MS m / z(ESI): 205.1 [M+H] +

[0397] 1 H NMR(400MHz,Chloroform-d)δ8.23(s,1H),7.32(s,1H),6.40-5.98(m,1H),5.11-4.78(m,2H),3.20-2.81(m,5H).

[0398] Step 3: Synthesis of compound 21-4:

[0399] Compound 21-3 (580 mg) was dissolved in 20 mL of dichloromethane, and N,N'-carbonyldiimidazole (1.23 g) and N,N-diisopropylethylamine (1.84 g) were added. The mixture was stirred at room temperature for 1 hour, followed by stirring at 40 °C for 24 hours. The reaction was monitored by LC-MS to ensure complete reaction. The reaction solution was concentrated under reduced pressure and slurried with dichloromethane / petroleum ether (1:1) to obtain the title compound 21-4 (570 mg).

[0400] MS m / z(ESI): 231.0 [M+H] +

[0401] 1 H NMR (400MHz, Methanol-d4) δ7.51(s,1H),6.50-6.08(m,1H),5.00-4.91(m,2H),3.36(s,3H).

[0402] Step 4: Synthesis of compound 21-5:

[0403] Compound 21-4 (100 mg) was dissolved in 1 mL of phosphorus oxychloride, and N,N-diisopropylethylamine (168 mg) was added. The mixture was heated to 100 °C and stirred for 48 hours until the reaction was complete. The reaction solution was concentrated under reduced pressure, and the pH was adjusted to 7–8 with saturated sodium bicarbonate aqueous solution. The solution was extracted with dichloromethane (10 mL * 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (dichloromethane / methanol: 0–5%) to obtain the title compound 21-5 (80 mg).

[0404] 1 H NMR(400MHz,Chloroform-d)δ7.91(s,1H),6.40-5.93(m,1H),5.09-4.93(m,2H),3.76(s,3H).

[0405] Step 5: Synthesis of compound 21-6:

[0406] Compound 21-5 (50.0 mg) and 7-tert-butoxycarbonyl-7-azaspiro[3.5]-2-nonanol (58.0 mg) were dissolved in 2 mL of tetrahydrofuran, and potassium tert-butoxide (27.0 mg) was added. The reaction was completed after stirring at room temperature for 1 hour. The reaction solution was diluted with 10 mL of ethyl acetate, washed with saturated brine and dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (dichloromethane / methanol: 0-2%) to obtain the title compound 21-6 (55.0 mg).

[0407] Step 6: Synthesis of Compounds 21-7:

[0408] Compound 21-6 (45.0 mg) was dissolved in 1 mL of dichloromethane, and a 1,4-dioxane solution of hydrogen chloride (4 M, 0.25 mL) was added. The mixture was stirred at room temperature for 2 hours until the reaction was complete. The reaction solution was concentrated to obtain the title compound 21-7 (38.0 mg).

[0409] m / z:ES + [M+H] + =354.2

[0410] Step 7: Synthesis of Compound 21:

[0411] Compound 21-7 (45.0 mg) was dissolved in N,N-dimethylformamide (1 mL), potassium carbonate (32.0 mg) and 2-trifluoromethyl-4-bromopyridine (26.0 mg) were added, and the mixture was heated to 80 °C and stirred for 2 hours until the reaction was complete. The reaction solution was diluted with 10 mL of ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by high performance liquid chromatography (column: Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; mobile phase: [water (containing 7 mmol / L ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 50%-80%) to obtain title compound 21 (20.0 mg).

[0412] 1H NMR(400MHz,DMSO-d6)δ8.27-8.17(m,1H),7.93(s,1H),7.24-7.16(m,1H),7.09-6.99(m,1H),6.62-6.19(m,1H),5.37-5.2 1(m,1H),5.04-4.86(m,2H),3.50-3.42(m,2H),3.43-3.37(m,5H),2.50-2.42(m,2H),2.04-1.95(m,2H),1.71-1.61(m,4H).

[0413] MS m / z(ESI): 499.1 [M+H] +

[0414] Example 22: 1-Methyl-5-(5-methyl-1,3,4-thiadiazol-2-yl)-3-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.5]non-7-yl)oxy)pyrazin-2(1H)-one

[0415] Step 1: Synthesis of intermediate 22-2:

[0416] Compound 22-1 (1.41 g), 4-bromo-2-(trifluoromethyl)pyridine (2.25 g), and potassium carbonate (2.76 g) were added to N,N-dimethylformamide (20 mL). The reaction was carried out overnight with stirring at 80 °C until completion. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain the title compound 22-2 (1.50 g).

[0417] Step 2: Synthesis of intermediate 22-3:

[0418] Compound 22-2 (400 mg) was dissolved in 5 mL of tetrahydrofuran. Potassium tert-butoxide (400 mg) was added at 0 °C, and the mixture was stirred for 5 minutes. Then, 3,5-dibromo-1-methylpyrazine-2(1H)-one (400 mg) was added, and the mixture was heated to 80 °C and stirred for 2 hours until the reaction was complete. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol: 50 / 1) to obtain the title compound 22-3 (300 mg).

[0419] Step 3: Synthesis of intermediate 22-4:

[0420] Compound 20-3 (250 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (50.0 mg), pinacol diborate (150 mg), and potassium acetate (100 mg) were added to 1,4-dioxane (5 mL). The mixture was heated to 100 °C and stirred for 2 hours until the reaction was complete. The reaction solution was concentrated and purified by silica gel column chromatography (dichloromethane / methanol: 50 / 1) to obtain the title compound 22-4 (150 mg).

[0421] Step 4: Synthesis of Compound 22:

[0422] Under nitrogen protection, compound 22-4 (100 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (10.0 mg), 2-bromo-5-methyl-1,3,4-thiadiazole (40.0 mg), and potassium phosphate (100 mg) were added to a mixed solution of 1,4-dioxane (4 mL) and water (1 mL). The mixture was heated to 100 °C and stirred for 2 hours until the reaction was complete. The reaction solution was added to 10 mL of water and extracted with ethyl acetate (20 mL * 2). The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by high performance liquid chromatography (column: Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; mobile phase: [water (containing 7 mmol / L ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 50%-80%) to obtain title compound 22 (50.0 mg).

[0423] 1 H NMR(400MHz, DMSO-d6)δ8.23-8.21(m,2H),6.81(d,J=2.2Hz,1H),6.68-6.52(m,1H),4.99-4.93( m,1H),3.83(s,2H),3.79(s,2H),3.53(s,3H),2.73(s,3H),2.03-1.92(m,4H),1.77-1.57(m,4H).

[0424] MS m / z(ESI): 493.4 [M+H] +

[0425] Examples 23-24:

[0426] Referring to the synthesis method of Example 22, except that the compound 2-bromo-5-methyl-1,3,4-thiadiazole in step 4 was replaced with the starting material in the table below, the following compounds 23-24 were synthesized in the same manner.

[0427] Examples 25-27:

[0428] Referring to the synthesis method of Example 22, except that compound 22-1 in step 1 is replaced with the starting material in the table below, the following compounds 25-27 are synthesized in the same way.

[0429] Example 28: 1-Methyl-5-(5-methyl-1,3,4-thiadiazol-2-yl)-3-((7-(2-(trifluoromethyl)pyridin-4-yl)-7-azaspiro[3.5]non-2-yl)oxy)pyridin-2(1H)-one

[0430] Step 1: Synthesis of intermediate 28-2:

[0431] Compound 28-1 (1.41 g), 4-bromo-2-(trifluoromethyl)pyridine (2.25 g), and potassium carbonate (2.76 g) were added to N,N-dimethylformamide (20 mL). The reaction was carried out overnight with stirring at 80 °C until completion. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain the title compound 28-2 (1.00 g).

[0432] Step 2: Synthesis of intermediate 28-3:

[0433] Compound 28-2 (300 mg) was dissolved in anhydrous N,N-dimethylformamide (5 mL). Sodium hydride (80.0 mg) was added at 0 °C, and the mixture was stirred for 30 minutes. Then, 3,5-dibromo-1-methylpyridin-2(1H)-one (270 mg) was added, and the mixture was heated to 60 °C and stirred for 16 hours until the reaction was complete. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol: 50 / 1) to obtain the title compound 28-3 (150 mg).

[0434] Step 3: Synthesis of intermediate 28-4:

[0435] Compound 28-3 (150 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (50.0 mg), pinacol diborate (120 mg), and potassium acetate (100 mg) were added to 1,4-dioxane (5 mL). The mixture was heated to 100 °C and stirred for 2 hours until the reaction was complete. The reaction solution was concentrated and purified by silica gel column chromatography (dichloromethane / methanol: 50 / 1) to obtain the title compound 28-4 (100 mg).

[0436] Step 4: Synthesis of compound 28:

[0437] Under nitrogen protection, compound 28-4 (100 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (10.0 mg), 2-bromo-5-methyl-1,3,4-thiadiazole (40.0 mg), and potassium phosphate (100 mg) were added to a mixed solution of 1,4-dioxane (4 mL) and water (1 mL). The mixture was heated to 100 °C and stirred for 2 hours until the reaction was complete. The reaction solution was added to 10 mL of water and extracted with ethyl acetate (20 mL * 2). The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by high performance liquid chromatography (column: Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; mobile phase: [water (containing 7 mmol / L ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 50%-80%) to obtain title compound 28 (42.0 mg).

[0438] 1 H NMR (400MHz, MeOD-d4) δ8.18(d,J=7.0Hz,1H),7.96(d,J=2.1Hz,1H),7.45(d,J=2.6Hz,1H),7.29(d,J=2.1Hz,1H),7.25- 7.12(m,1H),4.90-4.86(m,1H),3.79-3.62(m,7H),2.78(s,3H),2.71-2.54(m,2H),2.20-2.04(m,2H),1.96-1.72(m,4H).

[0439] MS m / z(ESI): 492.2 [M+H] +

[0440] Example 29:

[0441] Referring to the synthesis method of Example 28, except that compound 28-1 in step 1 is replaced with the starting material in the table below, compound 29 is synthesized in the same way.

[0442] Example 30:

[0443] The synthesis method of Example 28 was followed, except that the compound 3,5-dibromo-1-methylpyridin-2(1H)-one in step 2 was replaced with the starting material in the table below, and the following compound 30 was synthesized in the same manner.

[0444] Example 31:

[0445] Referring to the synthesis method of Example 28, except that compound 28-1 in step 1 and 2-bromo-5-methyl-1,3,4-thiadiazole in step 4 are replaced with starting materials 1 and 2 in the table below, respectively, and compound 31 is synthesized in the same manner.

[0446] Example 32: 9-(2,2-difluoroethyl)-7-methyl-2-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.4]oct-6-yl)oxy)-7,9-dihydro-8H-purine-8-one

[0447] Step 1: Synthesis of intermediate 32-2:

[0448] Compound 32-1 (1.50 g), 4-bromo-2-(trifluoromethyl)pyridine (2.50 g), and potassium carbonate (2.76 g) were added to N,N-dimethylformamide (20 mL). The reaction was carried out overnight with stirring at 80 °C until completion. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain the title compound 32-2 (2.00 g).

[0449] Step 2: Synthesis of compound 23:

[0450] Compound 32-2 (372 mg) was dissolved in anhydrous N,N-dimethylformamide (5 mL), and potassium tert-butoxide (200 mg) and 2-chloro-9-(2,2-difluoroethyl)-7-methyl-7,9-dihydro-8H-purine-8-one (250 mg) were added. The mixture was heated to 60 °C and stirred for 6 hours until the reaction was complete. The reaction solution was cooled to room temperature, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol: 50 / 1) to obtain the title compound 32 (150 mg).

[0451] 1H NMR (400MHz, MeOD-d4) δ8.15(d,J=6.6Hz,1H),8.14(s,1H),7.02(d,J=2.5Hz,1H),6.76-6.66(m,1H),6.23(tt ,J=55.3,3.9Hz,1H),5.63-5.40(m,1H),4.43-4.09(m,6H),3.44(s,3H),2.51-2.15(m,4H),2.19-1.90(m,2H).

[0452] MS m / z (ESI): 484.9 [M+H] +

[0453] Example 33: 9-(2,2-difluoroethyl)-7-methyl-2-((2-(2-(trifluoromethyl)pyrimidin-5-yl)-2-azaspiro[3.4]oct-6-yl)oxy)-7,9-dihydro-8H-purine-8-one

[0454] The title compound 33 was prepared by referring to the synthesis method of Example 32, except that 4-bromo-2-(trifluoromethyl)pyridine in step 1 was replaced with 5-bromo-2-trifluoromethylpyrimidine.

[0455] 1 H NMR(400MHz,MeOD-d4)δ8.14(s,1H),8.05(s,2H),6.43-6.06(m,1H),5.51-5.46(m,1H),4.35-4.26(m,2H), 4.11-4.04(m,4H),3.45(s,3H),2.40-2.35(m,1H),2.30-2.22(m,3H),2.09-2.03(m,1H),2.02-1.97(m,1H).

[0456] MS m / z (ESI): 485.9 [M+H] +

[0457] Example 33-1: 3-(2,2-difluoroethyl)-1-methyl-5-((2-(2-(trifluoromethyl)pyrimidin-5-yl)-2-azaspiro[3.4]oct-6-yl)oxy)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-one

[0458] Example 33-2: 3-(2,2-difluoroethyl)-5-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.4]oct-6-yl)oxy)oxazolo[4,5-d]pyrimidin-2(3H)-one

[0459] Example 33-3: 3-(2,2-difluoroethyl)-5-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.4]oct-6-yl)oxy)oxazolo[4,5-b]pyrazin-2(3H)-one

[0460] Example 34: 1-(4-(5-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyrazin-2-yl)piperidin-1-yl)acetoone

[0461] Step 1: Synthesis of intermediate 34-2

[0462] Compound 34-1 (3.00 g) and 5-bromopyrazine-2,3-diamine (4.31 g) were dissolved in pyridine (30 mL). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (6.72 g) was added at 0 °C, followed by heating to 30 °C and stirring for 16 hours. The reaction was monitored by LCMS until completion. The reaction solution was concentrated and diluted with ethyl acetate (50 mL). The organic phase was washed successively with dilute hydrochloric acid (2 M, 30 mL) and saturated brine. The solution was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by rapid silica gel column chromatography. 80g The title compound 34-2 (1.20 g) was obtained by rapid silica gel column chromatography with a gradient of 0–10% dichloromethane / methanol at a flow rate of 60 mL / min.

[0463] 1 H NMR(400MHz,DMSO-d6)δ9.92(s,1H),7.69(s,1H),6.61(br s,2H),4.38-4.34(m,1H),3.86-3.82(m,1H),3.15-2.94(m,1H),2.71-2.53( m,2H),2.00(s,3H),1.93-1.80(m,2H),1.58-1.55(m,1H),1.42-1.40(m,1H).

[0464] Step 2: Synthesis of intermediate 34-3

[0465] Compound 34-2 (1.20 g, 3.51 mmol) was dissolved in glacial acetic acid (12 mL) at room temperature, heated to 100 °C and stirred for 16 hours. The reaction was monitored by LC-MS to ensure complete reaction. The reaction solution was concentrated to obtain the crude product, which was then purified by rapid silica gel column chromatography. 12g The title compound 34-3 (920 mg) was obtained by rapid silica gel column chromatography with a gradient of 0–5% dichloromethane / methanol at a flow rate of 30 mL / min.

[0466] MS m / z(ESI): 326.0 [M+H] +

[0467] Step 3: Synthesis of intermediate 32-4

[0468] Compound 34-3 (920 mg) was dissolved in DMF (10 mL), cesium carbonate (1.85 g) was added, and iodomethane (1.85 g) was added at 0 °C. The mixture was then heated to 30 °C and stirred for 16 hours. The reaction was monitored by LCMS until complete. Ethyl acetate (40 mL) was added to the reaction solution to dilute it. The organic phase was washed with saturated brine (30 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by rapid silica gel column chromatography. 12g The title compound 34-4 (950 mg) was obtained by rapid silica gel column chromatography with a gradient of 0–5% dichloromethane / methanol at a flow rate of 30 mL / min.

[0469] MS m / z (ESI): 338.2 [M+H] +

[0470] Step 4: Synthesis of Compound 34

[0471] Compound 34-4 (900 mg) and (4-methoxyphenyl)boronic acid (606 mg) were dissolved in 1,4-dioxane (10 mL), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (217 mg) and saturated sodium carbonate aqueous solution (2 mL) were added. The mixture was then stirred at 100 °C for 2 hours under nitrogen protection, and the reaction was monitored by LCMS until complete. Water (5 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by preparative high performance liquid chromatography (column: Ultimate C18 150 × 40 mm × 10 μm; mobile phase: [water (ammonia-ammonia bicarbonate)-acetonitrile]; acetonitrile gradient: 25%-45%) to give title compound 34 (268 mg).

[0472] 1H NMR (400MHz, DMSO-d6) δ8.87(s,1H),8.08(d,J=8.4Hz,2H),7.07(d,J=8.4Hz,2H),4.46(d,J=1 2.9Hz,1H),3.96(d,J=13.8Hz,1H),3.86(s,3H),3.82(s,3H),3.46-3.36(m,1H),3.31-3.20(m 1H),2.8-2.74(m,1H),2.06(s,3H),2.03-1.93(m,2H),1.90-1.76(m,1H),1.73-1.58(m,1H).

[0473] MS m / z (ESI): 366.3 [M+H] +

[0474] Example 35:

[0475] The synthesis method of Example 34 was used, except that the compound 5-bromopyrazine-2,3-diamine in step 1 was replaced with the starting material in the table below, and the following compound 35 was synthesized in the same way.

[0476] Example 36: 1-(4-(6-(4-methoxyphenyl)imidazo[1,2-b]pyridazin-2-yl)piperidin-1-yl)ethyl-1-one

[0477] Step 1: Synthesis of intermediate 36-2

[0478] Under nitrogen protection, compound 36-1 (2.20 g) was dissolved in tetrahydrofuran (20 mL), and bis(trimethylsilylaminolithium) THF solution (1 M, 11.6 mL) was added dropwise at -78 °C over 30 min. Stirring continued for 1 hour, followed by the addition of trimethylchlorosilane (1.26 g). The reaction mixture was stirred at 0 °C for 1.5 hours. The temperature was then lowered to -78 °C, and bromine (1.55 g) was added dropwise. Finally, the temperature was slowly raised to 25 °C, and stirring continued for 20 min. Product formation was detected by LC-MS. The reaction mixture was quenched with sodium thiosulfate solution (20 mL, 10%) and ammonium chloride solution (20 mL). Extraction was performed twice with ethyl acetate (80 mL × 2). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the title compound 36-2 (2.50 g), which was directly used in the next reaction.

[0479] MS m / z(ESI): 252.0 [M-56] +

[0480] Step 2: Synthesis of intermediate 36-3

[0481] Compound 36-2 (2.60 g) and 6-chloropyridazine-3-amine (1.10 g) were dissolved in ethanol (20 mL), and the reaction mixture was stirred at 90 °C for 2 hours under nitrogen protection. LC-MS showed that the reaction was complete. The reaction mixture was concentrated to obtain a crude product, which was purified by silica gel column chromatography (dichloromethane / methanol, 0–5%) to obtain the title compound 36-3 (1.90 g).

[0482] 1 H NMR (400MHz, DMSO-d6) δ8.19(s,1H),8.12(d,J=9.5Hz,1H),7.30(d,J=9.5Hz,1H),4. 02-3.98(m,2H),2.94-2.89(m,3H),2.02-1.94(m,2H),1.58-1.51(m,2H),1.41(s,9H)

[0483] MS m / z (ESI): 337.3 [M+H] + .

[0484] Step 3: Synthesis of intermediate 36-4

[0485] Under nitrogen protection, compound 36-3 (500 mg) was dissolved in 1,4-dioxane (5 mL) and water (1.5 mL), followed by the addition of (4-methoxyphenyl)boronic acid (338 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (182 mg) and cesium carbonate (1.45 g). The reaction mixture was stirred at 90 °C for 4 hours under nitrogen protection. LC-MS showed that the reaction was complete. The reaction mixture was quenched with saturated brine (20 mL), diluted with ethyl acetate (20 mL), and extracted twice with ethyl acetate (20 mL × 2). The organic phases were combined and washed with saturated brine (100 mL), dried, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether / tetrahydrofuran, 0–50%) to obtain the title compound 36-4 (400 mg).

[0486] MS m / z (ESI): 409.4 [M+H] + .

[0487] Step 4: Synthesis of intermediate 36-5

[0488] Under nitrogen protection, compound 36-4 (100 mg) was dissolved in hydrochloric acid / dioxane (2 M, 5 mL) solution, and the reaction mixture was stirred at 25 °C for 12 hours. LC-MS showed that the reaction was complete, and the crude product of title compound 3-5 (100 mg) was obtained by concentration. It was used directly in the next reaction without purification.

[0489] MS m / z (ESI): 309.3 [M+H] + .

[0490] Step 5: Synthesis of Compound 36

[0491] Intermediate 36-5 (75.0 mg) was dissolved in dichloromethane (3 mL), and acetic anhydride (74.5 mg) and triethylamine (123 mg) were added. The reaction mixture was stirred at 25 °C for 12 hours. LC-MS showed that the reaction was complete. The crude product was concentrated and purified by preparative high-performance liquid chromatography (column: Phenomenex Gemini NX 150 × 30 mm, 5 μm; mobile phase: [water (formic acid)-acetonitrile]; gradient: 11%-51%) to obtain the title compound 36 (26.5 mg).

[0492] 1 H NMR(400MHz, DMSO-d6)δ8.04(s,1H),8.00(d,J=9.5Hz,1H),7.99-7.95(m,2H),7.64(d,J=9.5Hz,1H),7.12-7.06(m,2H), 4.48-4,29(m,1H),3.95-3.82(m,1H),3.80(s,3H),3.10-2.67(m,3H),2.11-1.98(m,2H),2.03(s,3H),1.67-1.51(m,2H)

[0493] MS m / z (ESI): 351.3 [M+H] + .

[0494] Example 37: 1-(2,2-difluoroethyl)-6-(6-(phenoxymethyl)-2-azaspiro[3.3]hept-2-yl)-1H-pyrazolo[3,4-b]pyrazine

[0495] Step 1: Synthesis of intermediate 37-2

[0496] Under nitrogen protection, compound 37-1 (269 mg) and tert-butyl 6-(hydroxymethyl)-2-azaspiro[3.3]heptane-2-carboxylate (500 mg) were dissolved in toluene (5 mL), followed by the addition of cyanomethylene tri-n-butylphosphine (1.59 g). The reaction mixture was stirred for 12 hours under nitrogen protection and heating at 100 °C. LC-MS showed that the reaction was complete. The reaction mixture was quenched with sodium hydroxide solution (2 M, 20 mL), then diluted with ethyl acetate (40 mL). The organic phase was washed twice with sodium hydroxide solution (2 M, 20 mL × 2), and then washed with saturated brine (50 mL). The crude product was concentrated and purified by rapid silica gel column chromatography. 20g Rapid silica column chromatography with a gradient of 0–50% tetrahydrofuran / petroleum ether at a flow rate of 80 mL / min yielded the title compound 37-2 (370 mg).

[0497] MS m / z(ESI): 248.3 [M-56] + .

[0498] Step 2: Synthesis of intermediate 37-3

[0499] Compound 37-2 (150 mg) was dissolved in dichloromethane (2 mL), followed by the addition of trifluoroacetic acid (1 mL). The reaction mixture was stirred at 25 °C for 12 hours. LC-MS showed that the reaction was complete. The solution was concentrated to obtain crude product of title compound 37-3 (220 mg), which was directly used in the next reaction.

[0500] MS m / z(ESI): 203.6 [M+H] + .

[0501] Step 3: Synthesis of Compound 37

[0502] Compound 37-3 (180 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (187 mg) were dissolved in DMF (2 mL), followed by the addition of sodium carbonate (362 mg). The reaction was stirred at 100 °C for 2 hours. LCMS showed complete reaction. The reaction solution was quenched with water (10 mL), followed by dilution with ethyl acetate (10 mL). The aqueous phase was extracted with ethyl acetate (10 mL × 2). The organic phases were combined and washed with saturated brine (10 mL). The crude product was concentrated and purified by preparative high performance liquid chromatography (column: Phenomenex Gemini NX 150 × 30 mm, 5 μm; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile gradient: 47%-87%) to obtain title compound 37 (90.5 mg).

[0503] 1 H NMR (400MHz, DMSO-d6) δ8.13(s,1H),7.90(s,1H),7.33-7.24(m,2H),6.94(dd,J=8.0,3.4Hz,3H),6.43(tt,J=54.9,3.8Hz,1H),4.6 6(td,J=15.0,3.8Hz,2H),4.21(s,2H),4.16(s,2H),3.94(d,J=6.3Hz,2H),2.67-2.56(m,1H),2.46-2.37(m,2H),2.18-2.09(m,2H).

[0504] MS m / z (ESI): 386.4 [M+H] +

[0505] Example 38:

[0506] The synthesis method of Example 37 was used, except that the compound 6-(hydroxymethyl)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester in step 1 was replaced with the starting material in the table below, and the following compound 38 was synthesized in the same way.

[0507] Example 39: 4-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-2-(((2-(trifluoromethyl)pyridin-3-yl)oxy)methyl)morpholine

[0508] Step 1: Synthesis of intermediate 39-2

[0509] Under nitrogen protection, tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (500 mg) was dissolved in DMF (10 mL), and sodium hydride (138 mg) was added at 0 °C. The mixture was stirred at 0 °C for 30 min, followed by the addition of compound 39-1 (500 mg). The reaction mixture was stirred at 25 °C for 12 h, and LC-MS showed that the reaction was complete. The reaction mixture was quenched with saturated ammonium chloride solution (10 mL), diluted with ethyl acetate (20 mL), and the aqueous phase was extracted with ethyl acetate (20 mL × 2). The organic phases were combined, washed with saturated brine (100 mL), and concentrated to obtain the crude product. The crude product was purified by rapid silica gel column chromatography. 40g The title compound 39-2 (0.80 g) was obtained by rapid silica gel column chromatography with a gradient of 0–50% tetrahydrofuran / petroleum ether at a flow rate of 80 mL / min.

[0510] MS m / z(ESI): 307.2 [M-56] + .

[0511] Step 2: Synthesis of intermediate 39-3

[0512] Compound 39-2 (500 mg) was dissolved in hydrochloric acid / dioxane (2 M, 10 mL) solution, and the reaction mixture was stirred at 25 °C for 12 hours. LC-MS showed that the reaction was complete. The solution was concentrated to obtain crude product of title compound 39-3 (350 mg), which was directly used in the next reaction.

[0513] MS m / z(ESI): 263.7 [M+H] + .

[0514] Step 3: Synthesis of Compound 39

[0515] Compound 39-3 (150 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (188 mg) were dissolved in DMF (3 mL), and sodium carbonate (242 mg) was added. The reaction was stirred at 110 °C for 2 hours. LCMS showed that the reaction was complete. The reaction solution was quenched with water (10 mL), diluted with ethyl acetate (10 mL), and the aqueous phase was extracted with ethyl acetate (10 mL × 2). The organic phases were combined and washed with saturated brine (10 mL). The crude product was concentrated and purified by preparative high performance liquid chromatography (column: Phenomenex Gemini NX 150 × 30 mm, 5 μm; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile gradient: 30%-70%) to obtain title compound 39 (120 mg).

[0516] 1 H NMR (400MHz, DMSO-d6) δ8.46 (s, 1H), 8.30-8.27 (m, 1H), 8.18 (s, 1H), 7.89-7.85 (m, 1H), 7.72 (dd, J = 4.6, 8.4Hz, 1H), 6.78-6. 17(m,1H),4.75-4.59(m,3H),4.41-4.22(m,3H),4.06-3.88(m,2H),3.78-3.60(m,1H),3.20-3.13(m,1H),3.05-2.95(m,1H).

[0517] MS m / z (ESI): 445.3 [M+H] + .

[0518] Example 40:

[0519] The synthesis method of Example 39 was used, except that tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate in step 1 was replaced with the starting material in the table below, and compound 40 was synthesized in the same manner.

[0520] Examples 41-46:

[0521] The synthesis method of Example 39 was used, except that compounds 39-1 and tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compounds 41-46 were synthesized in the same manner.

[0522] Example 47: 2-(bicyclo[1.1.1]pentan-1-ylmethyl)-8-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-2,8-diazaspiro[4.5]decane-3-one

[0523] Step 1: Synthesis of intermediate 47-2

[0524] 907 mg of tert-butyl 3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate was dissolved in DMF (6 mL), and NaH (102 mg) was added at 0 °C with stirring for 0.5 h. Compound 47-1 (300 mg) was then added, and the mixture was stirred at 30 °C for 3 h. LC-MS showed that the reaction was complete. The reaction mixture was quenched with water (30 mL), extracted with ethyl acetate (30 mL * 2), and the combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product of title compound 47-2 (530 mg), which was directly used in the next reaction.

[0525] MS m / z (ESI): 335.2 [M+H] + .

[0526] Step 2: Synthesis of intermediate 47-3

[0527] Compound 47-2 (0.618 g) was dissolved in dichloromethane (20 mL), and 1,4-dioxane hydrochloride (20 mL) was added at 25 °C and stirred for 2 hours. LC-MS showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain crude product of title compound 47-3 (200 mg), which was used directly in the next step of the reaction.

[0528] MS m / z(ESI): 235.1 [M+H] + .

[0529] Step 3: Synthesis of Compound 47

[0530] Compound 47-3 (530 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (493 mg) were dissolved in DMF (8 mL), and sodium carbonate (544 mg) was added. The reaction mixture was stirred at 100 °C for 2 hours, and LC-MS showed that the reaction was complete. The reaction mixture was filtered and then subjected to C18 column chromatography (acetonitrile / 0.5% TFA aqueous solution = 0%–100%) to give the title compound 47 (199 mg).

[0531] 1H NMR(400MHz,MeOD-d4)δ8.38(s,1H),8.01(s,1H),6.43-6.12(m,1H),4.87-4.65(m,2H),3.98-3 .93(m,2H),3.81-3.74(m,2H),3.43(s,2H),3.33(s,2H),2.52-2.43(m,3H),1.82-1.78(m,10H).

[0532] MS m / z (ESI): 417.4 [M+H] + .

[0533] Examples 48-51:

[0534] Referring to the synthesis method of Example 47, except that compound 47-1 in step 1 is replaced with the starting material in the table below, the following compounds 48-51 are synthesized in the same way.

[0535] Synthesis of intermediate 48-1:

[0536] Step 1: Synthesis of intermediate 48-1

[0537] MsCl (262 mg) was added to an 8 mL solution of (3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methanol (380 mg) and TEA (231 mg) in DCM at 0 °C, and the mixture was stirred at room temperature for 2 h. After the reaction was complete, water (20 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL * 3). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give the title compound 48-1 (550 mg), a yellow oil.

[0538] 1 H NMR(400MHz,Chloroform-d)δ4.25(s,2H),3.03(s,3H),2.03(s,6H).

[0539] Synthesis of intermediate 49-1:

[0540] Step 1: Synthesis of intermediate 49-1-1

[0541] 10.0 g of 3-oxocyclobutane-1,1-dicarboxylic acid diisopropyl ester was dissolved in tetrahydrofuran (100 mL), and 2.94 g of TMSCF3 was added. The reaction mixture was stirred at 25 °C for 16 hours. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was quenched with water (100 mL) and then extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (petroleum ether / ethyl acetate: 5 / 1; Rf: 0.6) was purified to give the title compound 49-1-1 (4.20 g).

[0542] 1 H NMR (400MHz, DMSO-d6) δ6.79(s,1H),5.04-4.89(m,2H),2.89-2.81(m,2H),2.67-2.58(m,2H),1.21 -1.16(m,12H).

[0543] Step 2: Synthesis of intermediate 49-1-2

[0544] 49-1-1 (2.00 g) was dissolved in tetrahydrofuran (25 mL), and lithium aluminum hydride (486 mg) was added in portions at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred overnight at 25 °C. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was quenched with water (10 mL) and then extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (petroleum ether / ethyl acetate: 1 / 1; Rf: 0.6) was purified to give the title compound 49-1-2 (0.65 g).

[0545] 1 H NMR (400MHz, DMSO-d6) δ6.21(s,1H),4.63(t,J=5.2Hz,1H),4.52(t,J=5.5Hz,1H),3.52(d,J=5.0Hz,2H),3.31(d,2H),2.17 -1.99(m,2H),1.81-1.63(m,2H).

[0546] Step 3: Synthesis of intermediate 49-1-3

[0547] Under a nitrogen atmosphere, compound 49-1-2 (300 mg) was dissolved in pyridine (2 mL) and dichloromethane (5 mL). p-Toluenesulfonyl chloride (629 mg) was added in portions at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred at 25 °C for 2 hours. The reaction mixture was then stirred at 60 °C for 2 hours. LC-MS monitoring showed the reaction was complete. The reaction mixture was cooled to room temperature, and water (10 mL) was added. Extraction was then performed with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (petroleum ether / ethyl acetate: 4 / 1; Rf: 0.6) was purified to give the title compound 49-1-3 (600 mg).

[0548] 1H NMR(400MHz,DMSO-d6)δ7.86 -7.64(m,4H),7.60-7.39(m,4H),6.64(s,1H),4.12(s,2H),3.87(s,2H),2.47–2.40(m,6H),2.21 -2.12(m,2H),1.89-1.80(m,2H).

[0549] Step 4: Synthesis of intermediate 49-1

[0550] Under a nitrogen atmosphere, compound 49-1-3 (300 mg) was dissolved in tetrahydrofuran (50 mL). Sodium hydride (35.4 mg, 60% purity) was added in portions at 0 °C, and the reaction mixture was stirred at 60 °C for 2 hours. The reaction mixture was monitored by LC-MS and found to be complete. The reaction mixture was cooled to room temperature, and water (10 mL) was added. The filtrate was extracted with ethyl acetate (50.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 1 / 1; Rf: 0.6) to obtain the title compound 49-1 (190 mg).

[0551] 1 H NMR(400MHz, DMSO-d6)δ8.06 -7.76(m,2H),7.72 -7.44(m,2H),4.58-4.30(m,2H),3.86 -3.66(m,2H),2.43(s,3H),2.08-2.00(m,2H),1.82 -1.61(m,2H).

[0552] Synthesis of intermediate 51-1:

[0553] (1-Methyl-2-oxabicyclo[2.1.1]hex-4-yl)methanol (100 mg) was dissolved in dichloromethane (2.5 mL), and pyridine (0.5 mL) and methanesulfonyl chloride (164 mg) were added at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was monitored by LCMS and the reaction was complete. Water (20 mL) was added to the reaction mixture, and then hydrochloric acid (1 M) was added dropwise to adjust the pH to acidic. The mixture was then extracted with dichloromethane (10 mL × 3). The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 1 / 1; Rf: 0.6) to obtain the target compound 51-1 (140 mg).

[0554] MS m / z(ESI): 282.2 [M+H] +

[0555] Examples 52-54:

[0556] Referring to the synthesis method of Example 47, except that compounds 47-1 and tert-butyl 3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compounds 52-54 were synthesized in the same manner.

[0557] Synthesis of intermediate 52-1:

[0558] Step 1: Synthesis of intermediate 52-1-1

[0559] 5.00 g of 3-fluorobicyclo[1.1.1]pentane-1-carboxylic acid was dissolved in 195 mL of DCM. Under argon protection, DMF (281 mg) and (COCl)₂ (7.32 g) were added dropwise to the mixture in an ice-water bath. After the mixture was brought to room temperature and stirred for 4 hours, a mixture of 5.62 g of dimethylhydroxylamine hydrochloride and 14.9 g of DIEA in 195 mL of DCM was added to the mixture in an ice-water bath. After the addition was complete, the reaction mixture was brought to room temperature and stirred overnight. The reaction mixture was concentrated at low temperature to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 20:1 to 5:1) to obtain compound 52-1-1 (3.50 g).

[0560] MS m / z (ESI): 174.1 [M+H] +

[0561] Step 2: Synthesis of intermediate 52-1-2

[0562] Compound 52-1-2 (2.00 g) was dissolved in THF (10 mL), and methyl lithium diethyl ether solution (2.5 M, 46 mL) was added dropwise at 0 °C. After the addition was complete, the mixture was stirred at room temperature for 16 hours. The reaction solution was quenched with ice water, extracted with diethyl ether (50 mL × 2), and the combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude compound 52-1-2 diethyl ether solution (50 mL, 11.56 mmol), which was directly used in the next reaction.

[0563] Step 3: Synthesis of intermediate 52-1-3

[0564] To a crude diethyl ether solution (50 mL, 11.56 mmol) of compound 52-1-2, 2 mL of MeOH was added, followed by the addition of sodium borohydride (875 mg) in portions at 0 °C. After the addition was complete, the mixture was stirred at room temperature for 16 hours. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with diethyl ether (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude compound 52-1-3 (1.00 g), a colorless oil, which was used directly in the next reaction.

[0565] Step 4: Synthesis of intermediate 52-1

[0566] Under ice bath conditions, methanesulfonyl chloride (969 mg) was added to a solution of compound 52-1-3 (1.00 g) and triethylamine (1.16 g) in dichloromethane (20 mL). After the addition was complete, the mixture was stirred at room temperature for 16 hours. The reaction mixture was washed with water (50 mL) and extracted with dichloromethane (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound 52-1 (600 mg).

[0567] 1 H NMR (400MHz, Chloroform-d) δ5.08-5.00(m,1H),3.01(s,3H),2.19-2.03(m,6H),1.47-1.42(m,3H).

[0568] Example 55: 1-(2,2-difluoroethyl)-6-(3-(1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)azacyclobutane-1-yl)-1H-pyrazolo[3,4-b]pyrazine

[0569] Step 1: Synthesis of intermediate 55-2

[0570] Compound 55-1 (567 mg) and tert-butyl 3-(piperidin-4-yl)azacyclobutane-1-carboxylate (500 mg) were dissolved in N,N-dimethylformamide (5 mL), followed by the addition of sodium carbonate (661 mg). The reaction mixture was stirred at 100 °C for 2 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (30 mL) was added, followed by extraction with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 20 / 1; Rf: 0.6) to obtain the title compound 55-2 (500 mg), a colorless oil.

[0571] 1 H NMR(400MHz,Chloroform-d)δ8.42(dd,J=4.8,1.8Hz,1H),7.86(dd,J=7.8,1.9Hz,1H),6.98(dd,J=7.8,4.8Hz,1H),4.00-3.93(m,2H),3.71- 3.65(m,2H),3.54-3.36(m,2H),2.90-2.83(m,1H),2.58-2.52(m,1H), 2.47-2.33(m,1H),1.95-1.64(m,4H),1.43(s,9H),1.10-1.01(m,1H).

[0572] MS m / z (ESI): 329.9 [M+H-56] + .

[0573] Step 2: Synthesis of intermediate 55-3

[0574] Compound 55-2 (200 mg) was added to a solution of dioxane (1.3 mL, 4 M) and the reaction mixture was stirred at 25 °C for 1 hour under nitrogen protection. The reaction was monitored by LC-MS and found to be complete. After concentration under reduced pressure, crude compound 55-3 (160 mg) was obtained as a yellow oil, which was used directly in the next reaction step.

[0575] MS m / z(ESI): 286.0 [M+H] + .

[0576] Step 3: Synthesis of Compound 55

[0577] Compound 55-3 (150 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (102 mg) were dissolved in N,N-dimethylformamide (2 mL), followed by the addition of sodium carbonate (148 mg). The reaction mixture was stirred at 100 °C for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was cooled to room temperature, and water (30 mL) was added. The mixture was then extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 20 / 1; Rf: 0.6) and C-18 column chromatography (water (0.05% ammonium bicarbonate) / acetonitrile = 10 / 1) to obtain the title compound 55 (130 mg).

[0578] 1 H NMR(400MHz, DMSO-d6)δ8.50(dd,J=4.8,1.8Hz,1H),8.13(s,1H),8.04(dd,J=7 .8,1.8Hz,1H),7.92(s,1H),7.15(dd,J=7.8,4.8Hz,1H),6.44(tt,J=54.9,3.8H z,1H),4.71-4.62(m,2H),4.27-4.22(m,2H),4.00-3.90(m,2H),3.55-3.52(m,2 H),2.91-2.85(m,2H),2.63-2.59(m,1H),1.81-1.72(m,3H),1.28-1.20(m,2H).

[0579] MS m / z (ESI): 467.8 [M+H] + .

[0580] Example 56:

[0581] The synthesis method of Example 55 was used, except that tert-butyl 3-(piperidin-4-yl)azacyclobutane-1-carboxylate in step 1 was replaced with the starting material in the table below, and compound 56 was synthesized in the same manner.

[0582] Examples 57-60:

[0583] The synthesis method of Example 55 was used, except that compounds 55-1 and tert-butyl 3-(piperidin-4-yl)azacyclobutane-1-carboxylate in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compounds 57-60 were synthesized in the same manner.

[0584] Example 61: 1-(2,2-difluoroethyl)-6-(2-(6-(trifluoromethyl)pyridin-2-yl)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-yl)-1H-pyrazolo[3,4-b]pyrazine

[0585] Step 1: Synthesis of intermediate 61-2

[0586] Compound 61-1 (500 mg) was dissolved in a mixed solution of dioxane (5 mL) and water (1.5 mL), followed by the addition of 2-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentan-2-yl)-6-(trifluoromethyl)pyridine (678 mg), cesium carbonate (1.61 g), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (203 mg). The reaction mixture was stirred at 90 °C for 4 hours under nitrogen protection. LC-MS showed the reaction was complete. The reaction mixture was quenched with water (20 mL), diluted with ethyl acetate (20 mL), and extracted with ethyl acetate (20 mL × 2). The organic phase was then washed with saturated brine (50 mL). The crude product was concentrated and purified by rapid silica gel column chromatography. 40g The title compound 61-2 (0.60 g) was obtained by rapid silica gel column chromatography with a gradient of 0–80% tetrahydrofuran / petroleum ether at a flow rate of 80 mL / min.

[0587] 1 H NMR (400MHz, DMSO-d6) δ8.27-8.02(m,2H),7.80(d,J=7.4Hz,1H),6.77(s,1H),4.67(s,2H),4.23-4.19(m,2H),3.89-3.85(m,2H),1.45(s,9H).

[0588] MS m / z(ESI): 369.3 [M+H] + .

[0589] Step 2: Synthesis of intermediate 61-3

[0590] Under nitrogen protection, compound 61-2 (200 mg) was dissolved in hydrochloric acid / dioxane (2 M, 5 mL) solution, and the reaction mixture was stirred at 25 °C for 12 hours. LC-MS showed that the reaction was complete. The solution was concentrated to obtain crude product of title compound 61-3 (140 mg), which was directly used in the next reaction.

[0591] MS m / z(ESI): 269.3 [M+H] + .

[0592] Step 3: Synthesis of Compound 61

[0593] Compound 61-3 (140 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (140 mg) were dissolved in DMF (5 mL), followed by the addition of sodium carbonate (277 mg). The reaction was stirred at 100 °C for 16 hours, and LC-MS showed complete reaction. The reaction solution was quenched with water (10 mL), diluted with ethyl acetate (10 mL), and after separation, the aqueous phase was extracted again with ethyl acetate (10 mL × 2). The organic phases were combined and washed with saturated brine (10 mL), and concentrated to obtain the crude product. The crude product was purified by preparative high performance liquid chromatography (column: Phenomenex Gemini NX 150 × 30 mm, 5 μm; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile gradient: 37%-77%) to obtain the title compound 61 (63.9 mg).

[0594] 1 H NMR (400MHz, DMSO-d6) δ8.61(s,1H),8.22(s,1H),8.17(d,J=8.1Hz,1H),8.10(t,J=7.8Hz,1H),7.79(d,J= 7.6Hz,1H),6.83(s,1H),6.49(tt,J=54.9,3.8Hz,1H),5.10(s,2H),4.84-4.71(m,2H),4.44-4.31(m,4H).

[0595] MS m / z (ESI): 451.2 [M+H] + .

[0596] Example 62:

[0597] Referring to the synthesis method of Example 61, except that compound 61-1 in step 1 is replaced with the starting material in the table below, compound 62 is synthesized in the same way.

[0598] Example 63:

[0599] Referring to the synthesis method of Example 61, except that 2-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)-6-(trifluoromethyl)pyridine in step 1 was replaced with the starting material in the table below, and compound 63 was synthesized in the same manner.

[0600] Example 64: 1-(2,2-difluoroethyl)-6-(7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-1H-pyrazolo[3,4-b]pyrazin

[0601] Step 1: Synthesis of intermediate 64-2

[0602] Compound 64-1 (600 mg) and 2-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)-6-(trifluoromethyl)pyridine (1.14 g) were dissolved in a mixed solution of dioxane (10 mL) and water (2.5 mL), followed by the addition of potassium carbonate (1.15 g) and [1,1'-bis(di-tert-butylphosphine)ferrocene]palladium dichloride (272 mg). The reaction mixture was stirred at 85 °C for 3 hours under nitrogen protection. LC-MS showed that the reaction was complete. The reaction mixture was quenched with water (20 mL), diluted with ethyl acetate (20 mL), and after separation, the aqueous phase was extracted with 40 mL of ethyl acetate (20 mL × 2). The organic phases were combined and washed with saturated brine (100 mL), concentrated to obtain the crude product, which was then purified by rapid silica gel column chromatography. 40g The title compound 64-2 (700 mg) was obtained by rapid silica gel column chromatography with a gradient of 0–80% tetrahydrofuran / petroleum ether at a flow rate of 60 mL / min.

[0603] MS m / z(ESI): 282.3 [M+H] + .

[0604] Step 2: Synthesis of intermediate 64-3

[0605] Under nitrogen protection, compound 64-2 (300 mg) was dissolved in tetrahydrofuran (3 mL) solution, and a borane-tetrahydrofuran complex (1 M, 3.2 mL) was added under ice bath conditions. The reaction mixture was then stirred at 65 °C for 12 hours. LC-MS showed that the reaction was complete, and the crude product of title compound 64-3 (280 mg) was concentrated and used directly in the next reaction step.

[0606] MS m / z(ESI): 268.1 [M+H] + .

[0607] Step 3: Synthesis of Compound 64

[0608] Compound 64-3 (237 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (233 mg) were dissolved in DMF (4 mL), and potassium carbonate (612 mg) was added. The reaction was stirred at 100 °C for 12 hours. LCMS showed that the reaction was complete. The reaction solution was quenched with water (10 mL), diluted with ethyl acetate (10 mL), and after separation, the aqueous phase was extracted with 20 mL of ethyl acetate (10 mL × 2). The organic phases were combined and washed with saturated brine (10 mL), and concentrated to obtain the crude product. The crude product was purified by preparative high performance liquid chromatography (column: Phenomenex Gemini NX 150 × 30 mm, 5 μm; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile gradient: 43%-83%) to obtain the title compound 64 (113 mg).

[0609] 1 H NMR (400MHz, DMSO-d6) δ8.54(s,1H),8.20(s,1H),7.95(t,J=7.8Hz,1H),7.84(d,J=8.1Hz,1 H),7.58-7.53(m,2H),6.67-6.31(m,2H),4.97(s,2H),4.82-4.71(m,2H),4.29-4.11(m,4H).

[0610] MS m / z (ESI): 450.3 [M+H] + .

[0611] Example 65: 8-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3-(4-(trifluoromethyl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decane

[0612] Step 1: Synthesis of intermediate 65-2

[0613] Under a nitrogen atmosphere, compound 65-1 (1.00 g) was dissolved in tetrahydrofuran (20 mL). A solution of bis(trimethylsilyl)amino potassium tetrahydrofuran (1 M, 5.88 mL) was slowly added dropwise at -70 °C. After stirring the reaction mixture at -70 °C for 30 minutes, a solution of N-phenylbis(trifluoromethanesulfonyl)imide (1.82 g) in tetrahydrofuran (10 mL) was slowly added. The mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. LC-MS monitoring showed the reaction was complete. The reaction mixture was quenched by adding saturated ammonium chloride solution (20 mL) and water (30 mL). The reaction mixture was extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product. The crude product was subjected to column chromatography (petroleum ether / ethyl acetate: 10:1; Rf: 0.6) to give the title compound 65-2 (7.00 g).

[0614] MS m / z (ESI): 331.8 [M+H-56] + .

[0615] Step 2: Synthesis of intermediate 65-3

[0616] Under a nitrogen atmosphere, compound 65-2 (3.40 g), pinacol diborate (1.72 g), potassium acetate (2.59 g), 1,1'-bis(diphenylphosphine)ferrocene palladium dichloride (450 mg), and 1,1'-bis(diphenylphosphine)ferrocene (341 mg) were dissolved in 30 mL of 1,4-dioxane solution. The reaction mixture was stirred at 80 °C for 16 hours under a nitrogen atmosphere. LCMS monitoring showed that the reaction was complete. The reaction mixture was diluted with 100 mL of ethyl acetate, filtered, and the filtrate was concentrated under reduced pressure to give compound 65-3 (3.80 g), a yellow solid, which was used directly in the next reaction.

[0617] MS m / z (ESI): 309.9 [M+H-56] + .

[0618] Step 3: Synthesis of intermediate 65-4

[0619] Under a nitrogen atmosphere, compound 65-3 (500 mg), 2-bromo-4-(trifluoromethyl)pyridine (340 mg), cesium fluoride (233 mg), and 1,1'-bis(diphenylphosphine)ferrocene palladium dichloride (86.0 mg) were dissolved in 1,4-dioxane (10 mL). The reaction mixture was stirred at 80 °C for 16 hours under a nitrogen atmosphere. The reaction was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether / ethyl acetate: 5:1; Rf: 0.6) to give the title compound 65-4 (200 mg).

[0620] MS m / z(ESI): 328.9 [M+H-56]+ .

[0621] Step 4: Synthesis of intermediate 65-5

[0622] Compound 65-4 (200 mg) and palladium / carbon (126 mg, 10%) were dissolved in methanol (5 mL). The reaction mixture was stirred at 28 °C for 2 hours under a hydrogen atmosphere. The reaction was monitored by LCMS until complete. The reaction mixture was filtered, and the filtrate was concentrated under vacuum to obtain the title compound 65-5 (151 mg).

[0623] MS m / z (ESI): 330.9 [M+H-56] + .

[0624] Step 5: Synthesis of intermediate 65-6

[0625] Compound 65-5 (150 mg) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1.5 mL) was slowly added at 0 °C. The reaction mixture was stirred at 25 °C for 1 hour. LCMS monitoring showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the title compound 65-6 (289 mg), which was directly used in the next reaction step.

[0626] MS m / z(ESI): 286.9 [M+H] + .

[0627] Step 6: Synthesis of Compound 65

[0628] Compound 65-6 (155 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (84.6 mg) were dissolved in N,N-dimethylformamide (5 mL), and sodium carbonate (123 mg) was added. The reaction mixture was stirred at 100 °C for 2 hours. The reaction was complete as monitored by LCMS. After cooling to room temperature, water (30 mL) was added, and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate: 20:1; Rf: 0.6) to give the title compound 65 (60.0 mg).

[0629] 1H NMR (400MHz, DMSO-d6) δ8.83(d,J=5.1Hz,1H),8.49(s,1H),8.13(s,1H),7.76-7.72(m,1H),7.66-7.61(m,1H),6.44(tt,J=54.9,3.8Hz,1H),4.76- 4.64(m,2H),4.30-4.20(m,1H),4.09-3.96(m,2H),3.94-3.85(m,2H),3. 72-3.62(m,2H),2.37-2.28(m,1H),2.14-2.03(m,1H),1.84-1.68(m,4H).

[0630] MS m / z (ESI): 468.8 [M+H] + .

[0631] Examples 66-68:

[0632] The synthesis method of Example 65 was followed, except that 2-bromo-4-(trifluoromethyl)pyridine in step 3 was replaced with the starting material in the table below, and the following compounds 66-68 were synthesized in the same manner.

[0633] Examples 69-70:

[0634] Referring to the synthesis method of Example 65, except that compound 65-1 in step 1 and 2-bromo-4-(trifluoromethyl)pyridine in step 3 are replaced with starting materials 1 and 2 in the table below, respectively, and compounds 69-70 are synthesized in the same manner.

[0635] Example 71: 2-(1-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)piperidin-4-yl)-7-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline

[0636] Step 1: Synthesis of intermediate 71-2

[0637] Under nitrogen protection, compound 71-1 (500 mg, hydrochloride) and tert-butyl 4-oxopiperidin-1-carboxylate (545 mg) were dissolved in tetrahydrofuran (10 mL), followed by the addition of acetic acid (88.4 mg) and sodium triacetoxyborohydride (1.43 g), and the mixture was stirred at 25 °C for 12 hours. LC-MS showed complete reaction. The reaction was quenched with saturated sodium bicarbonate (20 mL), diluted with ethyl acetate (20.0 mL), and extracted twice with ethyl acetate (20 mL × 2). The organic phase was then washed with saturated brine (50.0 mL). The organic phase was dried and concentrated to obtain the crude product. The crude product was purified by rapid silica gel column chromatography. 40g Rapid silica column chromatography with a gradient of 0–80% petroleum ether / tetrahydrofuran at a flow rate of 40 mL / min yielded the title compound 71-2 (0.78 g).

[0638] MS m / z (ESI): 385.4 [M+H] +

[0639] Step 2: Synthesis of intermediate 71-3

[0640] Under nitrogen protection, compound 71-2 (220 mg) was dissolved in hydrochloric acid / dioxane (2 M, 5 mL) solution, and the reaction mixture was stirred at 25 °C for 12 hours. TLC (petroleum ether: tetrahydrofuran = 1:1) showed that the reaction was complete. The solution was concentrated to obtain crude product of title compound 71-3 (250 mg, hydrochloride), which was directly used in the next step of the reaction.

[0641] Step 3: Synthesis of Compound 71

[0642] Compound 71-3 (220 mg) was dissolved in DMF (2 mL), and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (203 mg) and sodium carbonate (410 mg) were added. The reaction was stirred at 100 °C for 12 hours. LCMS showed that the reaction was complete. The mixture was filtered, and the reaction solution was purified by preparative high performance liquid chromatography (column: Phenomenex Gemini NX 150×30 mm, 5 μm; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile gradient: 16%-56%) to obtain title compound 71 (159 mg).

[0643] 1H NMR (400MHz, DMSO-d6) δ8.49 (s, 1H), 8.14 (s, 1H), 7.48-7.39 (m, 2H), 7.31 (d, J = 8.4Hz, 1H), 6.71-6.22 (m, 1H), 4.76-4. 64(m,2H),4.62-3.54(m,2H),3.80(s,2H),3.12-3.00(m,2H),2.93-2.71(m,5H),1.99-1.89(m,2H),1.68-1.43(m,2H).

[0644] MS m / z (ESI): 467.2 [M+H] + .

[0645] Example 72: 6-(8-(bicyclo[1.1.1]pent-1-ylmethyl)-3,8-diazabicyclo[3.2.1]oct-3-yl)-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine

[0646] Step 1: Synthesis of intermediate 72-2

[0647] Compound 72-1 (1 g) and bicyclo[1.1.1]pentane-1-carboxylic acid (528 mg) were dissolved in pyridine (15 mL), and EDCI (1.81 g) was added at 0 °C. The reaction mixture was stirred at 30 °C for 16 hours under nitrogen protection. The reaction was monitored by LCMS until complete. The reaction mixture was concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography. 40g The title compound 72-2 (1.20 g) was obtained by rapid silica gel column chromatography with a gradient of 0–12% petroleum ether / tetrahydrofuran at a flow rate of 60 mL / min.

[0648] MS m / z (ESI): 307.3 [M+H] +

[0649] Step 2: Synthesis of intermediate 72-3

[0650] Compound 72-2 (500 mg) was dissolved in tetrahydrofuran (5.00 mL), and borane-tetrahydrofuran (1 M, 4.08 mL) was added at 0 °C. The reaction mixture was stirred at 60 °C for 16 hours under hydrogen protection. The reaction was monitored by TLC until complete. The reaction was quenched by slow dropwise addition of methanol (4.00 mL) at 0 °C, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure to obtain crude compound 72-3 (477 mg), which was used directly in the next step of the reaction.

[0651] Step 3: Synthesis of intermediate 72-4

[0652] Compound 72-3 (477 mg) was dissolved in dichloromethane (10.0 mL), and trifluoroacetic acid (3.72 g, 2.42 mL) was added. The reaction mixture was stirred at 30 °C for 16 hours. The reaction was monitored by LCMS until complete. The reaction mixture was concentrated under reduced pressure to obtain crude compound 72-4 (300 mg), which was used directly in the next step of the reaction.

[0653] MS m / z(ESI): 193.2 [M+H] +

[0654] Step 4: Synthesis of Compound 72

[0655] Intermediate 72-4 (110 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (125 mg) were dissolved in DMF (3.00 mL), and sodium carbonate (182 mg) was added. The reaction mixture was stirred at 100 °C for 4 hours. The reaction was monitored by LCMS until complete. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by preparative high performance liquid chromatography (column: Welch Xtimate C18 150×25 mm×5 μm; mobile phase: [water (ammonia-ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 63%-83%) to obtain title compound 72 (12.4 mg).

[0656] 1H NMR(400MHz,DMSO-d6)δ8.31(s,1H),8.11(s,1H),6.62-6.24(m,1H),4.79-4.73(m,2H),4.74-4.59(m,2H),2.7 9-2.67(m,2H),2.45(s,1H),2.35-2.88(m,2H),2.25(s,2H),2.03-1.95(m,2H),1.92-1.84(m,2H),1.69(s,6H).

[0657] MS m / z (ESI): 375.3 [M+H] +

[0658] Examples 73-74: The synthesis method of Example 72 was followed, except that 72-1 and bicyclo[1.1.1]pentane-1-carboxylic acid in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compounds 73-74 were synthesized in the same manner.

[0659] Example 75: 1'-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4'-piperidine]

[0660] Step 1: Synthesis of Compound 75

[0661] Compound 75-1 (100 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (96.8 mg) were dissolved in N,N-dimethylformamide (2 mL), followed by the addition of sodium carbonate (143 mg). The reaction mixture was stirred at 100 °C for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. After cooling to room temperature, water (30 mL) was added, followed by extraction with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 20 / 1; Rf: 0.6) and C18 column chromatography (water (0.05% ammonium bicarbonate) / MeCN = 1 / 10) to obtain compound 75 (140 mg).

[0662] 1 H NMR (400MHz, DMSO-d6) δ8.52(s,1H),8.15(s,1H),7.24-7.07(m,2H),6.87-6.76(m,2H),6.44(tt,J=54. 9,3.8Hz,1H),4.75-4.67(m,2H),4.10-4.05(m,2H),3.82-3.75(m,2H),3.07(s,2H),1.95-1.83(m,4H).

[0663] MS m / z(ESI): 371.8 [M+H] +

[0664] Example 76: 6-(2-(bicyclo[1.1.1]pentan-1-ylmethyl)-2,7-diazaspiro[3.5]nonane-7-yl)-1-(oxecyclobutane-3-yl)-1H-pyrazolo[3,4-b]pyrazine

[0665] Step 1: Synthesis of intermediate 76-2

[0666] Compound 76-1 (1.00 g) and 3,4-dihydro-2H-pyran (1.09 g) were dissolved in tetrahydrofuran (15.0 mL), and p-toluenesulfonic acid monohydrate (123 mg) was added. The reaction mixture was stirred at 25 °C for 16 hours. LC-MS showed that the reaction was complete. After the reaction was complete, the mixture was concentrated at low temperature to obtain the crude product. The crude product was purified by rapid silica gel column chromatography. 12g Compound 76-2 (1.46 g) was obtained by rapid silica gel column chromatography with a gradient of 0–10% ethyl acetate / petroleum ether at a flow rate of 36 mL / min.

[0667] Step 2: Synthesis of intermediate 76-3

[0668] Compound 76-2 (0.70 g) and 2-(bicyclo[1.1.1]pent-1-ylmethyl)-2,7-diazaspiro[3.5]nonane (1.51 g) were dissolved in acetonitrile (20.0 mL), and sodium carbonate (933 mg) was added. The reaction mixture was stirred at 80 °C for 16 hours. LCMS showed that the reaction was complete. After the reaction was complete, the reaction mixture was filtered and concentrated to obtain the crude product. The crude product was purified by rapid silica gel column chromatography. 12g Compound 76-3 (233 mg) was obtained by rapid silica gel column chromatography with a gradient of 0–50% tetrahydrofuran / petroleum ether at a flow rate of 36 mL / min.

[0669] MS m / z (ESI): 409.4 [M+H] +

[0670] Step 3: Synthesis of intermediate 76-4

[0671] Compound 76-3 (0.618 g) was dissolved in dichloromethane (4.00 mL), and trifluoroacetic acid (1.28 g, 836 μL) was added at 25 °C and stirred for 16 hours. LC-MS showed that the reaction was complete. After the reaction was complete, the reaction solution was concentrated, dissolved in ethyl acetate (10.0 mL), washed with saturated sodium bicarbonate solution (2.00 mL × 2), and the organic phase was dried and concentrated to obtain crude compound 76-4 (200 mg), which was directly used in the next reaction.

[0672] Step 4: Synthesis of Compound 76

[0673] Compound 76-4 (200 mg) and 3-iodohexacyclobutane (227 mg, 106 μL) were dissolved in acetonitrile (2.00 mL), and cesium carbonate (603 mg, 1.85 mmol) was added. The reaction mixture was stirred at 80 °C for 16 hours. LC-MS showed that the reaction was complete. After the reaction was complete, the crude product was obtained by filtration. The crude product was purified by preparative high performance liquid chromatography (column: C18 150 × 40 mm; mobile phase: [water (ammonia + ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 23%-63%) to obtain the target compound 76 (22.9 mg).

[0674] 1H NMR(400MHz,DMSO-d6)δ8.43(s,1H),8.17(s,1H),5.94-5.84(m,1H),5.07-4.93(m,4H ),3.72-3.62(m,4H),2.97(s,4H),2.45-2.41(m,3H),1.77-1.70(m,4H),1.66(s,6H).

[0675] MS m / z (ESI): 381.3 [M+H] + .

[0676] Example 77: The synthesis method of Example 76 was followed, except that 2-(bicyclo[1.1.1]pent-1-ylmethyl)-2,7-diazaspiro[3.5]nonane in step 2 was replaced with the reactants in the table below, and compound 77 was synthesized in the same manner.

[0677] Example 78: 1-(2,2-difluoroethyl)-6-(2-(4-(trifluoromethyl)pyridin-2-yl)-2-azaspiro[3.5]non-6-en-7-yl)-1H-pyrazolo[3,4-b]pyrazine

[0678] Step 1: Synthesis of intermediate 78-2

[0679] Under a nitrogen atmosphere, compound 78-1 (1.00 g) was dissolved in tetrahydrofuran (10 mL), and a solution of bis(trimethylsilyl)aminopotassium tetrahydrofuran (1 M, 6.27 mL) was slowly added dropwise at -70 °C. After stirring the reaction mixture at -70 °C for 30 min, a solution of N-phenylbis(trifluoromethanesulfonyl)imide (1.94 g) in tetrahydrofuran (5 mL) was slowly added. The reaction mixture was stirred at room temperature for 1 h under a nitrogen atmosphere. The reaction was monitored by LCMS and found to be complete. The reaction was quenched by adding saturated ammonium chloride aqueous solution (20 mL) and diluted with water (30 mL). The mixture was then extracted with ethyl acetate (20 mL × 3), the organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether / ethyl acetate: 10 / 1; Rf: 0.6) to give compound 78-2 (950 mg).

[0680] MS m / z(ESI): 316.0 [M+H-56] +

[0681] Step 2: Synthesis of intermediate 78-3

[0682] Under a nitrogen atmosphere, 301 mg of pinacol diboronate, 317 mg of potassium acetate, 78.8 mg of 1,1'-bis(diphenylphosphine)ferrocene palladium dichloride, and 59.7 mg of 1,1'-bis(diphenylphosphine)ferrocene were added to a 5 mL solution of compound 78-2 (400 mg). The reaction mixture was stirred at 80 °C for 16 hours under a nitrogen atmosphere. The reaction was monitored by LCMS and found to be complete. The mixture was diluted with 100 mL of ethyl acetate. After filtration, the filtrate was concentrated under reduced pressure to give compound 78-3 (360 mg).

[0683] MS m / z(ESI): 294.2 [M+H-56] +

[0684] Step 3: Synthesis of intermediate 78-4

[0685] Under a nitrogen atmosphere, compound 78-3 (350 mg), 6-chloro-1-(2,2-difluoroethyl)pyrazolo[3,4-b]pyrazine (263 mg), cesium fluoride (197 mg), and 1,1'-bis(diphenylphosphine)ferrocene palladium dichloride (73.3 mg) were dissolved in 1,4-dioxane (5 mL) and water (1 mL). The reaction mixture was reacted at 80 °C for 1 hour under a nitrogen atmosphere. The reaction was complete as monitored by LCMS. The reaction mixture was cooled to room temperature, water (50 mL) was added, and then extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 5 / 1; Rf: 0.6) to give compound 78-4 (360 mg).

[0686] MS m / z (ESI): 350.2 [M+H-56] +

[0687] Step 4: Synthesis of intermediate 78-5

[0688] Compound 78-4 (150 mg) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was slowly added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure to give compound 78-5 (150 mg), a yellow oil.

[0689] MS m / z (ESI): 306.2 [M+H] +

[0690] Step 5: Synthesis of Compound 78

[0691] Compound 78-5 (150 mg), 2-bromo-4-(trifluoromethyl)pyridine (88.9 mg), and potassium carbonate (148 mg) were dissolved in N,N-dimethylformamide (2 mL). The reaction mixture was stirred overnight at 80 °C. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 20 / 1; Rf: 0.6) and high performance liquid chromatography (column: YMC TAR-C18, 30 × 150 mm, 5 μm; mobile phase: [water (ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 70-100%) to obtain the target compound 78 (63.0 mg).

[0692] 1 H NMR(400MHz,Chloroform-d)δ8.84(s,1H),8.31-8.25(m,2H),6.90-6.84(m,1H),6.79-6.73(m,1H),6.45(s,1H),6.28(tt,J=55.5,4.4Hz ,1H),4.85(td,J=13.3,4.4Hz,2H),3.94(d,J=7.9Hz,2H),3.86(d,J=7.9Hz,2H),2.84-2.78(m,2H),2.73-2.65(m,2H),2.15-2.05(m,2H).

[0693] MS m / z (ESI): 451.2 [M+H] +

[0694] Example 78(2): The synthesis method of Example 78 was followed, except that the compound 78-1 in step 1 and the 2-bromo-4-(trifluoromethyl)pyridine in step 5 were replaced with starting materials 1 and 2 in the table below, respectively, and the following compound 78(2) was synthesized in the same way.

[0695] Example 79: 4-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-1-(4-(trifluoromethyl)pyridin-2-yl)piperazin-2-one

[0696] Step 1: Synthesis of intermediate 79-2

[0697] Compound 52-A (100 mg), 2-bromo-4-(trifluoromethyl)pyridine (169 mg), palladium acetate (11.2 mg), 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthracene (43.4 mg), and cesium carbonate (244 mg) were dissolved in 1,4-dioxane (2.00 mL), purged with nitrogen three times, and stirred at 110 °C for 10 hours. The reaction mixture was monitored by LCMS and the reaction was complete. After cooling to room temperature, water (50.0 mL) was slowly added to quench the reaction, followed by extraction with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 10 / 1; Rf: 0.5) to obtain compound 79-2 (120 mg).

[0698] MS m / z(ESI): 290.1 ​​[M+H-56] +

[0699] Step 2: Synthesis of intermediate 79-3

[0700] Compound 79-2 (120 mg) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1.00 mL) was slowly added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure to obtain compound 79-3 (120.00 mg), which was directly used in the next step of the reaction.

[0701] MS m / z(ESI): 246.1 [M+H] +

[0702] Step 3: Synthesis of Compound 79

[0703] Compound 79-3 (100 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (60.8 mg) were dissolved in N,N-dimethylformamide (2.00 mL), followed by the addition of sodium carbonate (88.5 mg). The reaction mixture was stirred at 100 °C for 2 hours. The reaction was monitored by LCMS and found to be complete. After the reaction solution was cooled to room temperature, water (50.0 mL) was added, followed by extraction with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 20 / 1; Rf: 0.5) and high performance liquid chromatography (column: YMC TAR-C18, 30 × 150 mm, 5 μm; mobile phase: [water (ammonium bicarbonate) - acetonitrile]; acetonitrile gradient: 50-80%) to obtain the target compound 79 (50.0 mg), a white solid.

[0704] 1H NMR(400MHz,Chloroform-d)δ8.61(d,J=5.2Hz,1H),8.50-8.48(m,1H),8.21(s,1H),8.12(s,1H),7.38-7.34(m,1H),6.23 (tt,J=55.5,55.5,4.4,4.4Hz,1H),4.72(td,J=13.4,13.3,4.4Hz,2H),4.65(s,2H),4.48-4.43(m,2H),4.12-4.07(m,2H).

[0705] MS m / z (ESI): 428.1 [M+H] +

[0706] Example 80: 6-(6-(bicyclo[1.1.1]pentan-1-ylmethyl)-6-azaspiro[3.4]octane-2-yl)-1-(2,2-difluoroethyl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

[0707] Step 1: Synthesis of intermediate 80-2

[0708] Compound 80-1 (5.50 g) and methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylic acid (6.28 g) were dissolved in THF (110 mL), and DBU (7.40 g) was added. The reaction mixture was heated and stirred at 60 °C for 16 hours. LC-MS showed that the reaction was complete. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to give compound 80-2 (4.70 g).

[0709] MS m / z (ESI): 374.2 [M+H-56] +

[0710] Step 2: Synthesis of intermediate 80-3

[0711] Compound 80-2 (4.70 g) was dissolved in an ethanol / water solution (4 / 1, 80 mL), and iron powder (3.10 g) and ammonium chloride (5.90 g) were added. The reaction mixture was heated and stirred at 80 °C for 1 hour. LC-MS showed that the reaction was complete. After the reaction was complete, the reaction mixture was filtered and concentrated to obtain compound 80-3 (4.30 g).

[0712] MS m / z (ESI): 398.1 [MH] -

[0713] Step 3: Synthesis of intermediate 80-4

[0714] Compound 80-3 (4.30 g) was dissolved in formamide (60 mL), and the reaction mixture was stirred in a microwave at 120 °C for 1 hour. LC-MS showed that the reaction was complete. After the reaction was complete, water (300 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (100 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1) to give compound 80-4 (1.20 g).

[0715] MS m / z (ESI): 354.1 [M+H-56] +

[0716] Step 4: Synthesis of intermediate 80-5

[0717] Compound 80-4 (1.20 g) was dissolved in DCM (24.0 mL), and 1,4-dioxane hydrochloride (24 mL) was added. The reaction mixture was stirred at 30 °C for 1 hour. LCMS showed that the reaction was complete. After the reaction was complete, the reaction mixture was concentrated under reduced pressure to obtain crude compound 80-5 (1.10 g), which was directly used in the next reaction step.

[0718] Step 5: Synthesis of Compound 80

[0719] Compound 80-5 (30.0 mg) and bicyclo[1.1.1]pentane-1-ylmethylmethanesulfonate (51.3 mg) were dissolved in anhydrous NMP (1.00 mL), and DIEA (62.6 mg) was added. The reaction mixture was stirred in a microwave oven at 120 °C for 1 hour. LCMS showed that the reaction was complete. After the reaction was complete, the reaction mixture was purified by preparative high performance liquid chromatography (column: C18; mobile phase: [water (ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 10-100%) to obtain the target compound 80 (3.00 mg).

[0720] 1 H NMR(400MHz,MeOD-d4)δ8.17(s,1H),7.97(s,1H),6.46-6.13(m,1H),5.06-4.9 7(m,4H),2.78-2.74(m,4H),2.60-2.57(m,6H),2.15-2.12(m,2H),1.83(s,6H).

[0721] MS m / z(ESI): 390.1 [M+H] +

[0722] Examples 81-83: The synthesis method of Example 80 was followed, except that the bicyclo[1.1.1]pentane-1-ylmethylmethanesulfonate in step 5 was replaced with the reactants in the table below, and compounds 81-83 were synthesized in the same manner.

[0723] Examples 84-94: The synthesis method of Example 80 was followed, except that compound 80-1 in step 1 and bicyclo[1.1.1]pentane-1-ylmethylmethanesulfonate in step 5 were replaced with reactants 1 and 2 in the table below, respectively, and compounds 84-94 were synthesized in the same manner.

[0724] Synthesis of intermediate 96-1:

[0725] Step 1: Synthesis of intermediate 96-1-2

[0726] Methanesulfonyl chloride (142 mg) was added to a DCM mixture of compound 96-1-1 (200 mg) and TEA (252 mg) at 0 °C (4 mL), and the mixture was stirred at room temperature for 2 h. After the reaction was complete, the reaction mixture was diluted with water (20 mL) and extracted with dichloromethane (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give crude compound 96-1-2 (228 mg), which was used directly in the next reaction.

[0727] Step 2: Synthesis of intermediate 96-1-3

[0728] NaN3 (480 mg) was added to a DMF (20 mL) solution of compound 96-1-2 (1.18 g), and the mixture was heated and stirred at 100 °C for 16 h. LC-MS showed the formation of the target product. The reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain crude compound 96-1-3 (825 mg), a yellow oil, which was used directly in the next reaction.

[0729] Step 3: Synthesis of intermediate 96-1

[0730] Pd / C (10%, 200 mg) was added to a MeOH (20 mL) solution of compound 96-1-3 (825 mg), and the mixture was stirred at 30 °C for 16 h under H2 protection. LC-MS showed that the reaction was complete. The reaction solution was filtered and concentrated under reduced pressure to obtain the crude product. The crude product was subjected to silica gel column chromatography (ethyl acetate / petroleum ether = 0%–50%) to obtain compound 96-1 (220 mg).

[0731] MS m / z(ESI): 241.2 [M+H]+

[0732] Example 99: 1-(2,2-difluoroethyl)-6-(7-(2-(trifluoromethyl)pyridin-4-yl)-5-oxaspiro[3,4]octane-2-yl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

[0733] Step 1: Synthesis of intermediate 99-2

[0734] Compound 99-1 (4.00 g) was dissolved in toluene (60 mL), and methoxyformylmethylenetriphenylphosphine (CMMTPP, 10.83 g) was added under nitrogen protection. The reaction mixture was heated to 110 °C and stirred for 8 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 19:1 to 4:1) to obtain compound 99-2 (4.30 g).

[0735] 1 H NMR(400MHz,Chloroform-d)δ5.74-5.68(m,1H),5.13-4.96(m,1H),4.34-4.17(m,1H),3.69(s ,3H),3.63-3.5(m,1H),3.25-3.11(m,1H),3.02-2.90(m,1H),2.82-2.72(m,1H),1.45(s,9H).

[0736] Step 2: Synthesis of intermediate 99-3

[0737] Under nitrogen protection, methyl 2-hydroxyacetic acid (941 mg) was slowly added to a suspension of NaH (251 mg) in diethyl ether (15 mL). The mixture was stirred at room temperature for 30 minutes, and then the solvent was removed under reduced pressure. The reaction mixture was cooled to 0 °C, and dimethyl sulfoxide (20 mL) and 99-2 (2.10 g) were added to the mixture. The mixture was stirred overnight at room temperature. The aqueous layer was separated with 5% hydrochloric acid aqueous solution and diethyl ether, and extracted twice with diethyl ether. The organic layers were combined. The organic layer was dried with anhydrous sodium sulfate. The organic layer was concentrated under reduced pressure. A pale yellow oil was dissolved in a mixture of dimethyl sulfoxide (30 mL) and water (3 mL). Sodium chloride (1.02 g) was added to the reaction mixture, and the mixture was heated to 120 °C for 2 hours under nitrogen protection. The reaction mixture was cooled to room temperature. The mixture was separated with brine and diethyl ether. The aqueous layer was extracted twice with diethyl ether. The organic layers were combined. The organic layer was washed once with water. The organic layer was dried with anhydrous sodium sulfate. The organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (MeOH / DCM = 0%–3%) to give compound 99-3 (1.20 g).

[0738] MS m / z(ESI):142.2 / 186.1[M+H-Boc / M+H-56] +

[0739] Step 3: Synthesis of intermediate 99-4

[0740] Compound 99-3 (500 mg) was dissolved in tetrahydrofuran (5 mL). A tetrahydrofuran solution of bis(trimethylsilyl)amino potassium (1 M, 3.11 mL) was slowly added dropwise at -70 °C under a nitrogen atmosphere. The reaction mixture was stirred at -70 °C for 0.5 h. Subsequently, a tetrahydrofuran solution of N-phenylbis(trifluoromethanesulfonyl)imide (962 mg) was slowly added dropwise. The reaction mixture was brought to room temperature and stirred for 0.5 h. LC-MS monitoring showed the reaction was complete. The reaction was quenched with saturated brine (50 mL) and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated brine, dried, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 1:10) to obtain compound 99-4 (700 mg), a colorless oily liquid.

[0741] 1 H NMR (400MHz, Chloroform-d) δ5.90-5.81(m,1H),4.67-4.54(m,2H),4.22-3.78(m,2H),2.88-2.59(m,2H),2.53-2.15(m,2H),1.44(s,9H).

[0742] MS m / z(ESI):274.0 / 318.1[M+H-Boc / M+H-56] +

[0743] Step 4: Synthesis of intermediate 99-5

[0744] Under nitrogen protection, compound 99-4 (600 mg), pinacol diborate (449 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (118 mg), and potassium acetate (473 mg) were added to 1,4-dioxane (6 mL). The reaction mixture was heated to 80 °C and stirred for 3 hours. LC-MS analysis showed the reaction was complete. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (5 mL) was added. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain compound 99-5 (550 mg). The crude product did not require further purification and was used directly in the next reaction step.

[0745] MS m / z(ESI):252.2 / 296.2[M+H-Boc / M+H-56] +

[0746] Step 5: Synthesis of intermediate 99-6

[0747] Compound 99-5 (550 mg), 4-bromo-2-(trifluoromethyl)pyridine (425 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (115 mg), and cesium fluoride (715 mg) were dissolved in 1,4-dioxane (5 mL) and water (1 mL). The reaction mixture was heated to 80 °C and stirred for 1 hour. The reaction mixture was monitored by LCMS and the reaction was complete. Saturated brine (5 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried, and concentrated under reduced pressure. The residue was purified by column chromatography (methanol / dichloromethane: 0%–2%) to obtain the title compound 99-6 (520 mg).

[0748] 1 H NMR(400MHz,Chloroform-d)δ8.75-8.65(m,1H),7.63-7.50(m,1H),7.36-7.29(m,1H),6.68-6.54(m,1H),5 .06-4.94(m,2H),4.83-4.67(m,1H),4.24-3.87(m,1H),2.92-2.66(m,2H),2.63-2.24(m,2H),1.44(s,9H).

[0749] MS m / z (ESI): 371.2 [M+H] +

[0750] Step 6: Synthesis of intermediate 99-7

[0751] Compound 99-6 (200 mg) and Pd / C (10%, 132 mg) were dissolved in methanol (5 mL), and the mixture was stirred at room temperature for 6 hours after hydrogen was introduced. The reaction solution was monitored by LCMS and the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain compound 99-7 (200 mg).

[0752] 1 H NMR(400MHz,Chloroform-d)δ8.73-8.57(m,1H),7.60-7.47(m,1H),7.43-7.30(m,1H),4.82-4.63(m,1H),4.25-4.06 (m,1H),3.91-3.73(m,2H),3.56-3.39(m,1H),2.55-2.40(m,2H),2.36-2.23(m,1H),2.14-1.97(m,3H),1.44(s,9H).

[0753] MS m / z (ESI): 373.2 [M+H] +

[0754] Step 7: Synthesis of intermediate 99-8

[0755] Compound 99-7 (150 mg) was dissolved in dichloromethane (2 mL), and 1,4-dioxane hydrochloride solution (4 M, 2 mL) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. The reaction was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure to give compound 99-8 (120 mg, hydrochloride).

[0756] MS m / z(ESI): 273.2 [M+H] +

[0757] Step 8: Synthesis of intermediate 99-9

[0758] Compound 99-8 (100 mg) and methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylic acid (114 mg) were dissolved in tetrahydrofuran (2 mL), and DBU (197 mg) was added. The reaction mixture was heated to 60 °C and stirred for 3 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure, and the concentrate was purified by column chromatography (ethyl acetate / petroleum ether: 20%-60%) to obtain compound 99-9 (134 mg).

[0759] 1 H NMR(400MHz,Chloroform-d)δ8.78-8.56(m,1H),8.44-8.32(m,1H),8.20(s,1H),7.60-7.46(m,1H),7.46-7.33(m,1H),6.58-5.92(m,1H),5.06-4 .83(m,2H),4.65-4.18(m,2H),3.92-3.80(m,1H),3.60-3.46(m,1H),2.9 6-2.63(m,2H),2.63-2.38(m,2H),2.39-2.20(m,1H),2.19-1.99(m,1H).

[0760] MS m / z (ESI): 476.2 [M+H] +

[0761] Step 9: Synthesis of intermediate 99-10

[0762] Compound 99-9 (120 mg), iron powder (70 mg), and ammonium chloride (135 mg) were dissolved in ethanol (4 mL) and water (1 mL). The reaction mixture was heated to 80 °C and stirred for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to remove ethanol. Ethyl acetate was added for extraction (20 mL × 3). The organic phases were combined, dried, and concentrated under reduced pressure to obtain compound 99-10 (100 mg).

[0763] MS m / z (ESI): 446.2 [M+H] +

[0764] Step 10: Synthesis of Compound 99

[0765] Compound 99-10 (100 mg) was dissolved in formamide (2 mL), and the reaction solution was heated to 150 °C and stirred for 2 hours. The reaction was monitored by LC-MS and found to be complete. After cooling to room temperature, water (10 mL) was added, followed by extraction with ethyl acetate (5 mL × 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by preparative liquid chromatography (Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; using a mixture of water (containing 7 mmol / L ammonium bicarbonate) and acetonitrile with decreasing polarity (45%–75%) as eluent) to obtain target compound 99 (50.0 mg).

[0766] 1 H NMR(400MHz,Chloroform-d)δ8.74-8.63(m,1H),8.10-7.87(m,2H),7.66-7.56(m,1H),7.44-7.34(m,1H),6.50-5.94(m,1H),5.1 8-4.70(m,3H),4.36-4.19(m,1H),3.96-3.80(m,1H),3.66-3.47(m,1H),3.05-2.78(m,3H),2.77-2.52(m,2H),2.35-2.09(m,1H).

[0767] MS m / z (ESI): 456.2 [M+H] +

[0768] Example 100: 1-(2,2-difluoroethyl)-6-(5-oxo-6-(2-(trifluoromethyl)pyridin-4-yl)-6-azaspiro[3,4]octane-2-yl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

[0769] Step 1: Synthesis of intermediate 100-2

[0770] Compound 100-1 (300 mg), 4-bromo-2-trifluoromethylpyridine (423 mg), cuprous iodide (47.5 mg), trans-(1R,2R)-N,N'-dimethyl-cyclohexane-1,2-diamine (71.0 mg), and potassium phosphate (1.06 g) were dissolved in 1,4-dioxane (5 mL). The mixture was purged with nitrogen three times, and the reaction solution was heated and stirred overnight at 100 °C. The reaction solution was monitored by LCMS, and the reaction was complete. The reaction solution was cooled to room temperature, water (10 mL) was added, and then extracted with ethyl acetate (30 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (dichloromethane / methanol: 10 / 1; Rf: 0.6) was purified by reversed-phase chromatography (mobile phase: [water-acetonitrile]; acetonitrile gradient: 45-55%) to obtain the title compound 100-2 (380 mg).

[0771] MS m / z(ESI): 386.2 [M+H-Bu] +

[0772] Step 2: Synthesis of intermediate 100-3

[0773] Compound 100-2 (340 mg) was dissolved in 20 mL of 4 M hydrogen chloride / ethyl acetate solution under a nitrogen atmosphere, and the reaction mixture was stirred at 25 °C for 1 hour. The reaction was monitored by LC-MS and found to be complete. The reaction mixture was concentrated under reduced pressure to give compound 100-3 (220 mg).

[0774] MS m / z(ESI): 286.2 [M+H] +

[0775] Step 3: Synthesis of intermediate 100-4

[0776] Under a nitrogen atmosphere, compound 100-3 (200 mg), methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylate (235 mg), and DBU (427 mg) were dissolved in THF (10 mL). The reaction mixture was heated and stirred at 60 °C for 2 hours, and the reaction was monitored by LCMS until complete. The reaction mixture was cooled to room temperature, and water (10.0 mL) was added. The mixture was then extracted with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (dichloromethane / methanol: 10 / 1; Rf: 0.6) was purified to give the title compound 100-4 (280 mg).

[0777] MS m / z (ESI): 489.2 [M+H] +

[0778] Step 4: Synthesis of intermediate 100-5

[0779] Under a nitrogen atmosphere, compound 100-4 (280 mg) was added to ethanol (5 mL) and water (1 mL). At 25 °C, iron powder (160 mg) and ammonium chloride (307 mg) were added, and the reaction mixture was stirred at 70 °C for 2 hours. The reaction mixture was monitored by LCMS, and the reaction was complete. The reaction mixture was cooled to room temperature, filtered to remove the iron powder, and the filtrate was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1) to obtain the title compound 100-5 (240 mg).

[0780] MS m / z (ESI): 459.2 [M+H] +

[0781] Step 5: Synthesis of Compound 100

[0782] Compound 100-5 (100 mg) was dissolved in formamide (5 mL), and the reaction mixture was heated and stirred at 150 °C for 2 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (10 mL) was added, followed by extraction with ethyl acetate (20 mL * 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1; Rf: 0.6) and C-18 column chromatography (water (0.05% ammonium bicarbonate) / MeCN = 1 / 1) to obtain the target compound 100 (54.1 mg).

[0783] 1 H NMR (400MHz, DMSO-d6) δ8.71 (d, J = 5.6Hz, 1H), 8.40-8.35 (m, 1H), 8.31 (s, 1H), 8.19-8.14 (m, 1H), 7.88-7. 82(m,1H),6.62-6.27(m,1H),5.35-4.96(m,3H),3.99-3.84(m,2H),2.88-2.60(m,4H),2.49-2.34(m,2H).

[0784] MS m / z (ESI): 469.1 [M+H] +

[0785] Example 101: 2-(1-(2,2-difluoroethyl)-7-oxo-1,7-dihydro-6H-pyrazolo[4,3-d]pyrimidin-6-yl)-8-(2-(trifluoromethyl)pyridin-4-yl)-5-oxa-8-azaspiro[3.5]nonane-7-one

[0786] Step 1: Synthesis of intermediate 101-2

[0787] Compound 101-1 (500 mg), 4-bromo-2-(trifluoromethyl)pyridine (661 mg), Pd2(dba)3 (179 mg), XantPhos (226 mg), and cesium carbonate (1.91 g) were dissolved in dioxane (10.0 mL), purged three times with nitrogen, and the reaction mixture was stirred overnight at 100 °C. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was cooled to room temperature, water (10 mL) was added, and then extracted with ethyl acetate (30 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (dichloromethane / methanol: 50 / 1; Rf: 0.6) was purified by reversed-phase chromatography (mobile phase: [water-acetonitrile]; acetonitrile gradient: 45-55%) to obtain compound 101-2 (0.40 g).

[0788] MS m / z(ESI): 402.2 [M+H] +

[0789] Step 2: Synthesis of intermediate 101-3

[0790] Compound 101-2 (300 mg) was dissolved in 10 mL of 4 M hydrogen chloride / ethyl acetate solution under a nitrogen atmosphere, and the reaction mixture was stirred at 25 °C for 1 hour. The reaction was monitored by LC-MS and found to be complete. The reaction mixture was concentrated under reduced pressure to obtain compound 101-3 (220 mg), which was directly used in the next reaction step.

[0791] MS m / z(ESI): 302.1 [M+H] +

[0792] Step 3: Synthesis of intermediate 101-4

[0793] Under a nitrogen atmosphere, compound 101-3 (50.0 mg), methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylic acid (52.2 mg), and DBU (90.1 mg) were dissolved in THF (5 mL), and the reaction mixture was stirred at 60 °C for 2 hours. The reaction mixture was monitored by LCMS, and the reaction was complete. The reaction mixture was cooled to room temperature, water (10 mL) was added, and then extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (dichloromethane / methanol: 10 / 1; Rf: 0.6) was purified to obtain compound 101-4 (70.0 mg).

[0794] MS m / z (ESI): 505.2 [M+H]+

[0795] Step 4: Synthesis of intermediate 101-5

[0796] Under a nitrogen atmosphere, compound 101-4 (80.0 mg) was added to ethanol (2 mL) and water (0.5 mL). At 25 °C, iron powder (44.3 mg) and ammonium chloride (84.8 mg) were added, and the reaction mixture was stirred at 70 °C for 2 hours. The reaction mixture was monitored by LCMS, and the reaction was complete. The reaction mixture was cooled to room temperature, filtered to remove the iron powder, and the filtrate was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1) to obtain compound 101-5 (60.0 mg).

[0797] MS m / z (ESI): 475.2 [M+H] +

[0798] Step 5: Synthesis of Compound 101

[0799] Compound 101-5 (50.0 mg) was dissolved in formamide (2 mL), and the reaction mixture was stirred at 150 °C for 2 hours. The reaction mixture was monitored by LCMS and the reaction was complete. After cooling the reaction mixture to room temperature, water (10 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1; Rf: 0.6) and C-18 column chromatography (water (0.05% ammonium bicarbonate) / MeCN = 1 / 1) to obtain the target compound 101 (8.00 mg).

[0800] 1 H NMR(400MHz,DMSO-d6)δ8.79(d,J=5.7Hz,1H),8.44-8.02(m,3H),8.01-7.77(m,1H),6.60 -6.23(m,1H),5.10-4.82(m,3H),4.50-4.31(m,2H),4.16-4.04(m,2H),2.91-2.63(m,4H).

[0801] MS m / z (ESI): 485.2 [M+H] +

[0802] Examples 102-106: The synthesis method of Example 101 was followed, except that compounds 101-1 and 4-bromo-2-(trifluoromethyl)pyridine in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compounds 102-106 were synthesized in the same manner.

[0803] Example 107: 2-(trifluoromethyl)pyridin-4-yl 4-(1-(2,2-difluoroethyl)-7-oxo-1,7-dihydro-6H-pyrazolo[4,3-d]pyrimidin-6-yl)piperidine-1-carboxylic acid ester

[0804] Step 1: Synthesis of intermediate 107-2

[0805] Compound 107-1 (500 mg) and tert-butyl 4-aminopiperidine-1-carboxylic acid (638 mg) were dissolved in tetrahydrofuran (10 mL), and DBU (1.29 g) was added. The reaction mixture was heated to 65 °C and stirred for 3 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure, and the concentrate was purified by column chromatography (ethyl acetate / petroleum ether: 20%-60%) to obtain compound 107-2 (750 mg).

[0806] 1 H NMR(400MHz,Chloroform-d)δ8.19(s,1H),8.06-7.94(m,1H),6.41-5.95(m,1H),5.02-4.84(m ,2H),4.25-3.92(m,3H),3.05-2.93(m,2H),2.10-1.86(m,2H),1.69-1.48(m,2H),1.46(s,9H).

[0807] MS m / z (ESI): 348.2 [M+H-56] +

[0808] Step 2: Synthesis of intermediate 107-3

[0809] Compound 107-2 (500 mg), iron powder (346 mg), and ammonium chloride (663 mg) were dissolved in ethanol (20 mL) and water (5 mL). The reaction mixture was heated to 80 °C and stirred for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to remove ethanol. Ethyl acetate was added for extraction (30 mL × 3). The organic phases were combined, dried, and concentrated under reduced pressure to obtain compound 107-3 (450 mg).

[0810] 1H NMR(400MHz,Chloroform-d)δ8.52-8.37(m,1H),7.34(s,1H),6.40-5.92(m,1H),5.00-4.67(m ,2H),4.11-3.88(m,3H),3.08-2.88(m,4H),2.02-1.92(m,2H),1.55-1.47(m,2H),1.46(s,9H).

[0811] MS m / z(ESI): 274.1 [M+H-100] +

[0812] Step 3: Synthesis of intermediate 107-4

[0813] Compound 107-3 (450 mg) was dissolved in formamide (9 mL), and the reaction mixture was heated to 150 °C and stirred for 2 hours. After cooling to room temperature, water (20 mL) was added, followed by extraction with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Concentrated hydrochloric acid (20 mL) was added to the concentrate, and the reaction mixture was heated to 100 °C and stirred for 2 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure to give compound 107-4 (300 mg).

[0814] MS m / z(ESI): 284.2 [M+H] +

[0815] Step 4: Synthesis of Compound 107

[0816] Compound 107-4 (75.0 mg) and triphosgene (78.0 mg) were dissolved in tetrahydrofuran (3 mL), and triethylamine (40.0 mg) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the concentrate was dissolved in acetonitrile (3 mL). 2-(trifluoromethyl)pyridine-4-ol (46.0 mg), potassium carbonate (36.0 mg), and 4-dimethylaminopyridine (6 mg) were added. The reaction mixture was heated to 80 °C and stirred for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. After cooling to room temperature, water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by preparative liquid chromatography (Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; using a mixture of water (containing 7 mmol / L ammonium bicarbonate) and acetonitrile in decreasing polarity (40%-75%) as eluent) to obtain the target compound 107 (22.0 mg).

[0817] 1H NMR(400MHz,Chloroform-d)δ8.76-8.70(m,1H),8.01(s,1H),7.95(s,1H),7.60-7.54(m,1H),7.42-7.3 5(m,1H),6.39-6.04(m,1H),5.13-4.96(m,3H),4.62-4.35(m,2H),3.44-2.90(m,2H),2.18-1.94(m,4H).

[0818] MS m / z(ESI): 473.2 [M+H] +

[0819] Example 108: 2-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-7-(2-(trifluoromethyl)pyridin-4-yl)-5-oxa-2-azaspiro[3,4]oct-7-ene

[0820] Step 1: Synthesis of intermediate 108-1

[0821] Under a nitrogen atmosphere, compound 69-1 (2.00 g) was dissolved in tetrahydrofuran (20 mL), and a solution of bis(trimethylsilyl)amino potassium tetrahydrofuran (1 M, 13.2 mL) was slowly added dropwise at -70 °C. After stirring the reaction mixture at -70 °C for 30 min, a solution of N-phenylbis(trifluoromethanesulfonyl)imide (4.09 g) in tetrahydrofuran (15 mL) was slowly added. The reaction mixture was stirred at room temperature for 1 h under a nitrogen atmosphere. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction was quenched with ammonium chloride (20 mL) and water (30 mL). The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 10:1; Rf: 0.6) to give compound 108-1 (1.14 g).

[0822] MS m / z (ESI): 303.7 [M+H-56] +

[0823] Step 2: Synthesis of intermediate 108-2

[0824] Under a nitrogen atmosphere, 855 mg of pinacol diboronate, 1.34 g of potassium acetate, and 224 mg of [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride were added to a 20 mL solution of 1,4-dioxane (1.10 g) of compound 108-1. The reaction mixture was stirred at 80 °C for 16 hours under a nitrogen atmosphere. The reaction was monitored by LCMS and found to be complete. The mixture was diluted with 100 mL of ethyl acetate. After filtration, the filtrate was concentrated under reduced pressure to give 2.50 g of compound 108-2.

[0825] 1 H NMR (400MHz, Chloroform-d) δ7.32-7.31(m,1H),4.81-4.75(m,2H),4.11-4.06(m,2H),4.04-3.96(m,2H),1.28(s,9H),1.27(s,12H).

[0826] MS m / z(ESI): 282.1 [M+H-56] +

[0827] Step 3: Synthesis of intermediate 108-3

[0828] Under a nitrogen atmosphere, compound 108-2 (600 mg), 4-bromo-2-(trifluoromethyl)pyridine (483 mg), cesium fluoride (810.83 mg, 5.34 mmol), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (130 mg) were dissolved in water (1 mL) and 1,4-dioxane (5 mL). The reaction mixture was heated at 80 °C for 2 hours under a nitrogen atmosphere. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (50 mL) was added, followed by extraction with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 25 / 1; Rf: 0.6) to obtain compound 108-3 (500 mg).

[0829] 1 H NMR(400MHz, DMSO-d6)δ8.78(d,J=5.1Hz,1H),7.97-7.92(m,1H),7.72-7.65( m,1H),7.26-7.20(m,1H),5.05-5.00(m,2H),4.12-3.96(m,4H),1.40(s,9H).

[0830] MS m / z (ESI): 357.2 [M+H] +

[0831] Step 4: Synthesis of intermediate 108-4

[0832] Compound 108-3 (100 mg) was dissolved in dichloromethane (3.00 mL), and trifluoroacetic acid (0.50 mL) was slowly added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. LC-MS monitoring showed that the reaction was complete. After concentration under reduced pressure, compound 108-4 (100 mg) was obtained and used directly in the next reaction step.

[0833] MS m / z(ESI): 257.1 [M+H] +

[0834] Step 5: Synthesis of Compound 108

[0835] Compound 108-4 (100 mg) and 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (59.0 mg) were dissolved in N,N-dimethylformamide (2.00 mL), followed by the addition of sodium carbonate (85.9 mg). The reaction mixture was stirred at 100 °C for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. After cooling to room temperature, water (30.0 mL) was added, followed by extraction with ethyl acetate (10.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) and C-18 chromatography (mobile phase: [water (ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 35-45%) to obtain the target compound 108 (30.0 mg).

[0836] 1 H NMR (400MHz, DMSO-d6) δ8.80(d,J=5.1Hz,1H),8.19(s,1H),8.02(s,1H),7.97(s,1H),7.73(dd,J=5.2,1.6Hz,1H),7.32-7.29(m, 1H), 6.45 (tt, J = 54.9, 3.7Hz, 1H), 5.11 (d, J = 2.1Hz, 2H), 4.70 (td, J = 15.1, 3.7Hz, 2H), 4.51-4.46 (m, 2H), 4.36 (d, J = 9.5Hz, 2H).

[0837] MS m / z(ESI): 439.2 [M+H] +

[0838] Example 109: 4-(1-(2,2-difluoroethyl)-7-oxo-1,7-dihydro-6H-pyrazolo[4,3-d]pyrimidin-6-yl)-1-methyl-N-(2-(trifluoromethyl)pyridin-4-yl)cyclohexane-1-carboxamide

[0839] Step 1: Synthesis of intermediate 109-2

[0840] Compound 109-1 (623 mg) and 1-methyl-4-oxocyclohexane-1-carboxylic acid (500 mg) were dissolved in tetrahydrofuran (10.0 mL), followed by the addition of 2-chloro-1-methylpyridine iodide (1.23 g) and N,N-diisopropylethylamine (1.24 g). The reaction mixture was stirred overnight at room temperature. The reaction was monitored by LCMS and found to be complete. The reaction was quenched with water and extracted with ethyl acetate (25.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 10 / 1; Rf: 0.6) to give compound 109-2 (420 mg).

[0841] MS m / z (ESI): 301.2 [M+H] +

[0842] Step 2: Synthesis of intermediate 109-3

[0843] Compound 109-2 (400 mg) was dissolved in methanol (5 mL), followed by the addition of ammonium acetate (308 mg) and sodium cyanoborohydride (167 mg). The reaction mixture was refluxed and stirred overnight. LCMS monitoring showed the reaction was complete. Sodium bicarbonate was added to adjust the pH to >7, and the mixture was then concentrated. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1; Rf: 0.6) to obtain compound 109-3 (200 mg).

[0844] MS m / z (ESI): 302.2 [M+H] +

[0845] Step 3: Synthesis of intermediate 109-4

[0846] Compound 109-3 (200 mg) and methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylic acid (234 mg) were dissolved in tetrahydrofuran (4 mL), followed by the addition of 1,8-diazobisspirocyclic [5.4.0]undecyl-7-ene (202 mg) at 0 °C. The reaction mixture was stirred overnight at 60 °C. The reaction mixture was monitored by LCMS and found to be complete. After cooling to room temperature, water (50.0 mL) was added, followed by extraction with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 2 / 1; Rf: 0.6) to obtain compound 109-4 (240 mg).

[0847] MS m / z (ESI): 505.2 [M+H] +

[0848] Step 4: Synthesis of intermediate 109-5

[0849] Compound 109-4 (100 mg) was dissolved in ethanol / water (4.00 mL; 4:1), followed by the addition of iron powder (55.4 mg) and ammonium chloride (106 mg). The reaction mixture was stirred at 80 °C for 2 hours. LC-MS monitoring showed the reaction was complete. After cooling to room temperature, the mixture was filtered and concentrated under reduced pressure. Water (30.0 mL) was added, and the mixture was extracted with ethyl acetate (20.0 mL × 3), washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 109-5 (100 mg), which was directly used in the next reaction.

[0850] MS m / z (ESI): 475.2 [M+H] +

[0851] Step 5: Synthesis of Compound 109

[0852] Compound 109-5 (100 mg) was dissolved in amine formaldehyde (2.00 mL). The reaction solution was stirred at 150 °C for 4 hours. The reaction solution was monitored by LCMS and the reaction was complete. After cooling the reaction solution to room temperature, water (20.0 mL) was added and then extracted with ethyl acetate (10.0 mL × 3). The organic phase was washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) and high performance liquid chromatography (column: YMC TAR-C18, 30 × 150 mm, 5 μm; mobile phase: [water (ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 50-80%) to obtain the target compound 109 (20.0 mg).

[0853] 1H NMR (400MHz, DMSO-d6) δ10.03-10.01(m,1H),8.64-8.61(m,1H),8.49-8.21(m,2H),8.16-8.12(m,1H),8.02-7.98(m,1H),6.43(tt,J=54.8, 3.6Hz,1H),5.09-4.99(m,2H),4.69-4.63(m,1H),2.20-2.08(m,1H), 2.01-1.87(m,3H),1.82-1.74(m,2H),1.51-1.44(m,2H),1.25(s,3H).

[0854] MS m / z (ESI): 485.2 [M+H] +

[0855] Example 110: 1-(2,2-difluoroethyl)-5-methyl-6-((3aR,6aS)-2-(2-(trifluoromethyl)pyridin-4-yl)octahydrocyclopentano[c]pyrrolo-5-yl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

[0856] Step 1: Synthesis of intermediate 110-2

[0857] Compound 110-1 (5.00 g) was dissolved in DCM (120 mL), and dibenzylamine (8.76 g) and AcOH (133 mg) were added. After stirring at room temperature for 0.5 hours, sodium triacetoxyborohydride (14.1 g) was added, and the reaction was carried out at room temperature for 16 hours. LC-MS analysis showed that a product was formed. The reaction solution was neutralized with saturated sodium bicarbonate aqueous solution (100 mL), extracted with dichloromethane (200 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 110-2 (8.60 g).

[0858] MS m / z (ESI): 407.2 [M+H] +

[0859] Step 2: Synthesis of intermediate 110-3

[0860] 10% Pd / C (200 mg) was added to a MeOH (10 mL) solution of compound 110-2 (1.00 g), and the reaction was carried out at 60 °C for 4 hours under H2 protection. LCMS analysis showed that the starting material reacted completely. The reaction solution was filtered and concentrated directly to obtain compound 110-3 (0.50 g).

[0861] MS m / z(ESI): 227.0 [M+H] +

[0862] Step 3: Synthesis of intermediate 110-4

[0863] DBU (1.68 g) was added to a THF (10 mL) solution of compound 110-3 (0.50 g) and methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylic acid (675 mg), and the mixture was heated at 60 °C for 16 h. LC-MS analysis showed product formation. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 2:1) to give compound 110-4 (320 mg).

[0864] 1 H NMR(400MHz,Chloroform-d)δ8.16-8.15(m,2H),6.33-6.03(m,1H),4.94-4.86(m,2H),4.46-4.35(m,1H),3.46 -3.42(m,2H),3.31-3.28(m,2H),2.68-2.66(m,2H),2.47-2.41(m,2H),1.46-1.40(m,10H),1.27-1.23(m,1H).

[0865] Step 4: Synthesis of intermediate 110-5

[0866] Compound 110-4 (320 mg), iron powder (416 mg), and NH4Cl (395 mg) were dissolved in EtOH (10 mL) and H2O (2.5 mL), and the mixture was heated and stirred at 80 °C for 1 h. LCMS showed that the reaction was complete. The mixture was filtered and concentrated under reduced pressure, then dissolved in dichloromethane (20 mL), filtered, washed with dichloromethane, and the mother liquor was concentrated under reduced pressure to give compound 110-5 (240 mg).

[0867] MS m / z (ESI): 400.3 [M+H] +

[0868] Step 5: Synthesis of intermediate 110-6

[0869] Compound 110-5 (200 mg) and triethyl orthoacetate (0.50 mL) were placed in a microwave tube containing AcOH (2.00 mL) and microwaved at 120 °C for 2 hours. LC-MS showed the formation of the target product. After cooling to 25 °C, water (15.0 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10.0 mL × 3). The combined organic layers were washed with brine (10.0 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by passing through a silica gel plate [dichloromethane-methanol] gradient: 10:1 to obtain compound 110-6 (14.0 mg).

[0870] MS m / z (ESI): 424.1 [M+H] +

[0871] Step 6: Synthesis of intermediate 110-7

[0872] Compound 110-6 (14.0 mg) was dissolved in DCM (3.00 mL), and TFA (1 mL) was added at 0 °C. The mixture was then heated to 25 °C and stirred for 2 hours. LC-MS showed that the starting material was completely consumed and the desired compound was detected. The reaction solution was concentrated under reduced pressure to obtain crude compound 110-7 (12.0 mg), which was used directly in the next reaction step.

[0873] MS m / z(ESI): 324.1 [M+H] +

[0874] Step 7: Synthesis of Compound 110

[0875] Compound 110-7 (12.0 mg), 4-bromo-2-(trifluoromethyl)pyridine (8.39 mg), and DIEA (24.0 mg) were placed in a microwave tube containing NMP (1.00 mL) and microwave-heated at 120 °C for 1 h. LC-MS showed the formation of the target product. After cooling the reaction solution to 25 °C, water (10.0 mL) was added, and the mixture was extracted with ethyl acetate (10.0 mL × 3). The combined organic layers were washed with brine (10.0 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by reversed-phase high-performance liquid chromatography (column: Pursuit XRs 10C18 19 × 250 mm × 10 μm; mobile phase: [water (0.1% formic acid) - acetonitrile]; acetonitrile gradient: 36%-46%) to obtain the target compound 110 (8.89 mg).

[0876] 1 H NMR (400MHz, DMSO-d6) δ8.25(d,J=6.0Hz,1H),8.00(s,1H),6.93(d,J=2.4Hz,1H),6.76(dd,J=6.0,2.4Hz,1H),6.53-6.22(m,1H),5.01-4. 92(m,2H),4.88-4.82(m,1H),3.68-3.62(m,2H),3.60-3.54(m,2H),2 .93-2.84(m,2H),2.66(s,3H),2.57-2.52(m,2H),2.19-2.10(m,2H).

[0877] MS m / z (ESI): 469.3 [M+H] +

[0878] Example 111: 1-(2,2-difluoroethyl)-4-methyl-6-(5-oxo-6-(2-(trifluoromethyl)pyridin-4-yl)-6-azaspiro[3,4]octane-2-yl)-1,4-dihydro-5H-pyrazolo[4,3-d]pyrimidine-5,7(6H)-dione

[0879] Step 1: Synthesis of intermediate 111-1

[0880] Compound 100-5 (100 mg) was dissolved in tetrahydrofuran (3.00 mL), and CDI (94.2 mg) was added at room temperature. The reaction mixture was stirred at 70 °C for 2 hours. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was cooled to room temperature, and water (10.0 mL) was added. Then, it was extracted with ethyl acetate (30.0 mL × 3). The organic phase was washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (petroleum ether / ethyl acetate: 1 / 1; Rf: 0.6) was purified to give compound 111-1 (100 mg).

[0881] MS m / z (ESI): 485.1 [M+H] +

[0882] Step 2: Synthesis of Compound 111

[0883] Compound 111-1 (100 mg) and potassium carbonate (85.6 mg) were dissolved in DMF (3.00 mL). Iodomethane (58.6 mg) was added at room temperature, and the reaction mixture was stirred at 90 °C for 2 hours. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was cooled to room temperature, water (10.0 mL) was added, and then extracted with ethyl acetate (30.0 mL × 3). The organic phase was washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (dichloromethane / methanol: 10 / 1; Rf: 0.6) was purified by reversed-phase chromatography (mobile phase: [water-acetonitrile]; gradient: 45-55%) to obtain the target compound 111 (51.0 mg).

[0884] 1 H NMR(400MHz,DMSO-d6)δ8.76-8.64(m,1H),8.42-8.29(m,1H),7.93-7.88(m,1H),7.86-7.81(m,1H),6.61-6.20(m,1H ),5.14-4.85(m,3H),3.97-3.83(m,2H),3.44-3.35(m,3H),3.08-2.99(m,2H),2.65-2.56(m,1H),2.44-2.35(m,3H).

[0885] MS m / z(ESI): 499.2 [M+H] +

[0886] Example 112: 1-(2,2-difluoroethyl)-6-(6-(((6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)spiro[3.3]heptane-2-yl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

[0887] Step 1: Synthesis of intermediate 112-2

[0888] LiAlH4 (1.18 g) was added to a solution of compound 112-1 (4.20 g) dissolved in THF (50.0 mL), and the mixture was stirred at 0 °C for 5 min, then heated to 20 °C and stirred for 2 h. TLC showed that the reaction was complete. Na2SO4·10H2O (3.00 g) was added to the mixture, and the mixture was stirred for 0.5 h. The mixture was filtered and concentrated under reduced pressure. The residue was then purified by preparative high performance liquid chromatography to give compound 112-2 (3.00 g).

[0889] Step 2: Synthesis of intermediate 112-3

[0890] Compound 112-2 (1.50 g), 6-(trifluoromethyl)pyridin-2-ol (1.22 g), and PPh3 (2.61 g) were dissolved in THF (20.0 mL). TMAD (1.71 g) was slowly added in portions at 0 °C, and the mixture was heated to 25 °C and stirred for 16 hours. The desired compound was detected by LC-MS. The mixture was cooled to 0 °C and water (50.0 mL) was added. The aqueous phase was extracted with ethyl acetate (30.0 mL × 3). The combined organic phases were washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was further purified by preparative high-performance liquid chromatography to give compound 112-3 (1.20 g).

[0891] MS m / z(ESI): 287.3 [M+H-100] +

[0892] Step 3: Synthesis of intermediate 112-4

[0893] Compound 112-3 (0.30 g) was dissolved in DCM (9.00 mL), and TFA (3.00 mL) was added at 0 °C. The mixture was then heated to 25 °C and stirred for 16 hours. LC-MS showed that the starting material was completely consumed and the desired compound was detected. The reaction solution was concentrated under reduced pressure to obtain compound 112-4 (0.25 g), which was used directly in the next reaction step.

[0894] MS m / z(ESI): 287.1 [M+H] +

[0895] Step 4: Synthesis of intermediate 112-5

[0896] Compound 112-4 (250 mg) was dissolved in THF (10.0 mL), and methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylic acid (205 mg) and DBU (266 mg) were added. The reaction mixture was stirred at 60 °C for 16 hours. The desired compound was detected by LCMS. The mixture was added to water (30.0 mL) at room temperature. The aqueous phase was extracted with ethyl acetate (25.0 mL × 3). The combined organic phases were washed with saturated brine (15.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Compound 112-5 (230 mg) was further purified by preparative high-performance liquid chromatography.

[0897] MS m / z (ESI): 490.7 [M+H] +

[0898] Step 5: Synthesis of intermediate 112-6

[0899] Compound 112-5 (230 mg) was dissolved in ethanol (5.00 mL) / THF (1.00 mL) / H₂O (1.00 mL), and ammonium chloride (251 mg) and iron powder (131 mg) were added. The reaction mixture was stirred at 80 °C for 5 hours. The desired compound was detected by LCMS. The mixture was filtered, and water (30.0 mL) was added to the filtrate at room temperature. The aqueous phase was extracted with ethyl acetate (25.0 mL × 3). The combined organic phases were washed with saturated brine (15.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Compound 112-6 (200 mg) was further purified by preparative high-performance liquid chromatography.

[0900] MS m / z (ESI): 460.3 [M+H] +

[0901] Step 6: Synthesis of Compound 112

[0902] Compound 112-6 (50.0 mg) was placed in a microwave tube containing formamide (2.00 mL) and microwaved at 120 °C for 2 hours. LCMS showed the formation of the target product. After cooling to 25 °C, ethyl acetate (10.0 mL) and water (15.0 mL) were added. The aqueous layer was extracted with ethyl acetate (10.0 mL × 3). The combined organic layers were washed with brine (10.0 mL), dried over sodium sulfate, and concentrated under reduced pressure to give the crude product. The crude product was purified by reversed-phase high-performance liquid chromatography (column: Pursuit XRs 10C1819 × 250 mm × 10 μm; mobile phase: [water (0.1% formic acid) - acetonitrile]; acetonitrile gradient: 46%-56%) to obtain the target compound 112 (17.7 mg).

[0903] 1 H NMR (400MHz, DMSO-d6) δ8.26 (s, 1H), 8.13 (s, 1H), 7.96 (t, J = 8.0Hz, 1H), 7.47 (d,J=7.2Hz,1H),7.14(d,J=8.4Hz,1H),6.59-6.23(m,1H),5.09-4.96(m,2H), 4.92-4.80(m,1H),4.28(d,J=6.8Hz,2H),2.71-2.54(m,4H),2.48-2.46(m,1H ),2.36-2.29(m,1H),2.19-2.11(m,1H),2.08-2.00(m,1H),1.98-1.89(m,1H).

[0904] MS m / z(ESI): 470.0 [M+H] +

[0905] Example 113: 8-(1-(2,2-difluoroethyl)-7-oxo-1,7-dihydro-6H-pyrazolo[4,3-d]pyrimidin-6-yl)-2-((2-(trifluoromethyl)pyridin-4-yl)methyl)-2-azaspiro[4,5]decane-3-one

[0906] Step 1: Synthesis of intermediate 113-2

[0907] A toluene (150 mL) solution of compound 113-1 (15.2 g) and methoxyformylmethylenetriphenylphosphine (7.50 g) was stirred at 110 °C for 16 h. LC-MS showed the formation of the target product. The reaction solution was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography (ethyl acetate / petroleum ether = 0%–30%) to give compound 113-2 (6.30 g).

[0908] MS m / z (ESI): 304.1 [M+H]+

[0909] Step 2: Synthesis of intermediate 113-3

[0910] To a DMSO (100 mL) solution of compound 113-2 (5.20 g), K2CO3 (987 mg) and CH3NO2 (1.57 g) were added, and the mixture was stirred at 95 °C for 3 h. LC-MS showed the formation of the target product. The reaction solution was quenched with water (200 mL), extracted with ethyl acetate (100 mL × 3), and the combined organic phases were washed with saturated brine (200 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to obtain crude compound 113-3 (5.40 g), which was directly used in the next reaction.

[0911] MS m / z (ESI): 365.1 [M+H] +

[0912] Step 3: Synthesis of intermediate 113-4

[0913] Raney Ni (5.00 mL) was added to a 200 mL EtOH solution of compound 113-3 (5.40 g), and the mixture was stirred at room temperature under hydrogen protection for 72 h. LC-MS showed the formation of the target product. The reaction solution was filtered and concentrated under reduced pressure to obtain a crude product. The crude product was subjected to C18 column chromatography (acetonitrile / 0.1% TFA aqueous solution = 0%–70%) to obtain compound 113-4 (3.00 g).

[0914] MS m / z(ESI): 303.1 [M+H] +

[0915] Step 4: Synthesis of intermediate 113-5

[0916] NaH (198 mg, 60% purity) was added to a DMF (10.0 mL) solution of compound 113-4 (500 mg) at 0 °C, and the mixture was stirred at 30 °C for 0.5 h. Then, 4-(bromomethyl)-2-(trifluoromethyl)pyridine (793 mg) was added to the reaction solution, and the mixture was stirred at 30 °C for 16 h. LCMS showed that the target product was formed. The reaction solution was quenched with water (30.0 mL), extracted with ethyl acetate (20.0 mL × 3), and the combined organic phases were washed with saturated brine (30.0 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to silica gel column chromatography (methanol / dichloromethane = 0%–10%) to obtain compound 113-5 (181 mg).

[0917] MS m / z(ESI): 462.3 [M+H] +

[0918] Step 5: Synthesis of intermediate 113-6

[0919] A solution of compound 113-5 (141 mg) in HBr / AcOH (3.00 mL) was stirred at room temperature for 2 h, and the reaction was confirmed to be complete by LCMS. The reaction solution was concentrated under reduced pressure to obtain a crude product. A saturated NaHCO3 aqueous solution (20.0 mL) was added to the crude product, and the mixture was extracted with dichloromethane (20.0 mL × 2). The aqueous phase was lyophilized and dissolved in dichloromethane (20.0 mL). The solution was filtered, washed with dichloromethane, and the filtrate was concentrated under reduced pressure to obtain crude compound 113-6 (90.0 mg), which was directly used in the next reaction.

[0920] MS m / z(ESI): 328.1 [M+H] +

[0921] Step 6: Synthesis of intermediate 113-7

[0922] To a THF (2.00 mL) solution of compound 113-6 (104 mg), methyl 1-(2,2-difluoroethyl)-4-nitro-1H-pyrazole-5-carboxylic acid (149 mg) and DBU (96.7 mg) were added. The mixture was stirred at 60 °C for 2 h. LCMS showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to silica gel column chromatography (methanol / dichloromethane = 0%–10%) to obtain crude compound 113-7 (82.0 mg), which was directly used in the next step of the reaction.

[0923] MS m / z(ESI): 531.1 [M+H] +

[0924] Step 7: Synthesis of intermediate 113-8

[0925] Fe (43.2 mg) and NH4Cl (82.7 mg) were added to a solution of compound 113-7 (82.0 mg) in EtOH (1.60 mL) / H2O (0.40 mL). The mixture was stirred at 80 °C for 4 h, and LCMS showed that the reaction was complete. The reaction solution was concentrated under reduced pressure and dissolved in dichloromethane (30.0 mL). The solution was filtered, washed with dichloromethane, and the filtrate was concentrated under reduced pressure to obtain crude compound 113-8 (63.0 mg), which was directly used in the next reaction.

[0926] MS m / z (ESI): 501.1 [M+H] +

[0927] Step 8: Synthesis of Compound 113

[0928] A solution of compound 113-8 (55.0 mg) in formamide (4.95 mg) was microwave-irradiated at 120 °C for 2 h. The reaction was completed by LCMS. The reaction solution was directly subjected to C18 column chromatography (acetonitrile / 0.5% TFA aqueous solution = 0-100%) to obtain the target compound 113 (4.74 mg).

[0929] 1 H NMR (400MHz, MeOD-d4) δ8.69(d,J=5.0Hz,1H),8.26(s,1H),7.97(s,1H),7.73(s,1H),7.55(d,J=4.8Hz,1H),6.45-6.04(m,1H),5.0 7-4.98(m,2H),4.77-4.70(m,1H),4.59(s,2H),3.22(s,2H),2.61(s,2H),2.10-1.98(m,2H),1.96-1.84(m,4H),1.72-1.61(m,2H).

[0930] MS m / z (ESI): 511.5 [M+H] +

[0931] Examples 114-116: The synthesis method of Example 113 was followed, except that 4-(bromomethyl)-2-(trifluoromethyl)pyridine in step 4 was replaced with the reactants in the table below, and compounds 114-116 were synthesized in the same manner.

[0932] Example 117: 1-(2,2-difluoroethyl)-4-methyl-6-((7-(2-(trifluoromethyl)pyridin-4-yl)-2,7-diazaspiro[3.5]nonane-2-yl)methyl)-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one

[0933] Step 1: Synthesis of intermediate 117-2

[0934] Compound 117-1 (1.00 g) and cesium carbonate (3.29 g) were dissolved in N,N-dimethylformamide (15 mL). 2,2-difluoroethyl trifluoromethanesulfonate (1.19 g) was added dropwise at 0 °C, and the reaction mixture was stirred at 25 °C for 2 hours. The reaction mixture was monitored by LC-MS and found to be complete. The reaction mixture was cooled to room temperature, and water (100 mL) was added. The mixture was then extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 2 / 1) to obtain compound 117-2 (0.57 g).

[0935] 1 H NMR (400MHz, DMSO-d6) δ8.74-8.61(m,2H),8.46(d,J=1.0Hz,1H),6.69-6.28(m,1H),5.13-4.90(m,2H).

[0936] MS m / z(ESI): 261.8 [M+H] +

[0937] Step 2: Synthesis of intermediate 117-3

[0938] Compound 117-2 (420 mg) was dissolved in dichloromethane (10 mL) under a nitrogen atmosphere. At 0 °C, m-chloroperoxybenzoic acid (391 mg, 85% purity) was added, and the reaction mixture was stirred at 25 °C for 16 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was quenched with saturated sodium bisulfite (30 mL), then extracted with ethyl acetate (30 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 1 / 1) to obtain compound 117-3 (400 mg).

[0939] MS m / z(ESI): 277.7 [M+H] +

[0940] Step 3: Synthesis of intermediate 117-4

[0941] Under a nitrogen atmosphere, compound 117-3 (400 mg) was added to acetic anhydride (20 mL). The reaction mixture was refluxed and stirred for 2 hours. The reaction mixture was then cooled to 90 °C, and water (10 mL) was added. The reaction mixture was stirred at 90 °C for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was cooled to room temperature, and the pH was adjusted to 7 with 2 M sodium hydroxide solution. The mixture was extracted with ethyl acetate (30 mL * 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1) to obtain compound 117-4 (390 mg), a white solid.

[0942] 1 H NMR (400MHz, DMSO-d6) δ12.46-11.72(m,1H),8.63(s,1H),7.56(s,1H),6.60-6.19(m,1H),5.01-4.74(m,2H).

[0943] MS m / z(ESI): 277.8 [M+H] +

[0944] Step 4: Synthesis of intermediate 117-5

[0945] Under a nitrogen atmosphere, compound 117-4 (390 mg) and potassium carbonate (387 mg) were added to N,N-dimethylformamide (10 mL). Iodomethane (299 mg) was added at 0 °C, and the reaction mixture was stirred at 60 °C for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. The reaction mixture was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1) to obtain compound 117-5 (390 mg).

[0946] 1 H NMR (400MHz, DMSO-d6) δ8.65(s,1H),7.93(s,1H),6.57-6.22(m,1H),5.00-4.82(m,2H),3.58(s,3H).

[0947] MS m / z(ESI): 291.8 [M+H] +

[0948] Step 5: Synthesis of intermediate 117-6

[0949] Compound 117-5 (100 mg) was dissolved in tetrahydrofuran (3.00 mL), and the reaction solution was purged with nitrogen three times. Under a nitrogen atmosphere, isopropyl magnesium chloride tetrahydrofuran solution (2 M, 342 μL) was slowly added dropwise to the reaction solution at 0 °C, and the reaction solution was stirred at 0 °C for 30 min. Subsequently, N,N-dimethylformamide (125 mg, 133 μL) was slowly added dropwise at 0 °C, and the reaction solution was stirred at room temperature for 2 h. The reaction solution was monitored by LCMS, and the reaction was complete. The reaction was quenched with water, and then extracted with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) to obtain compound 117-6 (50.0 mg).

[0950] MS m / z(ESI): 242.0 [M+H] +

[0951] Step 2: Synthesis of intermediate 117-7

[0952] Compound 117-6 (63.9 mg) was dissolved in DCM (1.00 mL), followed by the addition of tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylic acid (60.0 mg). The reaction mixture was stirred at room temperature for 2 hours. Then, sodium triacetylborohydride (112 mg) was added, and the mixture was stirred overnight. The reaction was monitored by LCMS and found to be complete. Sodium bicarbonate aqueous solution was added to the reaction mixture to adjust the pH to >7, followed by extraction with dichloromethane (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) to obtain compound 117-7 (45.0 mg).

[0953] MS m / z (ESI): 452.2 [M+H] +

[0954] Step 3: Synthesis of intermediate 117-8

[0955] Compound 117-7 (45.0 mg) was dissolved in dichloromethane (2.00 mL), and trifluoroacetic acid (0.50 mL) was slowly added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction was monitored by LCMS and found to be complete. After concentration under reduced pressure, compound 117-8 (45.0 mg) was obtained.

[0956] MS m / z (ESI): 352.1 [M+H] +

[0957] Step 4: Synthesis of Compound 117

[0958] Compound 117-8 (45.0 mg), 4-bromo-2-(trifluoromethyl)pyridine (21.9 mg), and potassium carbonate (40.1 mg) were dissolved in N,N-dimethylformamide (1.00 mL). The reaction mixture was stirred overnight at 80 °C. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (50.0 mL) was added, followed by extraction with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) and preparative high performance liquid chromatography (column: YMC TAR-C18, 30 × 150 mm, 5 μm; mobile phase: [water (ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 50-80%) to obtain the target compound 117 (10.0 mg).

[0959] 1H NMR(400MHz, DMSO-d6)δ8.23(d,J=6.0Hz,1H),7.85(s,1H),7.77(s,1H),7.20(d,J=2.6Hz,1H),7.05-7.03(m,1H), 6.54-6.24(m,1H),4.96-4.88(m,2H),3.54-3.50(m,5H),3.44-3.41(m,4H),3.13-3.09(m,4H),1.79-1.76(m,4H).

[0960] MS m / z (ESI): 497.2 [M+H] +

[0961] Example 118: Following the synthesis method of Example 117, except that 2,7-diazaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester in step 2 was replaced with the reactants in the table below, and compound 118 was synthesized in the same manner.

[0962] Example 119: 1-(2,2-difluoroethyl)-4-methyl-6-(7-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.5]non-6-en-2-yl)-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one

[0963] Step 1: Synthesis of intermediate 119-2

[0964] Compound 119-1 (1.00 g) was dissolved in tetrahydrofuran (10.0 mL). A tetrahydrofuran solution of bis(trimethylsilyl)amino potassium (1 M, 6.27 mL) was slowly added dropwise at -70 °C under a nitrogen atmosphere. The reaction mixture was stirred at -70 °C for 0.5 h. Subsequently, a tetrahydrofuran solution of N-phenylbis(trifluoromethanesulfonyl)imide (2.24 g) (12 mL) was slowly added dropwise. The reaction mixture was brought to room temperature and stirred for 0.5 h. LC-MS monitoring showed the reaction was complete. The reaction was quenched with saturated brine (50.0 mL) and extracted with ethyl acetate (50.0 mL × 3). The organic phases were combined, washed with saturated brine, dried, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 1:10) to obtain compound 119-2 (900 mg).

[0965] 1H NMR (400MHz, Chloroform-d) δ7.41-7.27(m,1H),3.77-3.38(m,4H),2.57-2.35(m,2H),2.28-2.07(m,2H),1.44(s,9H),1.40-1.19(m,2H).

[0966] MS m / z (ESI): 316.1 [M+H-56] +

[0967] Step 2: Synthesis of intermediate 119-3

[0968] Under nitrogen protection, compound 119-2 (900 mg), pinacol diborate (762 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (177 mg), and potassium acetate (714 mg) were added to 1,4-dioxane (18.0 mL). The reaction mixture was heated to 80 °C and stirred for 3 hours. TLC analysis showed the reaction was complete. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (20.0 mL) was added. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain compound 119-3 (840 mg), which was directly used in the next reaction step.

[0969] Step 3: Synthesis of intermediate 119-4

[0970] Compound 119-3 (340 mg), 2-trifluoromethyl-4-bromopyridine (524 mg), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (114 mg), and cesium fluoride (704 mg) were dissolved in a mixed solvent of 1,4-dioxane (10.0 mL) and water (2.00 mL). The reaction solution was heated to 80 °C and stirred for 1 hour. The reaction solution was monitored by LCMS and the reaction was complete. Saturated brine (20.0 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20.0 mL × 3). The organic phases were combined, dried, and concentrated under reduced pressure. The residue was purified by column chromatography (methanol / dichloromethane: 0%–2%) to obtain the target compound 119-4 (260 mg).

[0971] MS m / z(ESI): 369.1 [M+H] +

[0972] Step 4: Synthesis of intermediate 119-5

[0973] Compound 119-4 (250 mg) was dissolved in dichloromethane (2.00 mL), and 1,4-dioxane hydrochloride solution (4 M, 1.70 mL) was slowly added. The reaction mixture was stirred at room temperature for 2 hours. The reaction was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure to give compound 119-5 (200 mg, hydrochloride).

[0974] MS m / z(ESI): 269.0 [M+H] +

[0975] Step 5: Synthesis of Compound 119

[0976] Under nitrogen protection, compound 119-5 (20.0 mg), 6-bromo-1-(2,2-difluoroethyl)-4-methyl-pyrrolo[4,3-b]pyridin-5-one (21.8 mg), Pd2(dba)3 (6.80 mg), XantPhos (8.60 mg), and cesium carbonate (72.8 mg) were dissolved in 1,4-dioxane (1 mL). The reaction mixture was heated to 100 °C and stirred for 2 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (5 mL) was added, followed by extraction with ethyl acetate (5 mL × 3). The organic phase was washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by preparative liquid chromatography (Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; using a mixture of water (containing 7 mM ammonium bicarbonate) and acetonitrile with decreasing polarity (40%-70%) as eluent) to obtain the target compound 119 (3.50 mg).

[0977] 1 H NMR(400MHz,Chloroform-d)δ8.74-8.59(m,1H),7.68-7.59(m,1H),7.47-7.38(m,2H),6.46-6.38(m,1H),6 .27-5.92(m,2H),4.58-4.43(m,2H),4.03-3.86(m,4H),3.57(s,3H),2.81-2.47(m,4H),2.11-2.02(m,2H).

[0978] MS m / z (ESI): 480.1 [M+H] +

[0979] Example 120: 1-(2,2-difluoroethyl)-4-methyl-6-(7-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.5]nonane-2-yl)-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one

[0980] Step 1: Synthesis of Intermediate 120-1

[0981] Under hydrogen protection, compound 119-5 (100 mg) and 10% palladium / carbon (45.3 mg) were dissolved in methanol (4.00 mL), and the reaction mixture was stirred at room temperature for 4 hours. The reaction was monitored by LCMS and found to be complete. The reaction mixture was filtered, and methanol was removed by vacuum concentration to obtain compound 120-1 (100 mg), which was directly used in the next reaction step.

[0982] MS m / z(ESI): 271.1 [M+H] +

[0983] Step 2: Synthesis of Compound 120

[0984] Under nitrogen protection, compounds 120-1 (70.0 mg), 117-5 (75.0 mg), Pd2(dba)3 (23.0 mg), XantPhos (30.0 mg), and cesium carbonate (253 mg) were dissolved in 1,4-dioxane (2.00 mL). The reaction mixture was heated to 100 °C and stirred for 2 hours. The reaction mixture was monitored by LCMS and found to be complete. After cooling to room temperature, water (5 mL) was added, followed by extraction with ethyl acetate (5 mL × 3). The organic phase was washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by preparative liquid chromatography (Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; using a mixture of water (containing 7 mM ammonium bicarbonate) and acetonitrile with decreasing polarity (40%-70%) as eluent) to obtain target compound 120 (30.0 mg).

[0985] 1 H NMR(400MHz,DMSO-d6)δ8.70-8.62(m,1H),7.85-7.77(m,1H),7.66(s,1H),7.64-7.56(m,1H),6.58(s,1H),6.54-6.09(m,1H),4.8 6-4.61(m,2H),3.84(s,2H),3.73(s,2H),3.47(s,3H),2.78-2.61(m,1H),2.12-1.93(m,2H),1.84-1.72(m,2H),1.72-1.49(m,4H).

[0986] MS m / z(ESI): 482.1 [M+H] +

[0987] Example 121: (R)-7-(1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-N-(1,1,1-trifluoropropane-2-yl)-7-azaspiro[3,5]nonane-2-amine

[0988] Step 1: Synthesis of intermediate 121-2

[0989] Compound 121-1 (1.00 g) was dissolved in ethyl chloride-ethyl acetate (20.0 mL), and the reaction mixture was stirred at 25 °C for 2 hours. The reaction was monitored by LCMS, and the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain compound 121-2 (550 mg), which was directly used in the next reaction step.

[0990] MS m / z (ESI): 140.1 [M+H] +

[0991] Step 2: Synthesis of intermediate 121-3

[0992] Compound 121-2 (500 mg), 6-chloro-1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazine (622 mg), and potassium carbonate (1.18 g) were dissolved in DMF (10.0 mL), and the reaction mixture was stirred overnight at 25 °C. The reaction mixture was monitored by LCMS, and the reaction was complete. The reaction mixture was cooled to room temperature, water (50.0 mL) was added, and then extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol: 20 / 1; Rf: 0.6) to obtain compound 121-3 (760 mg).

[0993] MS m / z(ESI): 322.1 [M+H] +

[0994] Step 3: Synthesis of Compound 121

[0995] Compound 121-3 (200 mg), (R)-1,1,1-trifluoropropane-2-amine (84 mg), and sodium acetate (153 mg) were dissolved in dichloromethane (5.00 mL) under a nitrogen atmosphere, and the reaction mixture was stirred at 25 °C for 2 hours. STAB (264 mg) was then added to the reaction mixture, and the mixture was stirred at 25 °C for 2 hours. The reaction was monitored by LC-MS, and the reaction was complete. The reaction solution was cooled to room temperature, and water (10.0 mL) was added. Then, it was extracted with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue (dichloromethane / methanol: 20 / 1; Rf: 0.6) was separated and purified by preparative high performance liquid chromatography (column: Phenomenex Gemini NX 150 × 30 mm, 5 μm; mobile phase: [water (ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 50%-90%) to obtain the target compound 121 (120 mg).

[0996] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.11(s,1H),6.63-6.12(m,1H),4.75-4.61(m,2H),3.74-3.66(m,2H),3.67-3.60(m,2H),3.36 -3.29(m,1H),3.25-3.12(m,1H),2.33-2.24(m,1H),2.22-2.05(m,2H),1.64-1.53(m,5H),1.57-1.48(m,1H),1.15(d,J=6.8Hz,3H).

[0997] MS m / z (ESI): 419.2 [M+H] +

[0998] Example 122: The synthesis method of Example 121 was followed, except that (R)-1,1,1-trifluoropropane-2-amine in step 3 was replaced with the reactants in the table below, and compound 122 was synthesized in the same manner.

[0999] Example 123: 1-(2,2-difluoroethyl)-4-methyl-6-(2-((2-(trifluoromethyl)pyridin-3-yl)oxy)-7-azaspiro[3.5]nonane-7-yl)-1,4-dihydro-5H-pyrazolo[3,4-b]pyrazin-5-one

[1000] Step 1: Synthesis of intermediate 123-2

[1001] Compound 123-1 (1.00 g) was dissolved in DMF (20 mL), and NaH (182 mg) was added. After stirring at room temperature for 0.5 hours, 3-bromo-2-(trifluoromethyl)pyridine (936 mg) was added to the reaction solution, and stirring was continued at room temperature for 16 hours. LC-MS analysis showed the presence of product. Water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by automated column chromatography (PE:EA = 2:1) to give compound 123-2 (0.80 g).

[1002] MS m / z (ESI): 387.2 [M+H] +

[1003] Step 2: Synthesis of intermediate 123-3

[1004] Compound 123-2 (100 mg) was dissolved in DCM (2 mL), and TFA (29.5 mg) was added. The mixture was reacted at room temperature for 2 hours. LC-MS analysis showed the presence of product. The reaction solution was concentrated to obtain crude compound 123-3 (74.0 mg), which was used directly in the next reaction step.

[1005] MS m / z(ESI): 287.0 [M+H] +

[1006] Step 3: Synthesis of Compound 123

[1007] Compound 123-3 (60.0 mg) was dissolved in DMF (2 mL), and potassium carbonate (86.9 mg) and 6-chloro-1-(2,2-difluoroethyl)-4-methyl-1,4-dihydro-5H-pyrazolo[3,4-b]pyrazin-5-one (52.1 mg) were added. The mixture was stirred at 100 °C for 2 hours. LC-MS analysis showed the presence of the product. The reaction solution was filtered and purified by reverse-phase chromatography (column: C18 150 × 40 mm; mobile phase: [water (FA)-acetonitrile]) to obtain the target compound 123 (99.0 mg).

[1008] 1 H NMR (400MHz, DMSO-d6) δ8.26 (d, J = 4.0Hz, 1H), 7.73-7.58 (m, 3H), 6.55-6.20 (m, 1H), 5.05-4.93 (m, 1H), 4. 67-4.54(m,2H),3.86-3.78(m,4H),3.47(s,3H),2.55-2.52(m,2H),1.91-1.82(m,2H),1.75-1.62(m,4H).

[1009] MS m / z(ESI): 499.2 [M+H] +

[1010] Example 124: 1-(2,2-difluoroethyl)-N-((3aR,5r,6aS)-2-(2-(trifluoromethyl)pyridin-4-yl)octahydrocyclopenta[c]pyrrolo-5-yl)-1H-pyrazole-5-carboxamide

[1011] Step 1: Synthesis of intermediate 124-1

[1012] Compound 110-2 (20.0 g) was dissolved in DCM (100 mL), and HCl / 1,4-dioxane (100 mL) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction was monitored by LCMS to ensure complete reaction. The reaction mixture was concentrated under reduced pressure to obtain crude compound 124-1 (16.0 g), which was directly used in the next step of the reaction.

[1013] MS m / z (ESI): 307.2 [M+H] +

[1014] Step 2: Synthesis of intermediate 124-2

[1015] Compound 124-1 (12.0 g) was dissolved in DMF (130 mL), and K2CO3 (16.2 g) and 4-bromo-2-(trifluoromethyl)pyridine (8.85 g) were added. The reaction mixture was stirred at 80 °C for 16 hours. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (100 mL × 2). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by rapid silica gel column chromatography (gradient 0–40% petroleum ether / ethyl acetate) to obtain compound 124-2 (8.00 g).

[1016] MS m / z (ESI): 452.7 [M+H] +

[1017] Step 3: Synthesis of intermediate 124-3

[1018] Compound 124-2 (8.00 g) was dissolved in MeOH (80 mL), followed by the addition of acetic acid (106 mg) and Pd / C (5.00 g, 10%). The reaction mixture was stirred at 60 °C for 16 hours under H₂ protection. The reaction was monitored by LCMS until complete. The reaction mixture was filtered and concentrated under reduced pressure to obtain crude compound 124-3 (4.00 g), which was used directly in the next reaction step.

[1019] MS m / z(ESI): 272.1 [M+H] +

[1020] Step 4: Synthesis of Compound 124

[1021] Compound 124-3 (50.0 mg) was dissolved in THF (1.00 mL), and methyl 1-(2,2-difluoroethyl)-1H-pyrazole-5-carboxylic acid (35.0 mg) and DBU (84.3 mg) were added. The reaction mixture was stirred at 60 °C for 16 hours. After the reaction was complete, water (10.0 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (10.0 mL × 2). The combined organic phases were washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative high performance liquid chromatography (mobile phase: 0.1% FA aqueous solution-acetonitrile; acetonitrile gradient: 0%-100%) to obtain the target product 124 (6.12 mg).

[1022] 1 H NMR (400MHz, DMSO-d6) δ8.45-8.41(m,1H),8.19(d,J=5.8Hz,1H),7.54(d,J=1.8Hz,1H),6.85(d,J=1.6Hz,2H),6.69(d,J=5.6Hz,1H),6.43-6.1 3(m,1H),4.99-4.89(m,2H),4.33-4.26(m,1H),3.50-3.46(m,2H),3.37 -3.32(m,2H),2.78-2.74(m,2H),2.27-2.20(m,2H),1.50-1.43(m,2H).

[1023] MS m / z(ESI): 430.0 [M+H] +

[1024] Example 125: The synthesis method of Example 124 was followed, except that methyl 1-(2,2-difluoroethyl)-1H-pyrazole-5-carboxylate in step 4 was replaced with the reactants in the table below, and compound 125 was synthesized in the same manner.

[1025] Example 126: 1-(2,2-difluoroethyl)-4-methyl-6-((1-(2-(trifluoromethyl)pyridin-4-yl)piperidin-4-yl)methyl)-1,4-dihydro-5H-pyrazolo[3,4-b]pyrazin-5-one

[1026] Step 1: Synthesis of intermediate 126-2

[1027] TFAA (19.2 g) was added to a solution of compound 126-1 (10.0 g) and urea peroxide (9.04 g) in ACN (200 mL) at 0 °C. After heating to room temperature, the mixture was stirred for 3 h, and LCMS showed that the reaction was complete. 0.5 M HCl aqueous solution (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was then slurried (ethyl acetate: petroleum ether = 1:1) to obtain compound 126-2 (7.20 g), which was directly used in the next step.

[1028] MS m / z(ESI): 235.0 [M+H] +

[1029] Step 2: Synthesis of intermediate 126-3

[1030] TFAA (32.2 g) and TMSCl (16.7 g) were added to a CHCl3 (140 mL) solution of compound 126-2 (7.20 g), and the mixture was stirred at room temperature for 1 h. Then, TEA (15.5 g) was added to the reaction solution, and the mixture was stirred at room temperature for 16 h. LC-MS showed that the reaction was complete. Water (150 mL) was added to the reaction solution, and after stirring for 15 min, a yellow solid precipitated. The solid was filtered, and the clean product was obtained. The filtrate was extracted with a mixed solvent (dichloromethane:methanol = 10:1; 100 mL × 3). The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was slurried with ethyl acetate:petroleum ether = 1:1 to obtain a clean product. The two batches of products were combined and concentrated under reduced pressure to obtain compound 126-3 (6.00 g).

[1031] 1 H NMR (400MHz, DMSO-d6) δ12.86(s,1H),8.30(s,1H),6.55-6.26(m,1H),4.81-4.73(m,2H).

[1032] MS m / z(ESI): 235.1 [M+H] +

[1033] Step 3: Synthesis of intermediate 126-4

[1034] K₂CO₃ (7.07 g) and MeI (4.36 g) were added to a DMF (100 mL) solution of compound 126-3 (6.00 g), and the mixture was heated at 50 °C and stirred for 2 h. LC-MS showed that the target product was formed. The reaction solution was quenched with water (100 mL), extracted with ethyl acetate (100 mL × 3), and the combined organic phases were washed with saturated brine (200 mL). After drying with anhydrous Na₂SO₄, the mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to silica gel column chromatography (ethyl acetate / petroleum ether = 0%–100%) to obtain compound 126-4 (4.50 g).

[1035] 1 H NMR (400MHz, DMSO-d6) δ8.01(s,1H),6.56-6.29(m,1H),4.84-4.76(m,2H),3.59(s,3H).

[1036] MS m / z(ESI): 249.1 [M+H] +

[1037] Step 4: Synthesis of intermediate 126-5

[1038] Compound 126-4 (200 mg) and 4-((4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)methylene)piperidine-1-carboxylic acid tert-butyl ester (312 mg) were dissolved in 1,4-dioxane (4 mL, 10% H2O), and Pd(dppf)Cl2 (58.9 mg) and sodium carbonate (171 mg) were added. The mixture was purged three times with nitrogen and reacted at 80 °C for 16 hours. LC-MS analysis showed the presence of product. The reaction solution was filtered and concentrated, and the crude product was purified by an automated column chromatography system (DCM:MeOH = 20:1) to obtain compound 126-5 (220 mg).

[1039] MS m / z (ESI): 410.1 [M+H] +

[1040] Step 5: Synthesis of intermediate 126-6

[1041] Compound 126-5 (200 mg) was dissolved in methanol (6 mL), and Pd / C (59.3 mg) was added to replace hydrogen gas. The reaction was carried out at room temperature for 16 hours. LC-MS showed the presence of product. The reaction solution was filtered and concentrated to obtain crude compound 126-6 (180 mg), which was used directly in the next step of the reaction.

[1042] MS m / z(ESI): 412.0 [M+H] +

[1043] Step 6: Synthesis of intermediate 126-7

[1044] Compound 126-6 (100 mg) was dissolved in DCM (1 mL), and TFA (27.7 mg, 1 mL) was added. The mixture was reacted at room temperature for 2 hours. TLC showed that the starting material disappeared. The reaction solution was concentrated to obtain crude compound 126-7 (75.0 mg), which was used directly in the next step of the reaction.

[1045] Step 7: Synthesis of Compound 126

[1046] Compound 126-7 (75.0 mg) was dissolved in DMF (2 mL), and K2CO3 (101.2 mg) and 4-bromo-2-(trifluoromethyl)pyridine (66.2 mg) were added. The mixture was stirred at 100 °C for 2 hours. LC-MS analysis showed the presence of the product. The reaction solution was filtered and purified by preparative high-performance liquid chromatography (column: C18 150 × 40 mm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile gradient: 0%-100%) to obtain the target compound 126 (25.0 mg).

[1047] 1H NMR (400MHz, DMSO-d6) δ8.24(d,J=6.0Hz,1H),7.91(s,1H),7.23(d,J=2.4Hz,1H),7.09-7.00(m,1H),6.60-6.20(m,1H),4.87-4.74(m ,2H),4.10-4.01(m,2H),3.54(s,3H),3.02-2.90(m,2H),2.79-2.73(m,2H),2.27-2.16(m,1H),1.82-1.73(m,2H),1.32-1.20(m,2H).

[1048] MS m / z (ESI): 457.2 [M+H] +

[1049] Example 127: The synthesis method of Example 126 was followed, except that compounds 126-1 and 4-((4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)methylene)piperidine-1-carboxylic acid tert-butyl ester in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compound 127 was synthesized in the same manner.

[1050] Example 128: 8-(1-(2,2-difluoroethyl)-4-methyl-5-oxo-4,5-dihydro-1H-pyrazolo[3,4-b]pyrazin-6-yl)-2-((3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2,8-diazaspiro[4.5]decane-3-one

[1051] Step 1: Synthesis of intermediate 128-2

[1052] TFAA (19.2 g) was added to a solution of 128-1 (10.0 g) and urea peroxide (9.04 g) in 200 mL of ACN at 0 °C. After heating to room temperature, the mixture was stirred for 3 h, and LC-MS showed that the reaction was complete. 50 mL of 0.5 M HCl aqueous solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was then slurried (ethyl acetate: petroleum ether = 1:1) to obtain compound 128-2 (7.20 g), which was directly used in the next reaction.

[1053] 1 H NMR (400MHz, Chloroform-d) δ8.33(s,1H),8.11(s,1H),6.39-6.10(m,1H),4.85-4.77(m,2H).

[1054] MS m / z(ESI): 235.0 [M+H] +

[1055] Step 2: Synthesis of intermediate 128-3

[1056] TFAA (32.2 g) and TMSCl (16.7 g) were added to a CHCl3 (140 mL) solution of compound 128-2 (7.20 g), and the mixture was stirred at room temperature for 1 h. Then, TEA (15.5 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 16 h. LC-MS showed that the reaction was complete. Water (150 mL) was added to the reaction mixture, and after stirring for 15 min, a yellow solid precipitated. The solid was filtered, and the yellow solid was the clean product. The filtrate was extracted with dichloromethane:methanol = 10:1; 100 mL × 3. The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was slurried with ethyl acetate:petroleum ether = 1:1 to obtain a clean product. The two batches of products were combined and concentrated under reduced pressure to obtain compound 128-3 (6.00 g).

[1057] 1 H NMR (400MHz, DMSO-d6) δ12.86(s,1H),8.30(s,1H),6.55-6.26(m,1H),4.81-4.73(m,2H).

[1058] MS m / z(ESI): 235.1 [M+H] +

[1059] Step 3: Synthesis of intermediate 128-4

[1060] K₂CO₃ (7.07 g) and MeI (4.36 g) were added to a DMF (100 mL) solution of compound 128-3 (6.00 g), and the mixture was stirred at 50 °C for 2 h. LC-MS showed the formation of the target product. The reaction solution was quenched with water (100 mL), extracted with ethyl acetate (100 mL × 3), and the combined organic phases were washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to silica gel column chromatography (ethyl acetate / petroleum ether = 0%–100%) to obtain compound 128-4 (4.50 g).

[1061] 1 H NMR (400MHz, DMSO-d6) δ8.01(s,1H),6.56-6.29(m,1H),4.84-4.76(m,2H),3.59(s,3H).

[1062] MS m / z(ESI): 249.1 [M+H]+

[1063] Step 4: Synthesis of Compound 128

[1064] Na₂CO₃ (52.6 mg) was added to a DMF (1.00 mL) solution of compound 128-4 (24.7 mg) and 2-((3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2,8-diazaspiro[4.5]dec-3-one (50.0 mg). The mixture was stirred at 100 °C for 2 h, and the reaction was confirmed by LC-MS. The reaction solution was filtered and then directly separated by C18 column chromatography (acetonitrile / 0.5% TFA aqueous solution = 0%–100%) to obtain the target compound 128 (24.8 mg).

[1065] 1 H NMR(400MHz,DMSO-d6)δ7.66(s,1H),6.51-6.24(m,1H),4.66-4.57(m,2H),4.04-4.01(m,2H),3.77 -3.73(m,2H),3.48(s,3H),3.35(s,2H),3.28(s,2H),2.28(s,2H),1.91(s,6H),1.71-1.63(m,4H).

[1066] MS m / z (ESI): 515.5 [M+H] +

[1067] Example 129: The synthesis method of Example 128 was followed, except that 2-((3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2,8-diazaspiro[4.5]dec-3-one in step 4 was replaced with the reactants in the table below, and compound 129 was synthesized in the same manner.

[1068] Example 130: 1-(2,2-difluoroethyl)-4-methyl-6-(2-(5-(trifluoromethyl)pyrimidin-2-yl)-2,6-diazaspiro[3,4]octane-6-yl)-1,4-dihydro-5H-pyrazolo[3,4-b]pyrazin-5-one

[1069] Step 1: Synthesis of intermediate 130-2

[1070] Compound 130-1 (1.00 g) and 6-chloro-1-(2,2-difluoroethyl)-4-methyl-1,4-dihydro-5H-pyrazolo[3,4-b]pyrazin-5-one (0.95 g) were dissolved in DMF (10 mL), and Na2CO3 (0.86 g) was added. The reaction mixture was stirred at 30 °C for 1 hour at room temperature. The reaction was monitored by LCMS until complete. The reaction mixture was concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography. 20g Compound 130-2 (1.40 g) was obtained by rapid silica gel column chromatography with a gradient of 0–50% petroleum ether / ethyl acetate at a flow rate of 30 mL / min.

[1071] MS m / z (ESI): 425.2 [M+H] +

[1072] Step 2: Synthesis of intermediate 130-3

[1073] Compound 130-2 (200 mg) was dissolved in DCM (2.00 mL), and a dioxane solution of HCl (4 M, 2.00 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction was monitored by LCMS and found to be complete. The reaction mixture was concentrated under reduced pressure to obtain crude compound 130-3 (170 mg), which was directly used in the next step of the reaction.

[1074] MS m / z (ESI): 325.3 [M+H] +

[1075] Step 3: Synthesis of Compound 130

[1076] Compound 130-3 (30.0 mg) and 2-bromo-5-(trifluoromethyl)pyrimidine (23.0 mg) were dissolved in DMF (1.00 mL), and K2CO3 (29.0 mg) was added. The reaction mixture was stirred at 100 °C for 2 hours. The reaction mixture was monitored by LCMS and the reaction was complete. After filtration, the reaction mixture was purified by preparative high performance liquid chromatography (column: Boston Prime C18 150×30 mm×5 μm; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile gradient: 10%-69%) to obtain the target compound 130 (9.41 mg).

[1077] 1 H NMR (400MHz, MeOD) δ8.09(s,2H),7.52(s,1H),6.38-6.06(m,1H),4.60-4.51(m,2H),4.20-3.80(m,8H),3.52(s,3H),2.30-2.26(m,2H).

[1078] MS m / z (ESI): 471.3 [M+H] +

[1079] Examples 131-133: The synthesis method of Example 130 was followed, except that 2-bromo-5-(trifluoromethyl)pyrimidine in step 3 was replaced with the reactants in the table below, and compounds 131-133 were synthesized in the same manner.

[1080] Examples 134-138: The synthesis method of Example 130 was followed, except that 130-1 in step 1 and 2-bromo-5-(trifluoromethyl)pyrimidine in step 3 were replaced with reactants 1 and 2 in the table below, respectively, and compounds 134-138 were synthesized in the same manner.

[1081] Example 139: (1-(2,2-difluoroethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)(7-(2-(trifluoromethyl)pyridin-4-yl)-2,7-diazaspiro[3,5]nonane-2-yl) methyl ketone

[1082] Step 1: Synthesis of intermediate 139-2

[1083] Under nitrogen protection, compound 139-1 (1.00 g), potassium vinyltrifluoroborate (1.53 g), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (334 mg), and triethylamine (2.31 g) were dissolved in anhydrous ethanol (80.0 mL). The reaction mixture was heated to 90 °C and stirred for 4 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 1:4) to obtain compound 139-2 (620 mg).

[1084] 1 H NMR(400MHz,Chloroform-d)δ8.68(s,1H),8.29(s,1H),7.07-6.87(m,1H),6.63-6.47(m,1H),6.44-6.05(m,1H),5.88-5.57(m,1H),5.03-4.65(m,2H).

[1085] MS m / z(ESI): 211.1 [M+H] +

[1086] Step 2: Synthesis of intermediate 139-3

[1087] Compound 139-2 (500 mg), potassium osmium tetroxide (88.0 mg), and sodium periodate (2.04 g) were dissolved in a mixed solvent of tetrahydrofuran (25.0 mL) and water (7.00 mL). The reaction mixture was stirred at room temperature for 2 hours. The reaction was monitored by LCMS and found to be complete. The reaction was quenched by adding saturated brine (50.0 mL) and extracted with ethyl acetate (50.0 mL × 3). The organic phases were combined, washed with saturated brine, dried, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 1:5) to obtain compound 139-3 (220 mg).

[1088] 1 H NMR (400MHz, Chloroform-d) δ10.23(s,1H),9.26(s,1H),8.48(s,1H),6.65-5.79(m,1H),5.42-4.58(m,2H).

[1089] MS m / z(ESI): 213.1 [M+H] +

[1090] Step 3: Synthesis of intermediate 139-4

[1091] Compound 139-3 (100 mg) and sodium dihydrogen phosphate aqueous solution (1.8 M, 0.10 mL) were dissolved in acetonitrile (2.00 mL). The reaction solution was cooled to 5 °C, and sodium chlorite aqueous solution (5 M, 0.20 mL) and hydrogen peroxide (30%, 107 mg) were added. The reaction solution was stirred at 15 °C for 3 hours. The reaction was monitored by LCMS and found to be complete. The precipitated solid was filtered by vacuum filtration, washed with water, and dried under vacuum at 40 °C to obtain compound 139-4 (84.0 mg).

[1092] 1 H NMR (400MHz, DMSO-d6) δ9.26(s,1H),8.69(s,1H),6.86-6.23(m,1H),5.15-4.89(m,2H).

[1093] MS m / z (ESI): 227.0 [MH] -

[1094] Step 4: Synthesis of Compound 139

[1095] Compound 139-4 (50.0 mg), 139-A (75.0 mg), HATU (124 mg), and N,N-diisopropylethylamine (85.0 mg) were dissolved in DMF (1.00 mL), and the reaction mixture was stirred at room temperature for 2 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (5.00 mL) was added, followed by extraction with ethyl acetate (5.00 mL × 3). The organic phase was washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by preparative liquid chromatography (Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; using a mixture of water (containing 7 mmol / L ammonium bicarbonate) and acetonitrile with decreasing polarity (35%–70%) as eluent) to obtain the target compound 139 (65.0 mg).

[1096] 1 H NMR(400MHz,DMSO-d6)δ9.19(s,1H),8.69(s,1H),8.33-8.13(m,1H),7.28-7.16(m,1H),7.15-7.04(m,1H ),6.70-6.25(m,1H),5.13-4.88(m,2H),4.48(s,2H),3.94(s,2H),3.60-3.41(m,4H),1.96-1.72(m,4H)..

[1097] MS m / z(ESI): 482.0 [M+H] +

[1098] Synthesis of intermediate 139-A:

[1099] Step 1: Synthesis of intermediate 139-A-1

[1100] 2,7-diazaspiro[3.5]nonane-2-carboxylic acid tert-butyl ester (2.00 g), 2-trifluoromethyl-4-bromopyridine (3.00 g), and potassium carbonate (3.66 g) were dissolved in DMF (20 mL). The reaction solution was heated to 80 °C and stirred for 10 hours. The reaction solution was monitored by LCMS and the reaction was complete. The reaction solution was diluted with water (20 mL), extracted with ethyl acetate (40 mL * 3), the organic phase was washed three times with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 5%-20%) to obtain compound 139-A-1 (3.00 g) as an oily liquid.

[1101] MS m / z(ESI): 372.2 [M+H] +

[1102] Step 2: Synthesis of intermediate 139-A

[1103] Compound 139-A-1 (2.60 g) was dissolved in dichloromethane (20 mL). A 4 M, 17.5 mL solution of hydrogen chloride / 1,4-dioxane was added to the reaction mixture, and the mixture was stirred at room temperature for 2 hours. The reaction was monitored by LC-MS and found to be complete. The solvent was removed from the reaction mixture under reduced pressure to obtain compound 139-A (1.70 g) as a yellow solid, requiring no further purification.

[1104] 1 H NMR (400MHz, MeOD-d4) δ8.41-8.10(m,1H),7.85-7.58(m,1H),7.52-6.83(m,1H),3.99(s,4H),3.92-3.73(m,4H),2.21-1.90(m,4H).

[1105] MS m / z(ESI): 272.2 [M+H] +

[1106] Example 140: The synthesis method of Example 139 was followed, except that compound 139-1 in step 1 was replaced with the starting material in the table below, and compound 140 was synthesized in the same manner.

[1107] Example 141: 1-(2,2-difluoroethyl)-5-methyl-6-(6-(2-(trifluoromethyl)pyridin-4-yl)-2,6-diazaspiro[3,4]octane-2-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one

[1108] Step 1: Synthesis of intermediate 141-2

[1109] 10.0 g of compound 141-1 in 100 mL of DMF was added with 11.0 g of 2,2-difluoroethyl trifluoromethanesulfonate and 49.0 g of Cs₂CO₃. The reaction mixture was stirred at 25 °C for 16 h. 100 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (80.0 mL × 2). The combined organic phases were washed with saturated brine (80.0 mL × 2) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure to obtain the crude product. The crude product was purified by an automated column chromatography (ethyl acetate / petroleum ether = 1:1) to obtain compound 141-2 (3.00 g).

[1110] MS m / z(ESI): 262.0 [M+H] +

[1111] Step 2: Synthesis of intermediate 141-3

[1112] Urea peroxide (2.20 g) and TFAA (4.80 g) were added to a solution of compound 141-2 (3.00 g) in ACN (30.0 mL), and the mixture was stirred at 25 °C for 16 h. Water (60.0 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (60.0 mL × 3). The combined organic phases were washed with saturated brine (60.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by an automated column chromatography (ethyl acetate / petroleum ether = 1:1) to obtain compound 141-3 (1.80 g).

[1113] MS m / z(ESI): 278.1 [M+H] +

[1114] Step 3: Synthesis of intermediate 141-4

[1115] TMSCl (3.53 g) and TFAA (6.79 g) were added to a chloroform (18.0 mL) solution of compound 141-3 (1.80 g), and the mixture was stirred at 25 °C for 1 h. Then, triethylamine (3.27 g) was added, and the mixture was stirred overnight at room temperature. Water (50.0 mL) was added to the reaction mixture, and the mixture was extracted with DCM (50.0 mL × 3). The combined organic phases were washed with saturated brine (50.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (dichloromethane / methanol = 10:1) to obtain compound 141-4 (160 mg).

[1116] MS m / z(ESI): 278.1 [M+H] +

[1117] Step 4: Synthesis of intermediate 141-5

[1118] Iodomethane (122 mg) was added to a DMF (2 mL) solution of compound 141-4 (160 mg) and K2CO3 (159 mg) at 0 °C, and the mixture was stirred at 25 °C for 1 h. Water (20.0 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20.0 mL × 3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by an automated column chromatography (dichloromethane / methanol = 30:1) to obtain compound 141-5 (50.0 mg).

[1119] MS m / z(ESI): 292.2 [M+H] +

[1120] Step 5: Synthesis of Compound 141

[1121] To a solution of compound 141-5 (50.0 mg) in NMP (1.00 mL), 6-(2-(trifluoromethyl)pyridin-4-yl)-2,6-diazaspiro[3.4]octane (44.0 mg) and DIEA (0.50 mL) were added, and the mixture was stirred at 120 °C for 2 h under microwave conditions. The reaction solution was filtered and then purified directly by C18 column chromatography (acetonitrile / 0.1% TFA aqueous solution = 0%–100%) to obtain target compound 141 (2.70 mg).

[1122] 1 H NMR (400MHz, MeOD-d4) δ8.18(d,J=6.0Hz,1H),8.01(s,1H),6.91(d,J=2.4Hz,1H),6.71(dd,J=6.0,2.4Hz,1H),6.37 -6.21(m,1H),5.92(s,1H),4.85-4.60(m,2H),4.07-4.02(m,4H),3.58-3.54(m,4H),3.49(s,3H),2.43-2.39(m,2H).

[1123] MS m / z (ESI): 469.1 [M+H] +

[1124] Example 142: 8-(1-(2,2-difluoroethyl)-4-methyl-5-oxo-4,5-dihydro-1H-pyrazolo[4,3-b]pyridin-6-yl)-2-((2-(trifluoromethyl)pyridin-4-yl)methyl)-2,8-diazaspiro[4,5]decane-3-one

[1125] Step 1: Synthesis of intermediate 142-2

[1126] Compound 142-1 (500 mg) and 4-(bromomethyl)-2-(trifluoromethyl)pyridine (708 mg) were dissolved in DMF (10.0 mL). Sodium hydride (60%, 70.0 mg) was then added to the reaction mixture, and the mixture was stirred at 25 °C for 1 hour. The reaction was monitored by LCMS and found to be complete. The reaction mixture was diluted with water (5 mL), extracted with ethyl acetate (10.0 mL × 3), and the organic phase was washed three times with saturated brine. After drying with anhydrous sodium sulfate, the mixture was concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 10%-30%) to obtain compound 142-2 (440 mg).

[1127] MS m / z (ESI): 358.1 [M+H-56] +

[1128] Step 2: Synthesis of intermediate 142-3

[1129] Compound 142-2 (400 mg) was dissolved in dichloromethane (5.00 mL), followed by the addition of a 4 M, 2.42 mL solution of hydrogen chloride / 1,4-dioxane. The mixture was stirred at 25 °C for 2 hours. The reaction was monitored by LC-MS and found to be complete. The solvent was removed from the reaction mixture under reduced pressure to obtain compound 142-3 (270 mg), which was used directly in the next reaction step.

[1130] MS m / z (ESI): 314.1 [M+H] +

[1131] Step 3: Synthesis of Compound 142

[1132] Under nitrogen protection, compound 142-3 (64.4 mg), 6-bromo-1-(2,2-difluoroethyl)-4-methyl-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one (50.0 mg), Pd2(dba)3 (15.7 mg), XantPhos (19.8 mg), and cesium carbonate (167 mg) were dissolved in 1,4-dioxane (2.00 mL). The reaction mixture was heated to 100 °C and stirred for 8 hours. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, the reaction mixture was filtered. The filtrate was diluted with ethyl acetate (5 mL), the organic phase was washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; using a mixture of water (containing 7 mmol / L ammonium bicarbonate) and acetonitrile in decreasing polarity (35%-70%) as eluent) to obtain target compound 142 (20.0 mg).

[1133] 1 H NMR(400MHz,DMSO-d6)δ8.19-8.05(m,1H),7.98(s,1H),7.87-7.75(m,1H),7.66-7.40(m,2H),6.59-6.18(m,1H),4.9 2-4.76(m,2H),4.60(s,2H),3.92(s,3H),3.32-3.29(m,2H),3.12-2.93(m,4H),2.41-2.30(m,2H),1.90-1.63(m,4H).

[1134] MS m / z (ESI): 525.1 [M+H] +

[1135] Example 143: The synthesis method of Example 142 was followed, except that 142-1 and 4-(bromomethyl)-2-(trifluoromethyl)pyridine in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compound 143 was synthesized in the same manner.

[1136] Example 144: 1-(2,2-difluoroethyl)-6-((2-((1,1,1-trifluoroprop-2-yl)oxy)-7-azaspiro[3.5]nonane-7-yl)methyl)-1H-pyrazolo[3,4-b]pyrazine

[1137] Step 1: Synthesis of intermediate 144-2

[1138] Compound 144-1 (1.00 g) was dissolved in DMF (10 mL), and NaH (0.25 g, 60%) was added. The mixture was stirred at room temperature for 0.5 hours, followed by the addition of 1,1,1-trifluoropropane-2-ylmethanesulfonate (1.20 g). The reaction mixture was sealed in a microwave-safe tube and stirred at 80 °C for 16 hours. LC-MS showed the presence of the product. Water (20.0 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by automated column chromatography (PE:EA:5:1) to give compound 144-2 (620 mg).

[1139] Step 2: Synthesis of intermediate 144-3

[1140] Compound 144-2 (100 mg) was dissolved in DCM (1.00 mL), and TFA (33.8 mg, 1 mL) was added. The mixture was reacted at room temperature for 2 hours. LC-MS analysis showed the presence of product. The reaction solution was concentrated, and saturated sodium bicarbonate aqueous solution (10.0 mL) was added. The mixture was extracted with ethyl acetate (5.00 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 144-3 (70.0 mg).

[1141] MS m / z(ESI): 238.0 [M+H] +

[1142] Step 3: Synthesis of Compound 144

[1143] Compounds 144-3 (50.0 mg), 139-3 (67.1 mg), and AcOH (5.44 mg) were dissolved in MeOH (2.00 mL) and stirred at room temperature for 1 hour. NaBH3CN (39.73 mg) was added, and the reaction was continued at room temperature for 16 hours. LC-MS analysis confirmed the presence of product. The reaction mixture was filtered and concentrated. The crude product was purified by preparative chromatography (column: C18 150 × 40 mm; mobile phase: [water (FA)-acetonitrile]) to obtain the target compound 144 (3.00 mg).

[1144] 1 H NMR(400MHz,MeOD)δ8.75(s,1H),8.47(s,1H),6.51-6.16(m,1H),5.03-4.91(m,2H),4.73(s,2H),4.30-4.19(m,1 H),3.97-3.85(m,1H),3.57(s,2H),3.20(s,2H),2.36(d,J=66.4Hz,2H),2.00-1.80(m,6H),1.27(d,J=6.4Hz,3H).

[1145] MS m / z (ESI): 434.1 [M+H] +

[1146] Example 145: The synthesis method of Example 144 is followed, except that intermediate 144-1 in step 1 is replaced with the starting material in the table below, and compound 145 is synthesized in the same way.

[1147] Examples 146-148: The synthesis method of Example 144 was followed, except that compounds 144-1 and 1,1,1-trifluoropropane-2-ylmethanesulfonate in step 1 were replaced with starting materials 1 and 2 in the table below, respectively, and compounds 146-148 were synthesized in the same manner.

[1148] Example 149: 4-Cyclopropoxy-1-(2,2-difluoroethyl)-6-(2-(2-(trifluoromethyl)pyridin-4-yl)-2,7-diazaspiro[3.5]nonane-7-yl)-1H-pyrazolo[3,4-d]pyrimidine

[1149] Step 1: Synthesis of intermediate 149-2

[1150] Under a nitrogen atmosphere, compound 149-1 (500 mg) and cyclopropanol (169 mg) were dissolved in 1,4-dioxane (10 mL). Potassium tert-butoxide (623 mg) was added in portions at 0 °C, and the reaction mixture was stirred overnight at 25 °C. The reaction mixture was monitored by LC-MS and found to be complete. Water (10.0 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (30.0 mL × 3). The organic phase was washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1; Rf: 0.6) to obtain compound 149-2 (300 mg).

[1151] Step 2: Synthesis of intermediate 149-3

[1152] Under a nitrogen atmosphere, compound 149-2 (300 mg) and 2,2-difluoroethyl trifluoromethanesulfonate (336 mg) were dissolved in N,N-dimethylformamide (10 mL), and cesium carbonate (928 mg) was added at 0 °C. The reaction mixture was stirred overnight at 25 °C. The reaction mixture was monitored by LCMS and the reaction was complete. Water (10.0 mL) was added to the reaction mixture, and then it was extracted with ethyl acetate (30.0 mL × 3). The organic phase was washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 1 / 1; Rf: 0.6) to obtain compound 149-3 (170 mg).

[1153] Step 3: Synthesis of Compound 149

[1154] Compound 149-3 (120 mg) and 2-(2-(trifluoromethyl)pyridin-4-yl)-2,7-diazaspiro[3.5]nonane hydrochloride (237 mg) were dissolved in N,N-dimethylformamide (3 mL), followed by the addition of potassium carbonate (181 mg). The reaction mixture was stirred at 90 °C for 2 hours. The reaction mixture was monitored by LCMS and the reaction was complete. After cooling the reaction mixture to room temperature, water (10.0 mL) was added, followed by extraction with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 10 / 1; Rf: 0.6) and C-18 column (water (0.05% ammonium bicarbonate) / MeCN = 1 / 1) to obtain the target compound 149 (87.1 mg).

[1155] 1H NMR (400MHz, DMSO-d6) δ8.23(d,J=5.7Hz,1H),7.94(s,1H),6.73(d,J=2.2Hz,1H),6.55(dd,J=5.7,2.3Hz,1H),6.54-6.25(m,1H ),4.63(td,J=14.9,3.9Hz,2H),4.55-4.45(m,1H),3.90-3.77(m,8H),1.87-1.76(m,4H),0.89-0.83(m,2H),0.83-0.77(m,2H).

[1156] MS m / z (ESI): 510.1 [M+H] +

[1157] Example 150: 1-(2,2-difluoroethyl)-5-ethyl-6-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3,4]octane-6-yl)oxy)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one

[1158] Step 1: Synthesis of Intermediate 150-2

[1159] Compound 150-1 (4.00 g) and potassium tert-butoxide (6.20 g) were dissolved in 1,4-dioxane (150 mL), and p-methoxybenzyl alcohol (5.00 mg) was slowly added at 0 °C. The reaction mixture was stirred at 25 °C for 16 hours. After the reaction was completed, water (500 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (200 mL * 3). The combined organic phases were washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate: 1 / 1) to obtain compound 150-2 (3.00 g).

[1160] MS m / z (ESI): 288.9 [MH] -

[1161] Step 2: Synthesis of intermediate 150-3

[1162] Compound 150-2 (2.50 g) and cesium carbonate (5.60 g) were dissolved in DMF (50 mL), and 2,2-difluoroethyl trifluoromethanesulfonate (2.02 g) was slowly added at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours. After the reaction was completed, the reaction mixture was diluted with water (150 mL), extracted with ethyl acetate (80 mL × 3), the combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate: 10 / 1) to obtain compound 150-3 (2.10 g).

[1163] MS m / z (ESI): 355.1 [M+H] +

[1164] Step 3: Synthesis of intermediate 150-4

[1165] Compound 150-3 (2.10 g) was dissolved in dichloromethane (42 mL), and TFA (42 mL) was added. The mixture was stirred at 30 °C for 2 hours. After the reaction was complete, the reaction solution was concentrated and slurryed with diethyl ether. The solid was concentrated to obtain crude compound 150-4 (1.40 g), which was used directly in the next step.

[1166] MS m / z (ESI): 232.9 [MH] -

[1167] Step 4: Synthesis of intermediate 150-5

[1168] Compound 150-4 (50.0 mg) was dissolved in N,N-dimethylformamide (1 mL). Potassium carbonate (88.4 mg) was added to the reaction solution at 0 °C, and the mixture was stirred for 5 minutes. Then, iodoethane (36.6 mg) was added. The reaction solution was stirred at room temperature for 2 hours. The reaction was monitored by LCMS and found to be complete. Water (30.0 mL) was added to the reaction solution, followed by extraction with ethyl acetate (10.0 mL × 3). The organic phase was washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 10 / 1; Rf: 0.6) to obtain compound 150-5 (50.0 mg).

[1169] 1 H NMR (400MHz, DMSO-d6) δ8.23(s,1H),6.43(tt,J=54.5,3.5Hz,1H),4.77-4.69(m,2H),4.24-4.19(m,2H),1.26(t,J=7.1Hz,3H).

[1170] MS m / z(ESI): 263.0 [M+H] +

[1171] Step 5: Synthesis of intermediate 150-6

[1172] Compound 150-5 (38.1 mg) was dissolved in tetrahydrofuran (1 mL). Potassium tert-butoxide (18.8 mg) was added to the reaction solution at 0 °C, and the mixture was stirred at low temperature for 5 minutes. Then, tert-butyl 6-hydroxy-2-azaspiro[3.4]octane-2-carboxylic acid was added (40.0 mg). The reaction solution was stirred at room temperature for 2 hours. The reaction was monitored by LCMS and found to be complete. The reaction solution was then extracted with water (30.0 mL) and then with ethyl acetate (10.0 mL × 3). The organic phase was washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) to obtain compound 150-6 (60.0 mg).

[1173] 1 H NMR(400MHz,DMSO-d6)δ8.04(s,1H),6.57-6.27(m,1H),4.68-4.60(m,2H),3.96-3.91(m,2H),3.85-3.77(m,4H),2 .28-2.21(m,2H),2.05-2.01(m,1H),1.92-1.86(m,2H),1.74-1.69(m,2H),1.37(s,9H),1.13(t,J=7.0,7.0Hz,3H).

[1174] MS m / z (ESI): 398.2 [M+H-56] +

[1175] Step 6: Synthesis of intermediate 150-7

[1176] Compound 150-6 (60.0 mg) was dissolved in dichloromethane (2.5 mL), and trifluoroacetic acid (0.50 mL) was slowly added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. LC-MS monitoring showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain compound 150-7 (60.0 mg), which was directly used in the next reaction step.

[1177] 1H NMR(400MHz, DMSO-d6)δ7.97(s,1H),6.35(tt,J=54.7,3.8Hz,2H),4.56(td,J=15.0,14.9,3.8Hz,2H),3.89-3 .71(m,6H),2.23-2.21(m,2H),2.07-2.02(m,2H),1.98-1.92(m,1H),1.90-1.81(m,2H),1.05(t,J=7.0Hz,3H).

[1178] MS m / z (ESI): 354.1 [M+H] +

[1179] Step 7: Synthesis of Compound 150

[1180] Compound 150-7 (31.9 mg), 4-bromo-2-(trifluoromethyl)pyridine (60.0 mg), and potassium carbonate (53.2 mg) were dissolved in N,N-dimethylformamide (1.00 mL). The reaction mixture was stirred overnight at 80 °C. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (30.0 mL) was added, followed by extraction with ethyl acetate (10.0 mL × 3). The organic phase was washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) and high performance liquid chromatography (column: YMC TAR-C18, 30 × 150 mm, 5 μm; mobile phase: [water (ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 50-80%) to obtain the target compound 150 (12.0 mg).

[1181] 1 H NMR (400MHz, DMSO-d6) δ8.23(d,J=5.6Hz,1H),8.05(s,1H),6.72(d,J=2.2Hz,1H),6.58-6.28(m,2H),5.57(d,J=6.2Hz,1 H),4.69-4.61(m,2H),4.07-3.91(m,6H),2.36-2.27(m,2H),2.23-2.12(m,2H),2.03-1.96(m,2H),1.18(t,J=7.0Hz,3H).

[1182] MS m / z(ESI): 499.1 [M+H] +

[1183] Example 151: 1-(2,2-difluoroethyl)-4-methoxy-6-((2-(2-(trifluoromethyl)pyrimidin-5-yl)-2-azaspiro[3.5]nonane-7-yl)oxy)-1H-pyrazolo[3,4-d]pyrimidine

[1184] Step 1: Synthesis of intermediate 151-2

[1185] Compound 151-1 (0.20 g) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. LCMS monitoring showed that the starting material was completely consumed. The reaction mixture was concentrated under reduced pressure to obtain title compound 151-2 (200 mg) as a viscous oily substance, which did not require further purification and was used directly in the next reaction step.

[1186] MS m / z (ESI): 140.1 [M+H] +

[1187] Step 2: Synthesis of intermediate 151-3

[1188] Compound 151-2 (125 mg), 5-bromo-2-(trifluoromethyl)pyrimidine (168 mg), RuPhos-Pd-G3 (41.0 mg), and cesium carbonate (483 mg) were dissolved in 1,4-dioxane (5.00 mL). The reaction mixture was heated to 80 °C and stirred for 2 hours. LC-MS analysis showed the reaction was complete. After removing the solvent under reduced pressure, ethyl acetate (20 mL) was added, and the mixture was washed with saturated brine (20 mL × 3). The organic phases were combined and dried over anhydrous sodium sulfate. The concentrate was purified by column chromatography (dichloromethane / methanol: 0-5%) to obtain the title compound 151-3 (75.0 mg).

[1189] 1 H NMR (400MHz, Chloroform-d) δ8.01(s,2H),3.95(s,4H),2.67-2.32(m,4H),2.30-2.03(m,4H).

[1190] MS m / z(ESI): 286.1 [M+H] +

[1191] Step 3: Synthesis of intermediate 151-4

[1192] Compound 151-3 (55.0 mg) was dissolved in methanol (1 mL), and sodium borohydride (15.0 mg) was added at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The reaction was monitored by LC-MS and found to be complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product of the title compound 151-4 (55.0 mg) as an oil. No further purification was required, and it was used directly in the next reaction step.

[1193] MS m / z(ESI): 288.1 [M+H] +

[1194] Step 4: Synthesis of Compound 151

[1195] Compound 151-4 (50.0 mg) was dissolved in tetrahydrofuran (1 mL), potassium tert-butoxide (23.0 mg) was added, and after stirring for 5 minutes, compound 10-1 (52.0 mg) was added. The reaction mixture was heated to 45 °C and stirred for 2 hours. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was diluted with ethyl acetate (10 mL) and washed with saturated brine (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, concentrated, and dissolved in acetonitrile (1 mL). The crude product was purified by preparative liquid chromatography (Boston Prime C18 column: 5 μm silica, 30 mm diameter, 150 mm length; using a mixture of water (containing ammonium bicarbonate) and acetonitrile with decreasing polarity (55%-85%) as eluent) to obtain the title compound 151 (10.5 mg).

[1196] 1 H NMR(400MHz,Chloroform-d)δ7.97(s,2H),7.97-7.92(m,1H),6.36-6.03(m,1H),5.48-5.10(m,1H ),4.74-4.60(m,2H),4.17-4.02(m,3H),3.89-3.73(m,4H),2.14-1.96(m,4H),1.87-1.78(m,4H).

[1197] MS m / z (ESI): 500.1 [M+H] +

[1198] Example 152: 1-(2,2-difluoroethyl)-4-methyl-6-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.4]octane-6-yl)methoxy)-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one

[1199] Step 1: Synthesis of intermediate 152-2

[1200] Methylenetriphenylphosphine bromide (2.06 g) was dissolved in 1,4-dioxane (15.0 mL), and potassium tert-butoxide (648 mg) was slowly added at 0 °C. The reaction mixture was purged with nitrogen three times and stirred at room temperature for 1 hour. Compound 152-1 (1.00 g) was dissolved in 1,4-dioxane at 0 °C and slowly added dropwise to the reaction mixture. The reaction mixture was stirred at room temperature overnight. The reaction mixture was monitored by LCMS and the reaction was complete. The reaction mixture was filtered, and the filtrate was added to water (50.0 mL) and then extracted with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate: 3 / 1; Rf: 0.6) to give compound 152-2 (450 mg).

[1201] 1 H NMR (400MHz, DMSO-d6) δ4.88-4.80(m,2H),3.65(s,4H),2.44-2.42(m,2H),2.28-2.23(m,2H),1.83-1.80(m,2H),1.37(s,9H).

[1202] MS m / z(ESI): 224.2 [M+H] +

[1203] Step 2: Synthesis of intermediate 152-3

[1204] Compound 152-2 (400 mg) was dissolved in tetrahydrofuran (5 mL). Under a nitrogen atmosphere at 0 °C, a borane dimethyl sulfide complex (2 M, 985 μL) was added to the reaction solution, and the mixture was stirred at room temperature for 1 hour. At 0 °C, an aqueous sodium hydroxide solution (2 M, 985 μL) was slowly added to the reaction solution, followed by hydrogen peroxide (223 mg, 30%). The mixture was stirred for 30 minutes. LC-MS monitoring showed the reaction was complete. The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate (20.0 mL), washed with water (30.0 mL) and saturated brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 152-3 (400 mg).

[1205] 1 H NMR (400MHz, DMSO-d6) δ4.48-4.45(m,1H),3.72-3.59(m,4H),3.25-3.22(m,2H),2.04-2.01(m ,1H),1.86-1.80(m,1H),1.78-1.58(m,3H),1.48-1.43(m,1H),1.36(s,9H),1.31-1.21(m,1H).

[1206] MS m / z(ESI): 186.0 [M+H-56] +

[1207] Step 3: Synthesis of intermediate 152-4

[1208] Compound 152-3 (400 mg) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2.00 mL) was added to the reaction solution at 0 °C. The reaction solution was stirred at room temperature for 2 hours. The reaction solution was monitored by LCMS, and the reaction was complete. The reaction solution was concentrated under reduced pressure to give compound 152-4 (400 mg).

[1209] 1 H NMR(400MHz,DMSO-d6)δ11.20-10.50(br s,1H),8.90-8.50(br s,1H),4.33-4.23(m,2H),3.91-3.73(m,4H),2.41-2.30(m,1H),2.12-2.06(m,1 H),1.96-1.83(m,2H),1.82-1.70(m,1H),1.61-1.54(m,1H),1.38-1.29(m,1H).

[1210] MS m / z (ESI): 142.2 [M+H] +

[1211] Step 4: Synthesis of intermediate 152-5

[1212] Compound 152-4 (400 mg), 4-bromo-2-(trifluoromethyl)pyridine (390 mg), and potassium carbonate (650 mg) were dissolved in N,N-dimethylformamide (4.00 mL). The reaction mixture was stirred overnight at 60 °C. The reaction was monitored by LCMS and found to be complete. After cooling to room temperature, water (50.0 mL) was added, followed by extraction with ethyl acetate (20.0 mL × 3). The organic phase was washed with saturated brine (50.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) to obtain compound 152-5 (210 mg).

[1213] 1H NMR (400MHz, DMSO-d6) δ8.21(d,J=5.7Hz,1H),6.68(d,J=2.3Hz,1H),6.51(dd,J=5.7,2.3Hz,1H),4.50(s,1H),4.26-4.18 (m,1H),3.94-3.87(m,1H),3.85-3.82(m,4H),2.13-2.06(m,1H),1.97-1.91(m,2H),1.75-1.64(m,2H),1.60-1.49(m,2H).

[1214] MS m / z(ESI): 287.1 [M+H] +

[1215] Step 5: Synthesis of Compound 152

[1216] Compound 152-5 (100 mg), 6-bromo-1-(2,2-difluoroethyl)-4-methyl-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one (204 mg), Rockphos-Pd-G3 (58.6 mg), and cesium carbonate (341 mg) were dissolved in 1,4-dioxane (2.00 mL), purged with nitrogen three times, and stirred overnight at 100 °C. The reaction mixture was monitored by LCMS and the reaction was complete. After the reaction solution was cooled to room temperature, water (30.0 mL) was added, followed by extraction with ethyl acetate (10.0 mL × 3). The organic phase was washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol: 50 / 1; Rf: 0.6) and high performance liquid chromatography (column: YMC TAR-C18, 30*150 mm, 5 μm; mobile phase: [water (ammonium bicarbonate)-acetonitrile]; acetonitrile gradient: 55-85%) to obtain the target compound 152 (10.0 mg).

[1217] 1 H NMR (400MHz, DMSO-d6) δ8.22(d,J=5.7Hz,1H),7.79(s,1H),7.46(s,1H),6.70(d,J=2.3Hz,1H),6.55-6.52(m,1H),6.51- 6.24(m,1H),4.87-4.77(m,2H),3.99-3.85(m,6H),3.52(s,3H),2.17-2.13(m,1H),2.01-1.88(m,4H),1.73-1.68(m,2H).

[1218] MS m / z (ESI): 498.1 [M+H] +

[1219] Examples 153-154: The synthesis method of Example 152 was followed, except that compound 152-1 in step 1 was replaced with the starting material in the table below, and compounds 153-154 were synthesized in the same manner.

[1220] Example 155: 1-(2,2-difluoroethyl)-7-((3aR,5s,6aS)-2-(4-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrolo-5-yl)-4,5,6,7-tetrahydropyrazolo[3,4-c]azapheno-8(1H)-one

[1221] Step 1: Synthesis of intermediate 155-2

[1222] Compound 155-1 (1.40 g) was dissolved in DMF (100 mL), and 4-bromo-1-(2,2-difluoroethyl)-1H-pyrazole-5-carboxylic acid (1.74 g) and NMI (1.52 g) were added, followed by TCFH (2.60 g). The reaction mixture was stirred at 60 °C for 16 h. Water (60 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (80 mL × 3). The combined organic phases were washed with saturated brine (60 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 1:2) to obtain compound 155-2 (1.50 g).

[1223] MS m / z (ESI): 407.2 [M+H-56] +

[1224] Step 2: Synthesis of intermediate 155-3

[1225] Compound 155-2 (1.50 g) was dissolved in a mixture of 1,4-dioxane (15 mL) / H2O (3 mL), and K2CO3 (894 mg), (E)-tert-butyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)allyl)oxy)silane (1.10 g) and Pd(dppf)Cl2 (237 mg) were added. The mixture was stirred at 100 °C for 6 h. Water (30.0 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL × 2). The combined organic phases were washed with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 1:3) to obtain compound 155-3 (1.30 g).

[1226] MS m / z (ESI): 553.5 [MH] -

[1227] Step 3: Synthesis of intermediate 155-4

[1228] Compound 155-3 (1.30 g) was dissolved in a mixture of THF (10 mL) and H₂O (5 mL), and NaOAc (1.92 g) and p-toluenesulfonyl hydrazine (4.36 g) were added. The mixture was stirred at 80 °C for 16 h. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (40 mL × 2). The combined organic phases were washed with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by an automated column chromatography (ethyl acetate / petroleum ether = 1:1) to obtain compound 155-4 (1.30 g).

[1229] MS m / z (ESI): 555.0 [MH] -

[1230] Step 4: Synthesis of intermediate 155-5

[1231] Compound 155-4 (1.30 g) was dissolved in THF (13 mL), and a TBAF THF solution (1 M, 7 mL) was added. The mixture was stirred at room temperature for 3 h. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (ethyl acetate / petroleum ether = 1:1) to obtain compound 155-5 (800 mg).

[1232] Step 5: Synthesis of intermediate 155-6

[1233] Compound 155-5 (800 mg) was dissolved in DCM (8 mL), and TEA (545 mg) and MsCl (310 mg) were added. The mixture was stirred at room temperature for 1 h. Water (20 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL × 2). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude compound 155-6 (650 mg), a yellow solid, which was used directly in the next reaction.

[1234] MS m / z (ESI): 519.2 [MH] -

[1235] Step 6: Synthesis of intermediate 155-7

[1236] NaH (100 mg, 60%) was added to a DMF (6 mL) solution of compound 155-6 (650 mg), and the mixture was stirred at room temperature for 3 h. Water (20 mL) was added to the reaction solution, and the mixture was extracted with EA (20.0 mL × 2). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 1:2) to obtain compound 155-7 (300 mg).

[1237] MS m / z (ESI): 369.1 [M+H-56] +

[1238] Step 7: Synthesis of intermediate 155-8

[1239] Add 1 ml of TFA to a 2 ml solution of compound 155-7 (300 mg) in DCM and stir at room temperature for 2 h. Concentrate the reaction solution directly to obtain crude compound 155-8 (200 mg), a colorless oil, which can be used directly in the next reaction.

[1240] MS m / z (ESI): 325.1 [M+H] +

[1241] Step 8: Synthesis of Compound 155

[1242] Compound 155-8 (50.0 mg) and 2-bromo-4-(trifluoromethyl)pyridine (42.0 mg) were dissolved in DMF (1.00 mL), and K2CO3 (64.0 mg) was added. The mixture was stirred at 100 °C for 3 h. Water (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL × 2). The combined organic phases were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by C18 column chromatography (acetonitrile / 0.1% FA aqueous solution = 0%–100%) to obtain the target compound 155 (8.90 mg).

[1243] 1 H NMR (400MHz, DMSO-d6) δ8.22(d,J=5.8Hz,1H),7.49(s,1H),7.12-6.88(m,2H),6.44-6.07(m,1H),5.02-4.89(m,1H),4.87-4. 73(m,2H),3.79-3.65(m,2H),3.45-3.36(m,2H),3.30-3.18(m,2H),3.10-2.98(m,2H),2.74-2.64(m,2H),2.03-1.77(m,6H).

[1244] MS m / z (ESI): 470.3 [M+H] +

[1245] Examples 156-157: The synthesis method of Example 155 was followed, except that compound 155-1 in step 1 and 2-bromo-4-(trifluoromethyl)pyridine in step 8 were replaced with reactants 1 and 2 in the table below, respectively, and compounds 156-157 were synthesized in the same manner.

[1246] Example 158: 6-(2-(2-(difluoromethyl)pyridin-4-yl)-2,6-diazaspiro[3,4]octane-6-yl)-1-ethyl-4-methyl-1,4-dihydro-5H-pyrazolo[3,4-b]pyrazin-5-one

[1247] Step 1: Synthesis of intermediate 158-2

[1248] Compound 158-1 (5.00 g) and cesium carbonate (21.3 g) were dissolved in DMF (100 mL), and iodoethane (5.57 g) was added. The reaction mixture was stirred at 25 °C for 2 hours. After the reaction was complete, the reaction mixture was diluted with water (300 mL), extracted with ethyl acetate (150 mL × 3), and the organic phase was washed with saturated brine (200 mL × 2). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (gradient 0–20% ethyl acetate / petroleum ether) to obtain compound 158-2 (3.20 g).

[1249] MS m / z (ESI): 183.1 [M+H] +

[1250] Step 2: Synthesis of intermediate 158-3

[1251] Compound 158-2 (3.20 g) was dissolved in acetonitrile (65 mL), and urea peroxide (3.47 g) was added. Trifluoroacetic anhydride (7.39 g) was then added at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours. After the reaction was complete, a saturated sodium thiosulfate aqueous solution was added to quench the reaction mixture. Extraction was performed using ethyl acetate (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (gradient 0–70% ethyl acetate / dichloromethane) to obtain compound 158-3 (3.00 g).

[1252] MS m / z (ESI): 199.1 [M+H] +

[1253] Step 3: Synthesis of intermediate 158-4

[1254] Compound 158-3 (3.00 g) was dissolved in chloroform (60.0 mL), and TFAA (15.9 g) and TMSCl (8.23 g) were added and stirred for 1 hour. TEA (8.12 g) was added at 0 °C, and the reaction mixture was stirred at 25 °C for 16 hours. The pH of the reaction mixture was adjusted to 8 with saturated sodium bicarbonate solution, and extraction was performed using dichloromethane:methanol = 10:1 (50.0 mL × 5). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by pulping (petroleum ether:ethyl acetate = 2:1) to obtain compound 158-4 (2.60 g).

[1255] MS m / z (ESI): 199.2 [M+H] +

[1256] Step 4: Synthesis of intermediate 158-5

[1257] Compound 158-4 (2.60 g) and potassium carbonate (3.62 g) were added to N,N-dimethylformamide (50 mL). Iodomethane (2.24 g) was added at 0 °C, and the reaction mixture was stirred at 25 °C for 2 hours. After the reaction was completed, the reaction mixture was diluted with water (150 mL), extracted with ethyl acetate (80.0 mL × 3), and the organic phase was washed with saturated brine (100 mL × 2). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (gradient 0–50% ethyl acetate / petroleum ether) to obtain compound 158-5 (1.90 g).

[1258] MS m / z(ESI): 213.1 [M+H] +

[1259] Step 5: Synthesis of Compound 158

[1260] Compound 158-5 (70.0 mg) and potassium carbonate (152 mg) were dissolved in DMF (1.00 mL), and 2-(2-(difluoromethyl)pyridin-4-yl)-2,6-diazaspiro[3.4]octane (52.6 mg) was added. The reaction mixture was stirred at 80 °C for 2 hours. After the reaction was completed, the filtrate was filtered and purified by preparative high performance liquid chromatography (mobile phase: [0.1% FA aqueous solution-acetonitrile]; gradient: 0-100%) to obtain the target compound 158 (36.1 mg).

[1261] 1H NMR(400MHz, DMSO-d6)δ8.19(d,J=5.6Hz,1H),7.46(s,1H),6.88-6.60(m,1H),6.60-6.56(m,1H),6.50-6 .45(m,1H),4.18-4.14(m,2H),4.13-3.59(m,8H),3.42(s,3H),2.19-2.16(m,2H),1.34(t,J=7.2Hz,3H).

[1262] MS m / z (ESI): 416.4 [M+H] +

[1263] Examples 159-161: The synthesis method of Example 158 was followed, except that 2-(2-(difluoromethyl)pyridin-4-yl)-2,6-diazaspiro[3.4]octane in step 5 was replaced with the reactants in the table below, and compounds 159-161 were synthesized in the same manner.

[1264] Synthesis of intermediate 159-A:

[1265] Step 1: Synthesis of compound 159-A:

[1266] Potassium carbonate (518 mg) was added to a DMF (3 mL) solution of 2-azaspiro[3.4]octane-6-ol hydrochloride (250 mg), followed by 4-bromo-2-(difluoromethyl)pyridine (260 mg). The reaction mixture was heated and stirred at 60 °C for 16 h. The product was detected by LCMS. The reaction mixture was cooled to room temperature, and water (30 mL) was added. The aqueous phase was extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give crude product compound 159-A (200 mg).

[1267] MS m / z (ESI): 255.3 [M+H] +

[1268] Examples 162-172: The synthesis method of Example 158 was followed, except that iodoethane in step 1 and 2-(2-(difluoromethyl)pyridin-4-yl)-2,6-diazaspiro[3.4]octane in step 5 were replaced with reactants 1 and 2 in the table below, respectively, and compounds 162-172 were synthesized in the same manner.

[1269] Example 173: 6-(2-(2-(difluoromethyl)pyridin-4-yl)-2,7-diazaspiro[3.5]nonane-7-yl)-1-ethyl-4-methyl-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one

[1270] Step 1: Synthesis of intermediate 173-2

[1271] Compound 173-1 (1.00 g) and tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylic acid were dissolved in DMF (10 mL), and K2CO3 (1.33 g) was added at room temperature. The reaction mixture was stirred at 120 °C for 3 hours. The reaction was monitored by LCMS until complete. The reaction mixture was diluted with H2O (30 mL), extracted with ethyl acetate (30 mL × 3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude product (2 g). The crude product was purified by rapid silica gel column chromatography. 20g Compound 173-2 (1.30 g) was obtained by rapid silica gel column chromatography with a gradient of 0–50% petroleum ether / ethyl acetate at a flow rate of 30 mL / min.

[1272] MS m / z (ESI): 354.2 [M+H] +

[1273] Step 2: Synthesis of intermediate 173-3

[1274] Compound 173-2 (1.30 g) was dissolved in EA (6 mL), and a dioxane solution of HCl (4 M, 6 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction was monitored by LCMS until complete. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain crude compound 173-3 (1.20 g), which was used directly in the next step of the reaction.

[1275] MS m / z(ESI): 254.2 [M+H] +

[1276] Step 2: Synthesis of Compound 173

[1277] The crude compound 173-3 (1.20 g) and 173-A (44.0 mg) were dissolved in dioxane (1 mL), and Xphos-Pd-G4 (15.0 mg) and Cs2CO3 (170 mg) were added. The reaction mixture was stirred at 100 °C for 5 hours. The reaction mixture was monitored by LCMS and the reaction was complete. H2O (10 mL) was added, and the mixture was extracted with ethyl acetate (5 mL × 3). After washing with saturated brine and drying with anhydrous sodium sulfate, the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative high performance liquid chromatography (mobile phase: [water (formic acid)-acetonitrile]; gradient: 0%-69%) to obtain the target compound 173 (54.8 mg).

[1278] 1 H NMR(400MHz,MeOD-d4)δ8.12(d,J=6.0Hz,1H),7.64(s,1H),7.23(s,1H),6.71-6.40(m,3H),4.35(q, J=7.2Hz,2H),3.85(s,4H),3.64(s,3H),3.16-3.11(m,4H),2.08-2.03(m,4H),1.44(t,J=7.2Hz,3H)

[1279] MS m / z (ESI): 429.4 [M+H] +

[1280] Synthesis of intermediate 173-A:

[1281] Step 1: Synthesis of intermediate 173-A-1:

[1282] 5.00 g of 6-bromo-1H-pyrazolo[4,3-b]pyridine was dissolved in 100 mL of DMF, and 16.4 g of cesium carbonate and 5.51 g of bromoethane were added. The reaction mixture was stirred at 25 °C for 2 hours. After the reaction was completed, the reaction mixture was diluted with 300 mL of water and extracted with 150 mL × 3 ethyl acetate. The organic phase was washed with 200 mL × 2 saturated brine, dried, and concentrated to obtain the crude product. The crude product was purified by rapid silica gel column chromatography (gradient 0–30% ethyl acetate / petroleum ether) to obtain compound 173-A-1 (3.00 g).

[1283] MS m / z(ESI): 226.0 [M+H] +

[1284] Step 2: Synthesis of intermediate 173-A-2:

[1285] Compound 173-A-1 (3.00 g) was dissolved in acetonitrile (60 mL), and urea peroxide (2.65 g) was added. The mixture was cooled to 0 °C, and trifluoroacetic anhydride (5.62 g, 3.72 mL) was added. The reaction mixture was stirred at 25 °C for 2 hours. After the reaction was completed, the mixture was quenched with a saturated sodium thiosulfate aqueous solution. The mixture was extracted with dichloromethane (50 mL × 3), and the organic phase was dried and concentrated to give crude compound 173-A-2 (2.90 g), which was used directly in the next step.

[1286] MS m / z(ESI): 242.1 [M+H] + .

[1287] Step 3: Synthesis of intermediate 173-A-3:

[1288] Compound 173-A-2 (2.90 g) was dissolved in chloroform (60 mL). TFAA (12.6 g, 8.33 mL) and TMSCl (6.51 g, 7.60 mL) were added to the reaction solution, and the mixture was stirred for 1 hour. The solution was cooled to 0 °C, and TEA (6.42 g, 8.82 mL) was added. The reaction solution was stirred at 25 °C for 16 hours. After the reaction was complete, the solution was quenched with water. The pH was adjusted to 8 with saturated sodium bicarbonate solution, and the mixture was extracted using a 10:1 (50 mL × 5) dichloromethane:methanol mixed solvent. The organic phase was dried and concentrated. The crude product was purified by rapid silica gel column chromatography (gradient 0–80% ethyl acetate / petroleum ether) to obtain compound 173-A-3 (2.00 g).

[1289] MS m / z(ESI): 242.1 [M+H] +

[1290] Step 4: Synthesis of intermediate 173-A:

[1291] Compound 173-A-3 (2.00 g) and potassium carbonate (2.28 g) were dissolved in N,N-dimethylformamide (40 mL). Iodomethane (1.41 g, 617.4 μL) was added at 0 °C, and the reaction mixture was stirred at 25 °C for 2 hours until the reaction was complete. The reaction mixture was diluted with water (120 mL), extracted with ethyl acetate (70 mL × 3), and the organic phase was washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (gradient 0–100% ethyl acetate / petroleum ether) to obtain the title compound 173-A (1.00 g).

[1292] MS m / z(ESI): 256.1 [M+H] +

[1293] Example 174: The synthesis method of Example 173 was followed, except that 2,7-diazaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester in step 1 was replaced with the starting material in the table below, and compound 174 was synthesized in the same manner.

[1294] Example 175: 9-(2,2-difluoroethyl)-7-methyl-2-((2-(2-(trifluoromethyl)pyrimidin-5-yl)-2-azaspiro[3.4]octane-6-yl)oxy)-7,9-dihydro-8H-purine-8-one

[1295] Step 1: Synthesis of Compound 175

[1296] Compound 33-2 (200 mg) and potassium carbonate (556 mg) were dissolved in DMF (2.00 mL), and 2-chloro-9-(2,2-difluoroethyl)-7-methyl-7,9-dihydro-8H-purin-8-one (182 mg) was added. The reaction mixture was stirred at 150 °C for 2 hours. After the reaction was completed, the crude product was obtained by filtration. The crude product was purified by preparative high performance liquid chromatography (mobile phase: [0.1% FA aqueous solution-acetonitrile]; gradient: 0%-100%) to obtain the target compound 175 (5.20 mg).

[1297] 1 H NMR(400MHz,MeOD-d4)δ8.14(s,1H),8.05(s,2H),6.43-6.06(m,1H),5.51-5.46(m,1H),4.35-4.26(m,2H), 4.11-4.04(m,4H),3.45(s,3H),2.40-2.35(m,1H),2.30-2.22(m,3H),2.09-2.03(m,1H),2.02-1.97(m,1H).

[1298] MS m / z (ESI): 485.9 [M+H] +

[1299] Example 176: 1-(2,2-difluoroethyl)-4-methyl-6-((2-(6-(trifluoromethyl)pyrimidin-4-yl)-2-azaspiro[3.4]octane-6-yl)oxy)-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one

[1300] Step 1: Synthesis of intermediate 176-2

[1301] To a 5 mL solution of EA containing 1.00 g of compound 176-1, 4 M HCl in ethyl acetate solution (5 mL) was added, and the reaction was stirred at room temperature for 1 h. The reaction solution was concentrated under reduced pressure and dissolved in DMF solution (6 mL). K2CO3 (1.96 g) and 4-chloro-6-(trifluoromethyl)pyrimidine (1.03 g) were added, and the reaction solution was stirred at 80 °C for 3 h. Water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (40 mL × 3). The combined organic phases were washed with saturated brine (40 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0%–50%) to obtain compound 176-2 (800 mg).

[1302] MS m / z(ESI): 274.1 [M+H] +

[1303] Step 2: Synthesis of Compound 176

[1304] Compounds 176-2 (60.0 mg) and 176-A (50.0 mg) were dissolved in toluene (1.00 mL), and CMBP (106 mg) was added. The mixture was stirred at 80 °C for 3 h. Water (10.0 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20.0 mL × 2). The combined organic phases were washed with saturated brine (20.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by C18 column chromatography (acetonitrile / 0.1% TFA aqueous solution = 0%–100%) to obtain the target compound 176 (34.8 mg).

[1305] 1 H NMR(400MHz,DMSO-d6)δ8.57(s,1H),7.78(s,1H),7.38(s,1H),6.77(s,1H),6.53-6.23(m,1H),4.91-4.78(m,3 H),4.10-4.06(m,4H),3.52(s,3H),2.35-2.32(m,1H),2.15-2.06(m,3H),1.98-1.90(m,1H),1.84-1.80(m,1H).

[1306] MS m / z (ESI): 485.1 [M+H] +

[1307] Synthesis of intermediate 176-A:

[1308] Cs₂CO₃ (892 mg) and Rockphos-Pd-G₃ (115 mg) were added to a DMF (8 mL) / H₂O (2 mL) solution of compound 117-1 (400 mg). The mixture was heated and stirred at 80 °C for 2 h under argon protection. LC-MS showed that the reaction was complete. Water (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (30 mL × 2). The product was in the aqueous phase. The pH of the aqueous phase was adjusted to 6 with 1 N hydrochloric acid aqueous solution, and then extracted with dichloromethane (30 mL × 2). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound 176-A (290 mg).

[1309] MS m / z(ESI): 230.2 [M+H] +

[1310] Examples 177-178: The synthesis method of Example 176 was followed, except that 4-chloro-6-(trifluoromethyl)pyrimidine in step 1 and 1-(2,2-difluoroethyl)-6-hydroxy-4-methyl-1,4-dihydro-5H-pyrazolo[4,3-b]pyridin-5-one in step 2 were replaced with reactants 1 and 2 in the table below, respectively, and compounds 177-178 were synthesized in the same manner.

[1311] Synthesis of intermediate 178-A:

[1312] Cs₂CO₃ (892 mg) and Rockphos-Pd-G₃ (115 mg) were added to a DMF (8 mL) / H₂O (2 mL) solution of compound 173-A (350 mg). The mixture was heated and stirred at 80 °C for 2 h under argon protection. LC-MS showed that the reaction was complete. Water (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (30 mL × 2). The product was in the aqueous phase. The pH of the aqueous phase was adjusted to 6 with 1 N hydrochloric acid aqueous solution, and then extracted with dichloromethane (30 mL × 2). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound 178-A (210 mg).

[1313] MS m / z (ESI): 194.2 [M+H] +

[1314] Example 179: 5-(2,2-difluoroethyl)-1-methyl-3-((2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.4]octane-6-yl)oxy)-1,5-dihydro-2H-pyrrolo[2,3-b]pyrazin-2-one

[1315] Step 1: Synthesis of intermediate 179-2

[1316] Compound 179-1 (5.00 g) was dissolved in DMF (50 mL), and Cs₂CO₃ (16.0 g) was added at room temperature. 2,2-Difluoroethyltrifluoromethanesulfonate (8.39 g) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with H₂O (100 mL), extracted with ethyl acetate (50 mL × 3), and the organic phase was washed with saturated brine (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by rapid silica gel column chromatography (petroleum ether / ethyl acetate = 5:1) to obtain compound 179-2 (6.70 g), a brown solid.

[1317] MS m / z(ESI): 218.0 [M+H] +

[1318] Step 2: Synthesis of intermediate 179-3

[1319] Compound 179-2 (6.70 g) and urea peroxide (6.00 g) were dissolved in ACN (67.0 mL), and TFAA (13.0 g) was added at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction was quenched with saturated Na2S2O3 aqueous solution (100 mL), extracted with ethyl acetate (50.0 mL × 3), washed with saturated brine (50.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by pulping (petroleum ether: ethyl acetate = 5:1) to obtain compound 151-3 (7.20 g).

[1320] MS m / z(ESI): 234.2 [M+H] +

[1321] Step 3: Synthesis of intermediate 179-4

[1322] Compound 179-3 (7.20 g) was dissolved in CHCl3 (72.0 mL), and then TFAA (32.4 g) and TMSCl (6.71 g) were added. After stirring the reaction solution for 1 hour, TEA (15.6 g) was added at 0 °C. The reaction solution was stirred at room temperature for 2 hours. The reaction solution was quenched with water (200 mL), extracted with DCM (50.0 mL × 3), and the organic phase was washed with saturated brine (50.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by pulping with petroleum ether:ethyl acetate = 3:1 to obtain compound 179-4 (4.20 g).

[1323] MS m / z(ESI): 234.1 [M+H] +

[1324] Step 4: Synthesis of intermediate 179-5

[1325] Compound 179-4 (4.20 g) was dissolved in DMF (42 mL), and K2CO3 (4.97 g) was added and stirred for 5 min. Iodomethane (3.00 g) was then slowly added dropwise at 0 °C, and the reaction mixture was stirred at room temperature for 1 hour. The reaction was monitored by LCMS until complete. The reaction mixture was diluted with water (120 mL), extracted with ethyl acetate (40.0 mL × 3), and the organic phase was washed with saturated brine (40.0 mL × 3). After drying with anhydrous sodium sulfate, the mixture was filtered and concentrated under reduced pressure to obtain the crude product. The crude product was purified by rapid silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 179-5 (2.70 g).

[1326] 1 H NMR (400MHz, DMSO-d6) δ7.50 (d, J = 3.6Hz, 1H), 6.52-6.22 (m, 2H), 4.66-4.55 (m, 2H), 3.60 (s, 3H).

[1327] MS m / z(ESI): 248.1 [M+H] +

[1328] Step 5: Synthesis of Compound 179

[1329] Compound 179-5 (80.0 mg) and 2-(2-(trifluoromethyl)pyridin-4-yl)-2-azaspiro[3.4]octane-6-ol (88.0 mg) were dissolved in THF (8.00 mL), and then t-BuOK (72.0 mg) was added. The reaction mixture was stirred at room temperature for 2 hours. After filtration, the filtrate was purified by preparative high performance liquid chromatography (column: Boston Prime C18 150×30 mm×5 μm; mobile phase: [water (formic acid)-acetonitrile]; acetonitrile gradient: 18%-72%) to obtain the target compound 179 (36.2 mg).

[1330] 1 H NMR (400MHz, MeOD-d4) δ8.13(d,J=6.0Hz,1H),7.07(d,J=3.6Hz,1H),6.74(d,J=2.4Hz,1H),6.53(dd,J=5.6,2Hz,1H),6.31-6.01(m, 2H),5.50-5.46(m,1H),4.56-4.48(m,2H),4.12-4.10(m,1H),4.01-3.99(m,3H),3.67(s,3H),2.42-2.19(m,4H),2.08-1.96(m,2H).

[1331] MS m / z (ESI): 484.2 [M+H] +

[1332] Experimental Example 1: Imaging determination of the high lysosomal GCase activity of the disclosed compound in the SH-SY5Y cell line.

[1333] 1) Materials and reagents:

[1334] 2) Instruments:

[1335] 3) Experimental methods:

[1336] Complete cell culture medium: DMEM / F-12, HEPES, containing 10% FBS and 1% penicillin-streptomycin;

[1337] High-content imaging detection medium: DMEM / F-12, HEPES, phenol red-free, FBS-free;

[1338] 20,000 SH-SY5Y cells were seeded per well in a 384-well plate, and 40 μL of complete cell culture medium was added per well. The plates were then incubated overnight at 37°C with 5% carbon dioxide.

[1339] Dissolve the disclosed compound in DMSO to a concentration of 20 mM, and then dilute it 1:1 with DMSO to 10 mM. The 20 mM and 10 mM compound solutions were then diluted 1:400 with complete cell culture medium to obtain concentrations of 50 μM and 25 μM, respectively. Add 10 μL of culture medium containing 50 μM or 25 μM of the disclosed compound to the wells of a 384-well plate, resulting in final concentrations of the test compound of 10 μM or 5 μM, and a final DMSO concentration of 0.05%. Centrifuge at 500 rpm for 30 seconds and incubate at 37°C with 5% CO2 for 72 hours.

[1340] Prepare high-content imaging detection medium (DMEM / F-12, HEPES, phenol red-free, FBS-free), add 75 nM Lysotracker and 58 μM PFB-FDGlu to a final concentration; remove the original medium supernatant from the cell plate, add medium containing 40 μL Lysotracker and PFB-FDGlu, centrifuge at 500 rpm for 30 s, and incubate at 37°C and 5% CO2 for 45 minutes; remove the cell plate and perform continuous high-content imaging at 30-minute intervals for a total duration of 3 hours, acquiring images from brightfield, Alexa 488, and Alexa 647 channels, with 10 fields of view per well. Calculate the average fluorescence intensity of cells, lysosomes, and cell-lysosome colocalization. Using the untreated DMSO wells as a background, calculate the fluorescence intensity at the endpoint of each well. The drug concentration at which the fluorescence intensity of the analyte is twice the background fluorescence intensity is taken as the AC concentration. 100 The value (AC100 refers to the drug concentration at which the GCase activation activity is 200%).

[1341] The disclosed compound exhibited high GCase activation levels in SH-SY5Y cells, as shown in Table 1. (Compound AC was also tested.) 100 Value range: A: AC 100 ≤5μM; B: 5uM <AC 100 ≤10μM; C: >10μM;

[1342] Table 1. Results of the assay of the disclosed compound on GCase activity in SH-SY5Y cells.

[1343] Experimental Example 2: Inhibitory effect of the disclosed compound on the activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 enzymes.

[1344] Unless otherwise specified, all reagents and consumables used in this experiment are commercially available products.

[1345] The inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 enzyme activities by the disclosed compounds was determined using the following experimental method.

[1346] The experimental steps are as follows:

[1347] 1. Preparation of 100mM Phosphate Buffered Sodium (PBS): Weigh 7.098g Na₂HPO₄ and dissolve it in 500mL of pure water by sonication to obtain solution A. Weigh 3.400g KH₂PO₄ and dissolve it in 250mL of pure water by sonication to obtain solution B. Slowly add solution B to solution A on a stirrer until the pH reaches 7.4 to prepare a 100mM PBS buffer.

[1348] 2. Preparation of NADPH solution: Prepare 10mM NADPH (reduced coenzyme II) solution using 100mM PBS buffer.

[1349] 3. Preparation of working solutions for the test compounds: Dilute 10 mM of the DMSO stock solution of the compounds disclosed herein with DMSO to obtain working solutions of the compounds (10000 μM, 3333.3 μM, 1111.1 μM, 370.37 μM, 123.46 μM, 41.15 μM, 13.7 μM, 0 μM).

[1350] 4. Preparation of positive inhibitor working solution: Dilute the positive inhibitor DMSO stock solution with DMSO (CYP 2C9: sulfamethoxazole 1000μM, CYP 2D6: quinidine / CYP 3A4: ketoconazole, 100μM; CYP 1A2: α-naphthylflavonoid, 50μM; CYP 2C19: N...

Claims

1. A compound according to Formula (la) or (lb) or (Ic) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein Ring C is selected from the following structural groups: represents a single or double bond; G 1 selected from CR 2 , N or NR 3 ; G 2 selected from CR 2 , N or C(O); Q 1 , Q 2 are independently selected from CR 2 or N; V is selected from O, S or NH; Each R c The components are independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 heterocyclic or 5-6 heteroaryl is optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl. Each R 2 It is independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C4 alkoxy; R 3 selected from H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C4 alkoxy; W is selected from a bond, -CR a R b -, C(O), O, or S; R a , R b is independently selected from H, halogen, Ci-C6alkyl, Ci-C6haloalkyl or Ci-C4alkoxy; Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12 bridged cycloalkyl, 7-12 membered spirocyclic, 7-12 membered fused heterocyclic or 5-12 membered bridged heterocyclic; Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl; Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl. n is selected from 0, 1 or 2; p, q are independently selected from 0, 1 or 2. M1is selected from O, S or CR 6a R 7a ; M2is selected from CR 8a or N; M3is selected from CR 9a or N; R 6a , R 7a , R 8a , R 9a is independently selected from H, deuterium, NH2, OH, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, or C3-C6cycloalkyl; d1, d2, c1, c2, v1, v2 are independently selected from 0, 1 or 2. T is selected from CR 2 or N.

2. The compound of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein, R c selected from C1-C6alkyl, C1-C6alkoxy, 4-6 membered heterocyclyl, or 5-6 membered heteroaryl, each independently optionally substituted with NH2, OH, halogen, C1-C6alkyl, or C1-C6haloalkyl; or R c C1-C6alkyl, C1-C6alkoxy, 4-6 membered heterocyclyl, or 5-6 membered heteroaryl, each optionally substituted with halo, C1-C6alkyl, or C1-C6haloalkyl; or R c selected from C1-C3 alkyl, C1-C3 alkoxy, azetidinyl, piperidinyl, pyrazolyl, said C1-C3 alkyl, C1-C3 alkoxy, azetidinyl, piperidinyl, pyrazolyl, each independently optionally substituted with halogen, C1-C6 alkyl or C1-C6 haloalkyl.

3. The compound of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, according to claim 1 or 2, wherein, R 2 selected from H, C1-C6 alkyl or C1-C4 alkoxy; or R 2 is selected from H, CH3or -OCH3.

4. The compound according to any one of claims 1 to 3 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, R 3 selected from H or Ci-C6alkyl; or R 3 is selected from H or CH3.

5. The compound of formula (la) or (lb) or (lc) according to any one of claims 1-4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, Ring C is selected from the following structural groups: Alternatively, ring C is selected from the following structural groups: Alternatively, ring C is selected from the following structural groups: Alternatively, ring C is selected from the following structural groups: R 2 , R 3 , R c and n are defined as in any of claims 1 to 4.

6. The compound according to any one of claims 1-5 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, W is selected from a bond, -CH2-, C(O), O or S; or, W is selected from a bond or O; or, W is a bond.

7. The compound according to any one of claims 1-6 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, Ring B is selected from a 7-12 membered spiro heterocyclylenyl, 7-12 membered fused heterocyclylenyl or 5-12 membered bridged heterocyclylenyl; or, Ring B is selected from a 7-10 membered spiro heterocyclylenyl, 7-10 membered fused heterocyclylenyl or 5-10 membered bridged heterocyclylenyl; or, Ring B is selected from a 7-12 membered spiro heterocyclylenyl; or, Ring B is selected from a 3 / 6 membered spiro heterocyclylenyl, 4 / 4 membered spiro heterocyclylenyl, 4 / 5 membered spiro heterocyclylenyl, 4 / 6 membered spiro heterocyclylenyl, 5 / 5 membered spiro heterocyclylenyl or 5 / 6 membered spiro heterocyclylenyl; or, Ring B is selected from a 4 / 4 membered spiro heterocyclylenyl, 4 / 5 membered spiro heterocyclylenyl or 4 / 6 membered spiro heterocyclylenyl. Alternatively, ring B is selected from the following structural groups: wherein X1is selected from O, S or CR 6 R 7 ; X2is selected from CR 8 or N; X3is selected from CR 9 or N; R 6 , R 7 , R 8 , R 9 is independently selected from H, deuterium, NH2, OH, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, or C3-C6cycloalkyl; s, m, r are independently selected from 0, 1 or 2; Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; q' is selected from 0 or 1; q" is selected from 0 or 1.

8. The compound of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, according to claim 8, wherein, X1is selected from O or CR 6 R 7 ; or X1is CR 6 R 7 ; or X1is CH2.

9. The compound of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, according to claim 8, wherein, X2, X3 are at least one N; or, X2 is selected from CH or N; or, X3 is selected from CH or N.

10. The compound of claim 8 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, R 6 , R 7 , R 8 , R 9 are independently selected from H, deuterium, or Ci-C6alkyl; or, R 6 , R 7 , R 8 , R 9 are each independently H.

11. The compound according to any one of claims 1-11 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, Ring A is selected from C5-C10cycloalkyl, 4-9 membered heterocyclyl, 5-6 membered heteroaryl, or phenyl; 10 cycloalkyl, 4-9 membered heterocyclyl, 5-6 membered heteroaryl, or phenyl; or, Ring A is a 5-10 membered heteroaryl or phenyl; or, Ring A is a 5-10 membered heteroaryl; or, Ring A is a 5-6 membered heteroaryl; or, Ring A is a pyridyl or pyrimidinyl; Alternatively, ring A is 12. The compound according to any one of claims 1-11 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, R 1 selected from halogen, Ci-C6alkyl, Ci-C6haloalkyl, or Ci-C6alkoxy, each independently optionally substituted with NH2, OH, halogen, or Ci-C6alkyl; or R 1 selected from halogen, Ci-C6alkyl or Ci-C6haloalkyl; Or, R 1 Selected from C1-C6 haloalkyl groups; or R 1 is CF3.

13. The compound according to any one of claims 1-13 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, p is selected from 0 or 1; or, p is 1.

14. The compound according to any one of claims 1-14 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, q is selected from 0 or 1; or, q is 0.

15. The compound according to any one of claims 1-14 of formula (la) or (lb) or (lc) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, n is selected from 0 or 1; or, n is 1.

16. A compound of Formula (Ie) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein Each R c The group is independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups is independently and optionally substituted by NH2, OH, halogen, C1-C6 alkyl or C1-C6 haloalkyl; n is selected from 0, 1 or 2; L is selected from a bond, O, or -O-CR 11 R 12 -; R 11 , R 12 is independently selected from H or C1-C6 alkyl; W is selected from a bond, -CR a R b -, O, S, NHC(O), or C(O)O; R a , R b is independently selected from H, halogen, Ci-C6alkyl, Ci-C6haloalkyl or Ci-C4alkoxy; Ring B is selected from C7-C 12 Spirocycloalkyl, C7-C 12 Confusing cycloalkyl, C7-C 12 bridged cycloalkyl, 7-12 membered spirocyclic heterocyclic group, 7-12 membered fused heterocyclic group, 5-12 membered bridged heterocyclic group or 4-6 membered monocyclic heterocyclic group; Each R 4 It is independently selected from deuterium, OH, halogen, =O, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; Ring A is selected from C5-C 12 Cycloalkyl, 4-12 membered heterocyclic, 5-10 membered heteroaryl or C6-C 10 Aryl; Each R 1 The group is independently selected from CN, NH2, OH, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group, wherein each of the NH2, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or 4-10 heterocyclic group is optionally substituted by NH2, OH, halogen or C1-C6 alkyl. p, q are independently selected from 0, 1 or 2.

17. The following compounds or isomers thereof or pharmaceutically acceptable salts thereof, 18. A pharmaceutical composition comprising a compound of (la) or (lb) or (lc) according to any one of claims 1-15 or (le) according to claim 16 or (If) according to claim 17, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant.

19. A method of preventing or treating a GCase-mediated disease in a mammal, comprising administering to a mammal, preferably a human, in need of such treatment, a therapeutically effective amount of a compound of formula (la) or (lb) or (lc) according to any one of claims 1-15 or (le) according to claim 16 or (If) according to claim 17, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 18.

20. Use of a compound of formula (la) or (lb) or (lc) according to any one of claims 1-17 or (le) according to claim 16 or (If) according to claim 17, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 18, for the manufacture of a medicament for the prevention or treatment of a GCase-mediated disease.